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Alzheimer’s disease (AD), the leading etiology of dementia and the fifth cause of 
death worldwide, has been declared a public health priority by the World Health 
Organization in 2017. AD is incurable and no treatment can currently modify its 
natural history. Aberrant accumulation of soluble forms of the amyloid β 
(Aβ) peptide in AD mouse models has been associated with neuronal loss, 
hippocampal dysfunction and behavioral alterations, yet data about the 
underlying molecular synaptic changes are lacking. The novel small molecule 
anle138b has been found protective when orally administered, even at late 
stages, in an AD murine model. However, how this promising drug acts in the AD 
brain at a synaptic level remains unclear. One of the proposed mechanisms is 
the blockage of amyloid pores, a biophysical phenomenon mostly studied in vitro. 
Here, I established an in vitro model system of Aβ toxicity by means of incubating 
murine autaptic hippocampal cultures with synthetic Aβ oligomers, for functional 
and morphological characterization of AD-like synapses. Interestingly, I observed 
a marked deficit in synaptic function with no evidence of morphological or 
biochemical alterations. Furthermore, I preincubated the autaptic neurons with 
anle138b before Aβ exposure, as performed in other model membranes, to 
observe a putative inhibition of pore formation. In these experiments anle138b 
failed in protecting neurons from oligomer synaptotoxicity. In addition, I examined 
the membrane properties of Aβ-treated autaptic neurons. In contrast to previous 
literature, even though the oligomeric preparation that I used could induce pore 
formation in an artificial bilayer, no signs of loss of membrane integrity in neurons 
were found. Finally, experiments with the enantiomer AllD Aβ indicate that 
Aβ toxicity is stereospecific, a property that in vitro observed pores lack. In 
conclusion, I showed that Aβ oligomers impair synaptic glutamate release. These 
changes might be an early manifestation of AD and constitute a promising 
disease mechanism that requires further study and confirmation in another 
disease models. While anle138b failed as pore blocker, it is still possible that in 
the model system presented here, the autaptic glutamatergic neurons, it could 
act as an inhibitor of Aβ aggregation and further studies must be performed. 
Finally, these data suggest that pore formation is a phenomenon occurring mostly 




examining the evidence from in vitro studies and the need for a validation in 
biologically relevant models when studying the mechanisms of human diseases.  
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 Alzheimer’s disease and the amyloid cascade hypothesis 
Memory, the ability to acquire, store and retrieve information, is an essential 
process that allows us to perform in our daily life and, in all its modalities, 
constitutes the basis of individuality. The loss of this vital brain function is the 
cardinal symptom of dementia, a devastating neuropsychiatric disorder that 
affects approximately 50 million people worldwide (WHO, 2017a). With an 
estimated incidence of one new case every three seconds and 58% of the people 
with dementia living in low-medium income countries (Prince et al., 2015), 
dementia has been declared a public health priority by the World Health 
Organization in 2017 (WHO, 2017b, 2018). Clinically, dementia was defined in 
2011 by the National Institute on Aging - Alzheimer’s Association (NIA-AA) 
Workgroups as the presence of progressive and incapacitating cognitive decline 
affecting at least two of the following domains: ability to acquire and remember 
new information, reasoning and handling of complex tasks, visuospatial abilities, 
language function and/or changes in personality or comportment (McKhann et 
al., 2011). The etiology of 60-70% of the cases of dementia is Alzheimer’s 
disease (AD) (WHO, 2017b), a syndrome characterized by insidious onset of a 
multidomain cognitive decline, frequently with amnestic presentation (McKhann 
et al., 2011). Histopathological AD diagnosis and staging have classically 
occurred postmortem and relied on the presence, quantity and distribution of 
amyloid plaques and neurofibrillary tangles (Hyman et al., 2012). Amyloid 
plaques are extracellular deposits of amyloid β (Aβ), a 38-43 amino acid peptide 
that can aggregate into insoluble, β-pleated-sheet-rich fibrils. These fibrils are 
present in the so called dense-core or neuritic plaques, which are a specific 
finding of AD, in contrast with diffuse plaques that occur also in normally aged 
individuals (Delaère et al., 1990; Serrano-Pozo et al., 2011). Plaques are mainly 
distributed along the isocortex, while the allocortex and deep nuclei are 
compromised to a lesser extent and in later stages of the disease (Thal et al., 
2002). The histopathological burden of plaques correlates poorly with the 
presence of clinical symptoms (Arriagada et al., 1992; Dickson et al., 1992). 
Aβ deposits can also be found in the tunica media of small-medium size blood 
vessels constituting the pathological lesions called cerebral amyloid angiopathy, 
2 
 
found in ~80% of the AD patients (Jellinger, 2002). Neurofibrillary tangles are 
intracellular deposits of hyperphosphorylated and aggregated tau, a microtubule 
associated protein. The deposit of neurofibrillary tangles follows a predictable 
spatiotemporal distribution according to the staging by Braak and Braak, with 
initial compromise of limbic regions and later spreading towards associative 
cortical areas and subcortical nuclei (Braak and Braak, 1991). Aggregated tau 
deposition, unlike amyloid plaque accumulation, correlates with the magnitude of 
cognitive decline (Arriagada et al., 1992). In addition to the “positive findings” that 
constitute Aβ and hyperphosphorylated tau deposition there are “negative 
findings”, namely neuronal and synaptic loss. These negative findings, which 
match the topographical distribution of tangle deposition, are the best correlate 
of cognitive decline and are responsible for the atrophy of cortical areas in AD 
(Scheff, DeKosky and Price, 1990; Terry et al., 1991; Gómez-Isla et al., 1997; 
Ingelsson et al., 2004).  
With the advent of reliable biomarkers such as the detection of Aβ and tau in 
cerebrospinal fluid or positron emission tomography using Aβ and tau ligands, it 
is now possible to trace in vivo the progression of the histopathological lesions 
(Olsson et al., 2016; Villemagne et al., 2018). In this context, the 2018 NIA-AA 
Research Framework proposed a conceptual shift to defining AD as a bio-
pathological entity, regardless of the clinical symptoms; ‘“Alzheimer’s disease” 
refers to an aggregate of neuropathological changes and thus is defined in vivo 
by biomarkers and by postmortem histopathological examination, and not by 
clinical symptoms (Jack et al., 2018). The authors explain that the clinical 
presentation has low sensitivity and specificity to detect AD and for this reason 
should not be considered necessary for the diagnosis, although the severity of 
the symptoms is used in the staging of AD (Serrano-Pozo et al., 2014; 
Ossenkoppele et al., 2015; Jack et al., 2018). This new paradigm defines a 
pathological continuum (“Alzheimer’s continuum”) that begins with biomarker 
signs of Aβ deposition and progresses in later stages with tau accumulation and 
neuronal loss, regardless of the clinical presentation (Jack et al., 2013, 2018). 
AD is now considered as the presence of an in vivo biomarker or postmortem 
histopathological evidence of concomitant Aβ and tau accumulation. There is a 
great advantage in such a radical change in the paradigm of the AD definition: 
this pathological rather than clinical conception of the disease includes in the 




onset of the symptoms. This opens the doors to the description and 
understanding of events happening at the beginning of the natural history of the 
disease and will facilitate the study and implementation of earlier therapeutic 
interventions (Jack et al., 2018). 
Although Aβ deposition appears early in the Alzheimer’s continuum and 
correlates poorly with cognitive symptoms, great efforts and resources have been 
invested into researching its causative role in dementia (Arriagada et al., 1992; 
Villemagne et al., 2013). Solid evidence supports the so called “amyloid cascade 
hypothesis”, which posits that accumulation of Aβ initiates the pathological events 
that end in hyperphosphorylated tau deposition and massive neurodegeneration 
(Hardy and Higgins, 1992; Hardy and Selkoe, 2002; Selkoe and Hardy, 2016). A 
first hint of a causal relationship is given by the fact that both patients carrying 
mutations in the genes related to the amyloid precursor protein (APP) and its 
processing into Aβ as well as individuals living with Down syndrome, who have 
an extra dose of the APP gene, develop a form of early onset dementia before 
the age of 60 years (St. George-Hyslop et al., 1987; Tanzi and Bertram, 2005). 
Furthermore, the apolipoprotein E (ApoE), whose allele ε4 is the most important 
risk factor for late-onset AD, has been related to the regulation of Aβ clearance 
in the brain (Castellano et al., 2011). Finally, although tau deposition can precede 
Aβ accumulation, the pathogenic mutations in the gene encoding for tau do not 
cause amyloid plaque deposition or AD (Jack et al., 2013; Spillantini and Goedert, 
2013). Overall, despite being a topic of heated debate, the amyloid cascade 
hypothesis with its variations and updates is still valid after more than 25 years 
(Herrup, 2015; Karran and De Strooper, 2016). In this context, considering that 
Aβ is responsible for tau deposition and ultimately for neurodegeneration, the 
question that has remained unanswered is what cellular and molecular events 
link them, i.e., what the mechanism of toxicity is.  
 Physiology of APP and its cleavage products 
 APP structure 
APP was first sequenced and localized to chromosome 21 in 1987 a few years 
after its proteolytic product, Aβ, was isolated from cerebrovascular deposits 
(Glenner and Wong, 1984; Goldgaber et al., 1987; Kang et al., 1987; Tanzi et al., 
1987). The APP gene can produce three isoforms of the single-pass 
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transmembrane protein of 695, 751 and 770 amino acids in length via alternative 
splicing (Matsui et al., 2007). In addition, two more members of the APP family 
exist in mammals, the APP-like protein 1 and 2 (APLP-1 and -2) (Wasco et al., 
1992, 1993). For schematic representation of APP structure, see Figure 1. The 
extracellular portion of APP is composed of two folded domains, E1 and E2, 
separated by a flexible acidic region and a Kunitz-type protease inhibitor domain, 
the latter being absent in the shortest APP695 isoform. The intracellular domain is 
intrinsically disordered and is linked to the extracellular domain by the 
juxtamembrane - transmembrane regions (Coburger et al., 2013; Müller, Deller 
and Korte, 2017). The structure of the entire protein has not been resolved yet, 
but data are available for the E1 subdomain, the E2 and the intracellular tail 
(Rossjohn et al., 1999; Barnham et al., 2003; Keil et al., 2004; Wang and Ha, 
2004; Dahms et al., 2010). The APP extracellular domains can dimerize forming 
cis-, trans- or heparin-mediated interactions as well as heterodimers with other 
family members, in addition to binding components of the extracellular matrix 
(Kibbey et al., 1993; Scheuermann et al., 2001; Ho and Südhof, 2004; Soba et 
al., 2005; Dahms et al., 2010). These contacts have been shown to modulate 
APP neurotrophic and synaptogenic functions (Wang et al., 2009). The E1 region 
also contains a copper-binding domain that is thought to act as a metal buffer, 
since knock-out (KO) mice lacking APP or APLP2 show increased copper 
Figure 1. APP structure and cleavage sites of the secretases.  The schematic represents a 
molecule of APP inserted into the plasma membrane, and its corresponding domains. The sites 




concentration in the cerebral cortex (White et al., 1999). The intracellular domain 
contains a conserved GYENPTY sequence that plays an important role in 
trafficking and clathrin-mediated endocytosis of APP, which in turn can regulate 
Aβ production (Perez et al., 1999). In addition, the cytoplasmic tail can bind 
adaptor molecules such as X11/Mint and Fe65 and it is required for the 
synaptogenic effects of APP (Borg et al., 1996; Tamayev, Zhou and D’Adamio, 
2009; Wang et al., 2009). Finally, the transmembrane region contains in APP, 
but not in APLP-1 or -2, the Aβ peptide sequence, whose effects on synaptic 
transmission will be investigated in the present study.  
 APP synthesis and processing 
APP is synthesized in the endoplasmic reticulum, trafficked to the trans-Golgi 
network and targeted to the plasma membrane in the secretory pathway 
(Weidemann et al., 1989). In neurons, APP is modified by N- and O-glycosylation 
during its production and transported to both the axonal and somatodendritic 
compartments (Kins et al., 2006; Laßek et al., 2013). A set of α-secretases in the 
plasma membrane surface can shed the APP ectodomain releasing soluble 
APPα (sAPPα) and leaving the membrane-anchored fragment αAPP carboxy-
terminal fragment (αAPP-CTF) (Sisodia, 1992; Parvathy et al., 1999). The 
physiologically essential enzyme in the group of α-secretases is a disintegrin and 
metalloproteinase-10 (ADAM-10) (Kuhn et al., 2010). The αAPP-CTF can be 
subsequently cleaved at the transmembrane region by the γ-secretase producing 
the extracellular p3 fragment and the APP intracellular domain (AICD) (Haass 
and Selkoe, 1993). The γ-secretase is a protein complex localized at the plasma 
membrane and endosomal compartment formed by four subunits: a presenilin 
(PS1 or 2) with the aspartyl-protease function essential for the intramembrane 
cleavage of substrates, the presenilin enhancer-2, anterior pharynx-defective 
phenotype-1 and nicastrin, which stabilizes the tripartite complex (De Strooper et 
al., 1998; Kaether, Haass and Steiner, 2006; Zhao et al., 2010). For schematic 
representation of the processing pathways see Figure 2. The α-secretase 
cleaves APP within the Aβ region, and therefore this processing pathway is 
described as non-amyloidogenic. Alternatively, if APP is endocytosed without 
passing through α-processing, sequential cleavage by the β- and γ- secretases 
occur in the acidic environment of endosomes generating intraluminal Aβ peptide 
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(Vassar et al., 1999). There is only one β-secretase for APP named β-site APP 
cleaving enzyme-1 (BACE-1), which is most active in the endocytic compartment 
(Vassar et al., 1999; Kaether, Haass and Steiner, 2006). At rest, dendritic BACE-
1 is located in vesicles that do not contain APP (Sannerud et al., 2011). However, 
under situations of increased neuronal activity, APP enters the endocytic 
pathway where APP and BACE-1 can be physically in contact (Das et al., 2013, 
2016). This amyloidogenic processing pathway produces the sAPPβ and AICD 
fragments in addition to giving rise to endosomal accumulation of Aβ, which once 
secreted is the main component of neuritic plaques, a hallmark of AD.  
 Effects of APP and APLPs genetic deletion on the murine central nervous 
system (CNS) 
APP KO mice are viable and fertile but show a 15-20% body weight reduction, 
abnormal grip strength and altered locomotor activity when compared to wild-
type (WT) littermates (Zheng et al., 1995). Histological analysis reveals 
astrogliosis in several cortical areas, and reduced overall cell size and dendrite 
length has been reported in Cornu Ammonis area 1 (CA1) pyramidal neurons of 
Figure 2. APP processing pathways and cleavage products. APP is cleaved in a first step by 
the α-secretase, ADAM10, in the non-amyloidogenic pathway (left), and by the β- secretase, 
BACE-1, in the amyloidogenic pathway (right). The α-shedding releases sAPPα (left, green 
dashed line), which is believed to be responsible for the physiological trophic effects attributed to 
APP. Sequential cleavage by BACE-1 and the γ-secretase produces Aβ (right, red dashed line), 




these animals (Zheng et al., 1995; Seabrook et al., 1999). Electrophysiological 
characterization of pyramidal neurons of the CA1 area shows a reduction in long-
term potentiation (LTP) using acute hippocampal slices from aged mice (>12 
months), with conserved membrane properties and unchanged paired-pulse 
facilitation (PPF) (Dawson et al., 1999; Seabrook et al., 1999). In turn, paired-
pulse depression is reduced in APP KO gamma-aminobutyric acid (GABA) -ergic 
synapses in the CA1, and similar effects can be found in hippocampal and striatal 
APP KO GABAergic neurons in dissociated cultures, accompanied by increased 
expression levels of L-type calcium channels (Seabrook et al., 1999; Yang et al., 
2009). The behavioral consequences of APP deletion consist of impaired 
learning and spatial memory in aged animals but not in young ones, as evidenced 
in the conditioned avoidance and water maze tests, as well as altered declarative 
long-term memory indicated by poor performance using a novel-object 
recognition test (Dawson et al., 1999; Ring et al., 2007; Zou et al., 2016). 
Furthermore, biochemical abnormalities have also been found in tissue from APP 
KO animals, such as elevated copper concentrations in the brain and liver (White 
et al., 1999), and increased brain levels of cholesterol and sphingomyelin (Grimm 
et al., 2005). Another mouse line expressing a truncated form of APP has been 
generated (Müller et al., 1994). Commissural alterations such as agenesis of the 
corpus callosum was observed in these mice, in addition to hypersensitivity to 
kainate-induced seizures (Steinbach et al., 1998).  
While single genetic deletion of APLP-1 or APLP-2 induces no striking 
phenotypes, combined KO of APLP-2 with either or both APP or APLP-1 results 
in a lethal perinatal phenotype, most likely due to alterations in the neuromuscular 
junction with normal brain morphology (von Koch et al., 1997; Heber et al., 2000; 
Wang et al., 2005; Klevanski et al., 2014). Finally, constitutive triple KO of APP, 
APLP-1, and APLP-2 also die after birth due to neuromuscular junction defects, 
but exhibit cortical dysplasia that resembles cobblestone lissencephaly with loss 
of Cajal-Retzius cells (Herms et al., 2004). 
Collectively, these data indicate that the members of the APP family are essential 
for the correct development of the CNS, neuronal, dendritic and spine growth, 
and adequate functioning of hippocampal synapses.  
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 Role of APP cleavage products on neuronal morphology and function 
While it is clear that APP plays an important role in CNS physiology, it is possible 
that its attributed functions are actually exerted by cleavage fragments produced 
in the amyloidogenic and non- amyloidogenic processing pathways (reviewed in 
Müller and Zheng, 2012; Andrew et al., 2016; and Müller, Deller and Korte, 2017).  
sAPPα, a secreted molecule produced by α- and γ-processing, is the main 
candidate that could mediate the neurotrophic effects of APP. Its expression is 
sufficient to rescue the lethal phenotype induced by knocking out both APP and 
APLP-2 genes, restoring the reduced grip force as well as the defective 
performance in the Morris water maze and Schaffer collateral (SC)/CA1 LTP 
deficits in aged animals (Ring et al., 2007). Similar restorative effects can be 
observed on LTP at SC synapses when the aforementioned two genes are 
deleted specifically in the forebrain, and exogenous recombinant sAPPα is 
acutely applied in the artificial cerebrospinal fluid at low nanomolar 
concentrations (Hick et al., 2015). Interestingly, higher concentrations of the 
homologous sAPPβ fragment, a molecule lacking the last 16 amino acids of 
sAPPα, fails to rescue the LTP defects in the forebrain-specific APP/APLP-2 
double KO (Hick et al., 2015). Furthermore, knocking in a gene encoding the 
sAPPα sequence can rescue the alterations in spine density and morphology in 
APP-KO CA1 neurons (Weyer et al., 2014). In addition to the trophic effects on 
the KO backgrounds, exogenous recombinant sAPPα applied at low nanomolar 
concentrations enhances in vivo LTP in the dentate gyrus (DG) of anesthetized 
rats and N-methyl-D-aspartate (NMDA) -receptor mediated currents during high 
frequency stimulation on granule cells of acute hippocampal slices (Taylor et al., 
2008). sAPPα also interacts with the sushi1 subunit of the GABAB receptor, 
reducing the vesicular release probability (Pvr) in cultured murine hippocampal 
neurons and incrementing short term facilitation in acute hippocampal slices on 
SC/CA1 synapses (Rice et al., 2019). Several lines of investigation have also 
indicated that sAPPα could play a role as a modulator of the processing pathway 
of its parent molecule, APP, and mitigate neurodegeneration. Obregon et al. 
demonstrated that sAPPα physically interacts with BACE1 in vitro and prevents 
APP cleavage in the amyloidogenic pathway, reducing Aβ deposition and neuritic 
plaques in the hippocampus and cortex of transgenic APPSwe/PS1ΔE9 mice (for 




2012). Additionally, Deng et al. showed that sAPPα reduces tau phosphorylation 
by enhancing phosphorylation, and thus inactivation, of glycogen synthase 
kinase 3 β in SH-SY5Y cells and transgenic APPSwe/PS1ΔE9 mice (Deng et al., 
2015). Finally, overexpression of sAPPα rescues behavioral, morphological and 
biochemical changes in APPSwe/PS1ΔE9 transgenic mice, possibly by enhancing 
microglial function (Fol et al., 2016).  
α- or β- proteolysis of APP releases APP-CTFs. A wide range of neurotoxic 
effects are associated with increased concentrations of these peptides either by 
intraventricular injection, transgenic introduction in a murine model or by 
inhibiting the γ-secretase (Nalbantoglu et al., 1997; Song et al., 1998; Bittner et 
al., 2009; Mitani et al., 2012; Tamayev et al., 2012). Reduced density and altered 
shape of spines as well as astro- and microgliosis are morphological and 
histopathological consequences of APP-CTFs accumulation (Nalbantoglu et al., 
1997; Bittner et al., 2009). In addition, mice with increased brain concentrations 
of APP-CTFs exhibit reduced performance in spatial memory tests like the Morris 
water maze and the Y-maze, and in a contextual memory test (Nalbantoglu et al., 
1997; Song et al., 1998; Mitani et al., 2012). Regarding the electrophysiological 
consequences, LTP impairment has been associated with increased APP-CTFs 
in the hippocampus (Nalbantoglu et al., 1997). Moreover, recently these peptides 
have been shown to modulate presynaptic function via regulation of 
synaptotagmin-7 expression (Barthet et al., 2018). Accumulation of APP-CTFs in 
acute hippocampal slices of PS1/2 conditional double-KO reduces presynaptic 
facilitation and synaptic vesicle replenishment as well as synaptotagmin-7 
concentrations in the mossy fiber/CA3 synapses (Barthet et al., 2018).  
In addition to the canonical APP processing pathways, novel cleaving enzymes 
have been described whose products could modulate synaptic function. Namely, 
the proteolytic products of the η-secretase, in particular the Aη-α has been shown 
to impair LTP in SC synapses and to reduce neuronal CA1 activity in vivo (Willem 
et al., 2015). In an alternative cleavage path, the successive proteolysis of CTFs 
by caspases -3, -6 and -8 and γ- secretase produces an intracellular fragment 
denominated JCasp (Fanutza et al., 2015). The peptide binds in vitro to release 
machinery proteins such as synaptotagmin-2 and synaptobrevin-2, and its 
intracellular application reduces basal synaptic transmission and Pvr in APP-
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containing synapses of the CA1 region of acute hippocampal slices (Fanutza et 
al., 2015).  
 Physiological role of Aβ at the synapse 
Aβ, the APP product used in this study, is produced as a consequence of normal 
neuronal metabolism in the 40 amino acid variant, and its production is increased 
with neuronal activity (Haass et al., 1992; Mori et al., 1992; Seubert et al., 1992; 
Shoji et al., 1992; Kamenetz et al., 2003; Cirrito et al., 2005). Toxic effects aside, 
only few studies have been performed to decipher the physiological role of Aβ on 
synapses, most of them concluding that it enhances synaptic transmission (see 
Table 1). Experiments where picomolar concentrations of “aged” Aβ 1-42 (Aβ42) 
were injected into mouse hippocampi showed that the peptide enhanced LTP in 
the CA1 and improved performance in the Morris water maze in a mechanism 
dependent on the α7 nicotinic acetylcholine receptor (α7-nAchR) (Puzzo, 
Privitera, Leznik, Fà, Staniszewski, Palmeri and Arancio, 2008; Puzzo et al., 
2011). Similar effects were found by visualizing anti-synaptotagmin-1 antibody 
uptake in rat neuronal cultures treated with thiorphan, an inhibitor of neprilysin 
and Aβ degradation, or with application of exogenous Aβ at high picomolar 
concentration (Lazarevic et al., 2017). The latter experiment showed that Aβ 
increases the open time of α7-nAchR, enhances the activity of calcineurin (CN) 
and reduces cyclin-dependent kinase 5 (CDK5) activation, thus enlarging the 
recycling pool of synaptic vesicles and in turn diminishing the resting pool 
(Lazarevic et al., 2017). Using a similar approach, experiments on mouse 
hippocampal neurons using the fluorescent membrane dye FM 1-43 to image 




synaptic activity indicated that elevated Aβ concentrations within picomolar range 
increase the Pvr and switch synapses from a high-pass to a low-pass filter mode 
(Abramov et al., 2009). Furthermore, using APP- Förster resonance energy 
transfer (FRET) on similar settings, i.e. on mouse hippocampal neurons exposed 
to picomolar Aβ concentrations, it was shown that APP dimerization is necessary 
for the enhancement of Pvr in a G-protein mediated mechanism that involves an 
increase in calcium transients (Fogel et al., 2014). An alternative mechanism has 
also been proposed in which short exposure to high picomolar Aβ42 
concentrations enhances LTP and miniature excitatory postsynaptic currents 
(mEPSC) frequency in an actin-dependent manner, with no change in the 
number of active synapses (Koppensteiner et al., 2016). Interestingly, some of 
the studies mentioned above have indicated additionally that longer exposures 
or higher concentrations of Aβ are detrimental to synaptic transmission, in most 
of the cases inhibiting LTP accompanied by a poor performance on memory tests 
(Puzzo, Privitera, Leznik, Fà, Staniszewski, Palmeri and Arancio, 2008; 
Koppensteiner et al., 2016).  
Taken together these data point to a hormetic behavior of Aβ at the synapse, with 
picomolar concentrations exerting trophic functions, and nanomolar 
concentrations being synaptotoxic. This highlights the importance of fine-tuning 
Aβ concentrations at the synapse and predicts catastrophic effects for its 
dysregulation.  
 Physiopathology of Aβ and models to study AD 
 Aβ aggregation, preparations to model synaptotoxicity and the controversy 
of the toxic species 
Aβ belongs to the group of amyloid proteins which are characterized by its 
propensity to adopt an alternative β-sheet-rich conformation to its native one and 
aggregate into large, insoluble and thermodynamically stable fibrils, structurally 
characterized by in-register parallel cross-β (Soto, 2003; Petkova et al., 2005; Lu 
et al., 2013; Xiao et al., 2015; Soto and Pritzkow, 2018). The aggregation process 
of monomeric Aβ starts with a conformational change from the random coil 
structure into a β-strand (Hou et al., 2004). Aβ primary structure is one of the 
factors with greatest influence in this interconversion. Using biochemical and 
imaging tools, Bitan et al. observed that Aβ 1-40 (Aβ40) and Aβ42 aggregate in 
12 
 
a different fashion, inducing the formation of distinct oligomeric species (Bitan et 
al., 2003). A potential explanation for the difference in aggregation propensity 
between the isoforms comes from nuclear magnetic resonance (NMR) 
spectroscopic studies, in which an increased rigidity was observed in the C-
terminus of Aβ42 which contains the extra isoleucine-alanine residues not 
present in the Aβ40 (Yan and Wang, 2006). In addition, several APP mutations 
within the Aβ region, in the vicinity of the α-cleavage site, result in enhanced 
amyloidogenicity (see section 1.3.2). Truncations in the Aβ N-terminus have also 
been observed in the AD brain, which can enhance the aggregation propensity 
in vitro (Pike et al., 1991; Schieb et al., 2011). Additionally, several 
posttranslational modifications have been reported in AD (reviewed in Kummer 
and Heneka, 2014). One of the most extensively studied modifications is 
pyroglutamylation, which enhances Aβ amyloidogenicity (He and Barrow, 1999). 
Pyroglutamate-3 Aβ displays a similar neurotoxic profile to Aβ42 and can be 
found in brains from several AD mouse models (Kawarabayashi et al., 2001; 
Tekirian et al., 2002; Christensen et al., 2008; Jawhar et al., 2011).  
Fibrils of Aβ constitute the core of the neuritic plaques found in the brains of 
patients suffering from AD. Despite representing a pathognomonic feature of the 
disease, accumulation of plaques correlates poorly with the symptoms of 
dementia (see section 1.1). This observation led to questioning the toxicity of 
fibrils per se and to hypothesize that the soluble oligomeric species generated 
during aggregation could be the culprit for neurodegeneration. Pioneering studies 
using human brain tissue demonstrated that soluble Aβ concentrations serve to 
correctly classify and distinguish between AD patients, controls and high-
pathology controls, i.e. non demented individuals with great load of neuritic 
plaques (Lue et al., 1999; McLean et al., 1999). But “Aβ oligomers” are far from 
being a unique, structurally well-defined species (Benilova, Karran and De 
Strooper, 2012). On the contrary, the nature of the toxic oligomer depends on the 
system used for its production and the tools to characterize its structural 
properties. Several criteria can therefore be used to classify oligomeric Aβ, 
namely the method of obtention (brain-derived, naturally secreted, recombinant 
or synthetic) (reviewed in Benilova, Karran and De Strooper, 2012; and Masters 
and Selkoe, 2012), whether they are intermediates in the production of fibrils (“on-




conformation-specific antibodies (A11 or OC positive, among others) (Kayed et 
al., 2010).  
One of the most widely used oligomeric species are dimers - trimers of Aβ 
naturally secreted by the 7PA2 line of Chinese hamster ovary (CHO) cells, which 
stably express the APPInd (see section 1.3.2) and were developed in the Selkoe 
lab to investigate Aβ toxicity (Walsh et al., 2002; Shankar et al., 2007, 2008). 
Another toxic oligomeric form obtained using synthetic Aβ42 by the Klein lab are 
the Aβ-derived diffusible ligands (ADDLs), mostly of globular structure and 
proposed to be off-pathway intermediates (Lambert et al., 1998; Zempel et al., 
2010). Within the group of brain-derived oligomers is the Aβ*56, a dodecamer 
which has been purified from Tg2576 mice brains (Lesné et al., 2006). All of the 
mentioned oligomeric species induce cognitive impairment in mice or rats and 
have been related to tau phosphorylation, N-methyl-D-aspartate receptor-
mediated toxicity, changes in synaptic transmission and cytotoxicity in neuronal 
hippocampal cultures (reviewed in Benilova, Karran and De Strooper, 2012).  
The main advantage of in vitro generation of Aβ oligomers is the possibility of 
controlling many of the factors that modulate aggregation. Synthetic peptides 
allow the use of a single, well-defined and pure Aβ isoform and additionally, the 
buffer composition, pH, temperature, agitation conditions and salt content can be 
manipulated to control the kinetics of aggregation. One of the critical steps in 
synthetic Aβ species preparation is the peptide dissolution (Teplow, 2006). It is 
possible that aggregates are formed during Aβ synthesis, especially in the case 
of the more amyloidogenic Aβ42, which can later act as nucleation seeds 
(Nilsson, 2004). In order to avoid rapid and uncontrolled aggregation, several 
strategies have been utilized to remove large, pre-formed aggregates like 
dissolution in organic solvents or alkaline solutions, size-exclusion 
chromatography and centrifugation (Fezoui et al., 2000; Teplow, 2006; Jan, 
Hartley and Lashuel, 2010). Once a monomeric solution is obtained, the 
aggregation process must be monitored and it is necessary to characterize the 
yielded preparation using biochemical and morphological tools in order to 
correlate the oligomers structure to putative toxic effects (Jan, Hartley and 
Lashuel, 2010). However, criticism has been raised concerning the in vitro Aβ 
preparations. While naturally produced dimers-trimers or recombinant oligomers 
are toxic at nanomolar concentrations, usually micromolar concentrations are 
14 
 
needed to reach a similar effect using synthetic peptides (Townsend, Mehta and 
Selkoe, 2007; Finder et al., 2010). Additionally, the question remains, as to 
whether the in vitro generated species are a faithful representation of the in vivo 
situation, and therefore the experimental results can be translated to the human 
AD brain.  
Finally, it is worth highlighting that still the nature of the “toxic oligomeric species” 
has neither been fully elucidated nor validated in the human situation. The 
concept of oligomeric Aβ toxicity arose, as stated before, with the failure of Aβ 
fibril deposition to correlate with and explain cognitive decline. In order to avoid 
a superficial description of circumstantial phenomena, it is highly desirable that 
studies of Aβ toxic effects always include a thorough description of the 
preparation used.  
 Considerations about murine models of AD 
In order to study the disease progression and mechanisms, several attempts of 
recapitulating AD in a murine model have been made and currently up to 169 
different mouse lines are available (Research Models Search | ALZFORUM, 
2019). In principle, a good murine model must exhibit the histopathological 
features of AD, namely synaptic and neuronal loss accompanied by the presence 
of amyloid plaques and neurofibrillary tangles in the areas affected in patients 
and within a time frame that incorporates the impact of aging but also provides a 
therapeutic window for drug testing (Götz, Bodea and Goedert, 2018). 
Furthermore, these histopathological alterations must be accompanied by 
progressive behavioral deficits that recapitulate the cognitive decline typical of 
AD. Mice do not develop AD endogenously and their Aβ sequence differs from 
the human in three amino acids, which is sufficient to prevent aggregation. For 
this reason, it is necessary to induce the expression of human Aβ in order to 
reproduce an AD-like pathology (Esquerda-Canals et al., 2017). The most widely 
used mouse models are transgenic, i.e. they have been created by random 
incorporation of one or multiple human genes of interest in the murine genome, 
such as mutant forms of APP or PS1 (Götz, Bodea and Goedert, 2018). To date, 
53 APP mutations have been reported, 31 of which are known to be pathogenic 
(Mutations Search | ALZFORUM, 2019). APP mutations can be grouped 




within the molecule (Haass et al., 2012). Mutations around the α- site, such as 
the Dutch (E693Q) and Arctic (E693G) mutations, are contained within the Aβ 
region and are pathogenic in that they enhance amyloidogenicity, i.e. Aβ 
propensity to misfold and aggregate (Levy et al., 1990; Nilsberth et al., 2001). 
Mutations close to the cleavage site of the β-secretase, of which the Swedish 
mutation (K670/M671L) is an example, enhance the APP-BACE interaction and 
therefore the amyloidogenic processing, increasing the Aβ concentration (Mullan 
et al., 1992). Finally, the mutations nearby the γ-site, such as the Indiana 
mutation (V717F), alter the γ-cleavage increasing the Aβ42/Aβ40 ratio (Murrell 
et al., 1991). Some examples of transgenic mouse models carrying these 
mutations are the PDAPP, the first AD mouse model developed, which expresses 
the APP Indiana mutation under the platelet-derived growth factor-β promoter; 
the Tg2576 that carries the APP Swedish mutations; or the J20, which combines 
the Indiana and Swedish mutations and displays and earlier onset of AD-like 
pathology, among others (Games et al., 1995; Hsiao et al., 1996; Mucke et al., 
2000).  
In addition, there are a great number of mutations in the PSEN1 gene (<200) 
most of which are pathogenic. The most frequently introduced mutations in AD 
murine models are the M146V, M146L, L286 and ΔE9, all of which increase the 
Aβ42/Aβ40 ratio (Esquerda-Canals et al., 2017). In order to recapitulate the AD 
pathology, these mutations have to be co-expressed with APP mutants as in the 
case of the APPSwe/PS1ΔE9 or the 5xFAD (APPSwe,Lnd,Flo /PS1M146V, L286) mice, 
accelerating Aβ deposition and the onset of cognitive decline (Jankowsky et al., 
2001; Oakley et al., 2006).  
The mouse models expressing pathogenic variants of human APP alone or 
accompanied by PS1 mutations exhibit functional defects like impaired LTP and 
basal synaptic transmission starting at 6 months of age, which is accompanied 
by poor performance in hippocampal-dependent tasks that can appear even 
earlier depending on the animal model (Spires-Jones and Knafo, 2012). 
Interestingly, none of these models show deposition of hyperphosphorylated tau 
in neurofibrillary tangles, thus not recapitulating the whole spectrum of AD 
pathology (Götz, Bodea and Goedert, 2018). In order to model tau deposition, 
transgenic mouse models have been combined, such as the case of the 3xTg 
mice, which carry the APPSwe together with PS1M146V and tauP301L (Oddo et al., 
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2003). Finally, knock-in and KO mice have also been developed to model the 
effects of protein variants which act as risk factors for late-onset AD such as ApoE 
and triggering receptor expressed on myeloid cells 2, among others (reviewed in 
Götz, Bodea and Goedert, 2018).  
 Consequences of Aβ accumulation on central synapses 
Several alterations in synapse quantity, structure and function have been 
described associated with Aβ accumulation (see Table 2).  
1.3.3.1. Alterations of synapse number and morphology 
A reduction in the number of synapses is one of the hallmarks of the AD brain 
and was proposed to be the most relevant neuropathological correlate of 
cognitive impairment more than twenty years ago (Scheff, DeKosky and Price, 
1990; Terry et al., 1991; Ingelsson et al., 2004; Duyckaerts, Delatour and Potier, 
2009; Serrano-Pozo et al., 2011). More recently, a study using the J20 and 
APPswe/PS1ΔE9 mouse models of AD associated synapse loss with abnormal 
synapse pruning by phagocytic microglia activation (Hong et al., 2016). In 
addition, a meta-analysis of 22 publications utilizing human tissue confirmed that 
synapses were reduced in AD-brain-affected areas and a larger loss of 
presynaptic markers was found in an additional review including 67 synaptic 
proteins (de Wilde et al., 2016). However, this concept has been challenged by 
a study including samples from a large cohort (171 patients spread in five 
degrees of cognitive status) in which a reduction in synaptic proteins was poorly 
correlated with cognitive decline, and the correlation was found mostly in the late 




stages of dementia (Poirel et al., 2018). Despite this recent controversy, the 
hypothesis that synapse loss contributes to impaired memory in AD remains 
widely accepted.  
In addition to the gross reduction in synapse quantity, Aβ accumulation has also 
been linked to morphological anomalies in synapses. Postsynaptic changes 
associated with Aβ pathology include a simplification of the dendritic tree and a 
loss of dendritic spines. A reduction of spine density in the hippocampus has 
been observed in transgenic mouse models of AD such as the J20 and 
APPswe/PS1ΔE9 (Moolman et al., 2004). In addition, Tg2576 mice showed a loss 
of spines near amyloid plaques in the cerebral cortex (<15 µm away) with no 
changes in spine morphology (Spires et al., 2005). Conversely, further studies in 
mice carrying this mutation indicated that the spine loss preceded plaque 
formation in the DG, which was accompanied by reduced freezing in fear 
conditioning tests (Jacobsen et al., 2006). Regarding dendritic arborization, a 
reduction in apical dendrite branching in the somatosensory cortex was observed 
in aged (11-months old) Tg2576 mice. Furthermore, cultured cortical neurons 
from these mice showed a reduced number of dendritic crossings in Sholl 
analysis (Wu et al., 2010). Although the pathogenic role of plaques remains 
controversial, the data obtained using AD mice models strengthen the inverse 
association between Aβ accumulation and spine number.  
Similar effects to those found in murine models are observed upon increasing 
extracellular Aβ concentration in hippocampal slices by means of APP 
overexpression, incubation with naturally secreted oligomers or application of 
Aβ species purified from brains of patients suffering from AD (Tsai et al., 2004; 
Shankar et al., 2007, 2008; Wei et al., 2010). These effects on spine density have 
been associated with reduced NMDA currents, loss of surface α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and activation of 
the CN - cofilin pathway (Hsieh et al., 2006; Lacor et al., 2007; Shankar et al., 
2007; Wu et al., 2010). Additionally, a direct interaction of Aβ oligomers with 
postsynaptic densities (PSD) has been described, accompanied by a reduction 
in PSD-95 staining and spine shrinkage observed in cell cultures as well as in 
murine and human brain tissue (Lacor et al., 2004; Koffie et al., 2009).  
Axons and presynaptic terminals are also altered in AD. Aβ accumulation has 
been detected within axons and axonal terminals of patients suffering from AD 
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with immunolabelling and electron microscopy (EM) (Kokubo et al., 2005). In 
addition, in synaptosomes purified from brains of AD patients, Aβ colocalizes 
preferentially with the remaining VGluT1-positive terminals (Sokolow et al., 
2012). An impaired vesicle trafficking through the axon and altered formation of 
presynaptic boutons induced by chemical LTP have additionally been reported 
upon Aβ exposure in cultured rat hippocampal neurons (Park et al., 2017). In 
accordance with these data, incubation of mouse hippocampal neurons with high 
nanomolar concentrations of synthetic Aβ40 for 24 hours has been associated 
with a reduction in the total vesicle pool evidenced by EM and decreased 
expression of pre- and postsynaptic proteins in Western blots (Parodi et al., 
2010).  
1.3.3.2. Alterations in synaptic transmission 
The functional correlates of the structural changes described in the previous 
section include a reduced basal synaptic transmission with lower Pvr and altered 
short-term plasticity, impaired LTP and enhancement of long-term depression, 
which have been linked to a lack of memory formation in behavioral tests. In 
mouse models of AD, loss of LTP at SC/CA1 synapses is the earliest sign of 
electrophysiological hippocampal dysfunction, affecting animals as young as 2-3 
months of age (Larson et al., 1999; Gong et al., 2004; Trinchese et al., 2004; Ma 
et al., 2010; reviewed in Spires-Jones and Knafo, 2012). After 6 months of age, 
basal synaptic transmission is additionally impaired in the AD mouse lines most 
frequently used in basic research (Chapman et al., 1999; Fitzjohn et al., 2001; 
Oddo et al., 2003; Gong et al., 2004; Trinchese et al., 2004; Kimura and Ohno, 
2009; Kimura, Devi and Ohno, 2010). Regarding short-term plasticity, only the 
PDAPP line shows a reduced PPF, which is observed in 4-5 months old mice. 
Since these animals do not exhibit amyloid deposition, the authors propose that 
oligomeric Aβ or other soluble APP product could alter presynaptic calcium and 
disrupt the mechanisms of transmitter release (Larson et al., 1999). Conversely, 
PPF is enhanced in acute hippocampal slices from aged 27-29 month old mice 
form the same mouse line, which exhibit a striking loss of synapses but, 
surprisingly, the remaining ones display a normal function with no presynaptic 




An equivalent phenotype to that induced by transgenic expression of human APP 
can be triggered by exogenous application of Aβ aggregates. Altered LTP 
induction has been found in organotypic slice cultures exposed to exogenous 
oligomeric Aβ and also in in vivo recordings from rats injected with Aβ (Lambert 
et al., 1998; D. M. Walsh et al., 2002; Hsieh et al., 2006). Similarly, a failure in 
LTP induction at SC/CA1 synapses was the most frequently reported functional 
defect in murine WT acute hippocampal slices exposed to high Aβ concentrations 
in the nanomolar range (Shankar et al., 2008; S. Li et al., 2011; Ripoli et al., 
2013). Furthermore, basal synaptic transmission can additionally be affected in 
acute slices by exposure to exogenous Aβ concentrations as low as 50 nM, as 
indicated by a progressive reduction of the slope of field excitatory postsynaptic 
potentials in the CA1 region (Talantova et al., 2013). Finally, dissociated mass 
and autaptic hippocampal neurons exposed to high nanomolar (200 – 500 nM) 
extracellular Aβ concentrations for 24 hours showed a reduced evoked response 
accompanied by a smaller readily releasable pool (RRP) and decreased mEPSC 
frequency (Parodi et al., 2010; Ripoli et al., 2013). Interestingly, when Aβ was 
allowed to diffuse through the patch pipette, i.e. applied intracellularly, an 
increased paired pulse ratio was observed indicating a possible reduction in the 
Pvr (Ripoli et al., 2014). 
1.3.3.3. Neuronal network dysfunction 
In association with the changes mentioned in the previous sections and possibly 
as their consequence, AD affects the functioning of neuronal networks (reviewed 
in Palop and Mucke, 2016). Using functional magnetic resonance imaging, it has 
been observed that patients with high amyloid deposition, mild cognitive 
impairment or carriers of AD associated mutations showed hippocampal 
hyperactivation and reduced deactivation of the default mode network (DMN) 
during memory encoding tasks, which has been associated with poor memory 
formation in healthy individuals (Bookheimer et al., 2000; Sperling et al., 2009, 
2010; Quiroz et al., 2010; Bakker et al., 2012; Sepulveda-Falla, Glatzel and 
Lopera, 2012). Conversely, patients at later stages of AD continued suffering 
from a deactivation deficit of the DMN but displayed hippocampal hypoactivation 
(Celone et al., 2006). The role of the hippocampal hyperactivation in the early 
stages of AD is not yet clear, but growing evidence suggests that it might be part 
of the pathophysiology of AD (Bakker et al., 2012). Network hypersynchrony is 
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another dysfunction associated to amyloid accumulation and AD-related 
mutations observed in mouse models, for which expression of WT soluble tau is 
a requisite (Palop et al., 2007; Roberson et al., 2007; Minkeviciene et al., 2009; 
Bezzina et al., 2015; Siwek et al., 2015). As a consequence of this network 
abnormality, patients suffering from AD have a 7-8-fold increase in the incidence 
of seizures when compared to controls, which is especially higher in patients 
suffering from early-onset AD (Amatniek et al., 2006; Imfeld et al., 2013; Vossel 
et al., 2013). In addition, AD is associated with an impairment of interneuron 
function. Inhibitory interneurons, especially parvalbumin-positive cells, are 
responsible of the generation of gamma oscillations in the brain and regulate 
cross-frequency interactions, both of which are necessary for effective memory 
encoding (Sederberg et al., 2006; Tort et al., 2009). Several lines of evidence 
indicate that the power of gamma oscillations and gamma-theta coupling are 
impaired in AD murine models and human patients (Ittner et al., 2010; Verret et 
al., 2012; Goutagny et al., 2013; Gurevicius, Lipponen and Tanila, 2013). The 
impairment of inhibitory interneuron function could explain the deactivation 
deficits in the DMN, but evidence supporting this hypothesis is still missing.  
1.3.3.4. Summary of pathological changes induced by Aβ 
On the whole, a great body of evidence supports the hypothesis that Aβ exposure 
at non-physiological concentrations has deleterious consequences on synapse 
number, morphology and function. Reduced number of synapses, loss of 
dendritic spines and morphologically aberrant axon terminals can only lead to an 
impaired synaptic transmission, plasticity and network function. The most 
prominent defects are observed in basal synaptic transmission and LTP, which 
are necessary for memory formation. At the network level, these mentioned 
phenomena and possibly others, result in abnormal activation-deactivation, 
network hypersynchrony and impaired oscillatory rhythms associated with 
dysfunction of inhibitory interneurons. The large number of models used to study 
Aβ-related changes can partly explain the diversity in the observed synaptotoxic 
effects. However, it is possible that this multiplicity of toxic effects coexists in the 
human AD brain acting as building blocks for cognitive decline, indicating that 





 Proposed mechanisms of Aβ toxicity 
Although there is a consensus about the main consequences of Aβ deposition in 
the human and murine brain, the underlying mechanisms of toxicity have not 
been yet fully elucidated. However, a number of hypotheses have been proposed 
based on the observed Aβ interactions and biochemical, morphological and 
functional alterations in neurons upon treatment (Figure 3).  
1.3.4.1. Aβ receptors  
Several cell surface molecules interact with Aβ (reviewed in Sakono and Zako, 
2010; and Kam, Gwon and Jung, 2014). However, the best candidates are those 
“receptors” that bind oligomeric over monomeric species of Aβ with nanomolar or 
higher affinity and have been validated by the absence of Aβ toxicity in several 
models upon its genetic deletion (Smith and Strittmatter, 2017). One of the most 
prominent candidates is the cellular prion protein (PrPC), a 
glycophosphatidylinositol-anchored protein located at postsynaptic sites that 
binds Aβ oligomers with nanomolar affinity (Laurén et al., 2009). Moreover, PrPC 
null mice are protected from Aβ-induced LTP impairment and age-related 
cognitive decline in murine models (Laurén et al., 2009; Gimbel et al., 2010). It 
has been proposed that the metabotropic glutamate receptor 5 (mGluR5) acts as 
a coreceptor with PrPC, which upon Aβ-oligomer binding mediate the activation 
of neuronal Fyn (Um et al., 2012, 2013). The activation of mGluR5-Fyn then 
would lead to a transient increase of surface NMDA receptor with excitotoxicity, 
followed by a reduction of surface receptors and spine loss (Um et al., 2012). The 
Leukocyte immunoglobulin-like receptor subfamily B2 (LilrB2) and its murine 
homolog, paired Ig-like receptor B (PirB), were initially described as receptors for 
the major histocompatibility complex class I. Both proteins were subsequently 
found to be expressed in neurons and it was proposed that they play a role in 
stabilizing neural circuits (Syken et al., 2006). LilrB2/PirB constitute nanomolar-
affinity receptors for oligomeric Aβ and PirB KO mice are resistant to functional 
and behavioral amyloid-induced defects (Kim et al., 2013). As activated cofilin is 
not found in PirB KO mice, it has been suggested that Aβ oligomers binding to 
PirB would be necessary to activate cofilin, an actin depolymerizing factor that 
promotes spine retraction (Kim et al., 2013). Likewise, the lack of IgG Fcγ 
receptor II-b (FcγRIIb) and erythropoietin-producing hepatocellular A4 
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Figure 3. Mechanisms of Aβ synaptotoxicity. The schematic shows the synaptic alterations 
induced by oligomeric Aβ. 1) Binding of Aβ oligomers to PrP and mGluR5 activates Fyn kinase, 
leading to loss of surface NMDA receptors. 2) Interaction of Aβ oligomers with LilrB2/PirB induces 
cofilin activation, actin depolymerization and spine retraction. 3) Interaction of oligomeric Aβ with 
the FCγRIIb receptor enhances JNK activity, which results in c-Jun mediated transcription of pro-
apoptotic genes. 4) Oligomeric Aβ binds syntaxin-1a and blocks vesicle fusion. 5) Synaptophysin-
1 interaction with Aβ oligomers disrupts the binding of the former with synaptobrevin-2, which at 
first enhances Pvr but leads to missorting of synaptobrevin-2 at a later stage. 6) Oligomeric 
Aβ activates CaMKIV, which phosphorylates synapsin and impairs its interaction with the actin 
cytoskeleton, altering synaptic vesicle trafficking. 7) Aβ oligomers reduce dynamin-1 cellular 
concentrations, impairing vesicle endocytosis. 8) mGluR5 activation by Aβ oligomers activates 
phospholipase C, which leads to PIP2 depletion and Pvr reduction. 9) Oligomeric Aβ induces de 
novo translation of mislocalized tau in a Fyn-dependent mechanism.10) Tau cross-links synaptic 
vesicles, reducing their mobility and the release rate at the terminal. 11) Dendritic tau induces 
Fyn activation. 12) Oligomeric Aβ interacts with the plasma membrane and disrupts its integrity 





prevent Aβ toxicity in vitro and in mouse models (Kam et al., 2013; Fu et al., 
2014). Some other cell surface molecules have been extensively studied in the 
context of AD, such as p75 neurotrophin receptor (p75NTR), the neuronal insulin 
receptor and the receptor for advanced glycation endproducts (Rabizadeh et al., 
1994; María Frade, Rodríguez-Tébar and Barde, 1996; Kuner and Hertel, 1998; 
Deane et al., 2003; Zhao et al., 2008; Vodopivec et al., 2009). Although the 
binding to Aβ and toxicity through a variety of intracellular cascades has been 
proposed, the role of these receptors has not yet been validated by strategies of 
genetic deletion. Finally, some surface molecules can bind monomeric Aβ with 
picomolar affinity, such as the α7-nAchR. These receptors most likely mediate 
the physiological functions of Aβ described in the section 1.2.4. 
1.3.4.2. Aβ interaction with presynaptic proteins and lipids 
Aβ also interacts with proteins within the presynaptic terminal (reviewed in 
Ovsepian et al., 2018). A reduction in soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE) complexes has been observed in 
APPswe/PS1ΔE9 mice brains accompanied by a normal concentration of the 
individual SNARE proteins (Sharma, Burré and Südhof, 2012; Yang et al., 2015). 
Moreover, an interaction between the SNARE motif of syntaxin-1a and Aβ 
oligomers has been shown, accompanied by a defect in fusion in a vesicle 
content-mixing assay, with unmodified docking in vitro (Yang et al., 2015). In 
addition to the syntaxin-1a interaction, Aβ oligomers are internalized by 
dissociated hippocampal rat neurons when applied extracellularly and bind 
synaptophysin-1, disrupting its interaction with synaptobrevin-2 (Russell et al., 
2012). This effect has been linked to an increase in the RRP in the short term, 
but the authors argue that a chronic sequestration of synaptophysin-1 by Aβ 
oligomers alters the sorting and endocytosis of synaptobrevin-2, leading to long-
term deficits in transmitter release. Additionally, Aβ oligomers may alter 
intersynaptic vesicle trafficking by means of disrupting the actin - synapsin 
interaction, as a consequence of synapsin phosphorylation by activated 
calcium/calmodulin-dependent protein kinase type IV (CaMKIV) (Park et al., 
2017). Exposure to oligomeric Aβ induced a reduction in dynamin 1 at 
transcriptional and posttranscriptional levels in a NMDA-calpain dependent 
manner, which has been correlated with deficits in endocytosis at the presynaptic 
terminal and depletion of the RRP in cultured rat hippocampal neurons (Kelly, 
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Vassar and Ferreira, 2005; Kelly and Ferreira, 2006, 2007). Finally, increased 
amounts of Aβ reduced the concentration of phosphatidylinositol-4,5-
diphosphate (PIP2) in acute hippocampal slices from AD mice as well as in WT 
slices and WT dissociated neurons treated with 400 nM oligomeric Aβ (He et al., 
2019). The loss of PIP2 at the neuronal membrane led to a reduction of Pvr, in a 
process that required mGluR5 and PrPC. 
1.3.4.3. Tau mediated effects 
Tau is an amyloid protein itself and can also act as a downstream toxic effector 
of Aβ. In its random-coil native conformation, tau fulfills its neuronal physiological 
function in the axon, binding to and stabilizing the microtubule cytoskeleton 
(reviewed in Guo, Noble and Hanger, 2017). However, under pathological 
conditions it can be relocated via hyperphosphorylation (Hoover et al., 2010; Xia, 
Li and Götz, 2015; Amar et al., 2017) and also synthesized de novo in the 
somatodendritic compartment through an Aβ-Fyn-dependent mechanism (Li and 
Götz, 2017). Hyperphosphorylated tau has been shown to inhibit microtubule 
assembly and affect the cytoskeleton stability by binding MAP (microtubule 
associated protein) 2 and normal tau (Li et al., 2007). In addition, oligomeric tau 
has been linked to memory loss in vivo and neuronal death with a reduction of 
synaptic markers in the injected areas (Lasagna-Reeves et al., 2011). Upon 
mislocalization, tau present at the presynaptic terminal can impair 
neurotransmitter release by anchoring synaptic vesicles to filamentous actin (F-
actin) and restricting their mobility (Zhou et al., 2017). On the postsynaptic side, 
dendritic tau increases the level of Fyn in spines, enhancing Aβ-mediated 
transient excitotoxicity and later loss of NMDA receptors (Ittner et al., 2010). 
Importantly, tau has been shown to be required for Aβ-mediated LTP impairment, 
since hippocampal slices from tau KO mice were protected from Aβ toxicity 
(Shipton et al., 2011). 
1.3.4.4. Effects on the plasma membrane, pore formation and calcium 
dyshomeostasis 
As a hydrophobic peptide, Aβ can interact with lipids at the plasma membrane. 
Disruption of membrane integrity has been proposed as toxicity mechanism and 
related to ion dyshomeostasis (Narayan et al., 2013). In artificial phospholipidic 




proteins) reduced the dielectric barrier for ions and increased membrane 
conductance (Kayed et al., 2004). Moreover, a detergent-like effect has been 
demonstrated for Aβ42 oligomers on mica-supported lipid bilayers and large 
unilamellar vesicles using atomic force microscopy (AFM) and EM (Bode et al., 
2019). In the same study the authors showed that fibrillar Aβ only interacted with 
the membrane leaflet that is exposed to the peptide, with less deleterious 
consequences when compared to its oligomeric counterparts (Bode et al., 2019). 
Alternatively, Aβ oligomers have been proposed to cross the lipidic membranes, 
accompanied by an influx of calcium ions (Drews et al., 2016). As Aβ can bind 
artificial bilayers directly, specific lipids have been proposed as candidates to 
facilitate the Aβ - plasma membrane interaction. For example, the 
monosialotetrahexosylganglioside ganglioside (GM1) binds Aβ42 oligomers with 
great affinity and is necessary for Aβ-induced LTP impairment and calcium 
dyshomeostasis (Ariga et al., 2001; Hong et al., 2014; Evangelisti et al., 2016). 
In addition, subpopulations of cells in PC12, GT1-7 and primary rat neuronal 
cultures susceptible to Aβ toxicity expose phosphatidylserine on their surface, 
and its levels are correlated with Aβ binding (Simakova and Arispe, 2007).  
Besides the described transient binding or crossing, Aβ oligomers can 
additionally assembly within membranes and span them forming ion-conducting 
pores. Channel-like activity was first described in artificial palmitoyl-oleoyl 
phosphatidylethanolamine (POPE)/ phosphatidylserine (POPS) bilayers 
exposed to Aβ-containing liposomes (Arispe, Rojas and Pollard, 1993). The 
formation of these amyloid pores was further investigated using other techniques 
like double-dip (Arispe, Pollard and Rojas, 1993) and excised patches of 
hypothalamic GT1-7 cells (Kawahara et al., 1997). These studies described Aβ40 
or Aβ42 channels with multiple conductance levels ranging from 300 to 3500 pS, 
that were cation-selective and could be blocked by zinc and aluminum, among 
other substances (Arispe, Pollard and Rojas, 1993, 1996; Kawahara et al., 1997). 
In an attempt to correlate cytotoxicity with Aβ aggregation states and pore 
formation, a multivariate analysis was performed using Aβ40 and Aβ42, 
analyzing the mentioned parameters over the course of 20 days of Aβ 
aggregation (Prangkio et al., 2012). This study concluded that oligomeric 
isoforms of both Aβ40 and Aβ42 could induce pore formation in artificial bilayers 
and displayed concomitantly the highest cytotoxicity. In another set of 
experiments, seeking to describe the impact of amyloid pore formation in 
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neuronal membranes, cell-attached recordings were performed in human 
embryonic kidney (HEK) 293 cells, and the same oligomeric preparation was 
applied to rat primary hippocampal neurons (Sepúlveda et al., 2014). The authors 
showed that intra-pipette oligomeric Aβ induced a progressive increase in HEK 
293 cells membrane permeability, in a “perforated-patch-like” effect, with no 
evidence of discrete pore formation. Subsequently, Aβ oligomers were applied to 
hippocampal neurons from the patch pipette together with a fluorescent glucose 
analog during cell-attached recordings.  The authors described that after 30 
minutes the membrane perforations grew in size enough to allow the glucose 
analog entry into the cytoplasm. Similarly, cell-attached recordings on HEK 293 
cells described amyloid pore formation with an initial cation selectivity, which 
shifted towards an ohmic behavior at the end of the experiments. In the same set 
of experiments, cultured hippocampal neurons incubated with a similar 
preparation of oligomers as used the for patch-clamp experiments displayed a 
loss of synaptobrevin-2 puncta, which was interpreted as a morphological 
correlate of amyloid pore toxicity (Sepúlveda et al., 2014). In order to visualize 
the amyloid pores, AFM was combined with florescence microscopy. These 
experiments showed that artificial vesicles reconstituted with Aβ42, in whose 
surface Aβ could be observed by AFM, displayed an increased calcium influx that 
could be blocked by zinc application (Rhee, Quist and Lal, 1998). Moreover, AFM 
at high resolution revealed globular doughnut-shaped oligomers on Aβ40-
reconstituted lipid bilayers (Quist et al., 2005). These same aggregates induced 
channel-like behavior in Aβ-reconstituted dioleoyl-glycero-phosphocholine 
(DOPC) membranes. In support of an Aβ pores-mediated ion dyshomeostasis, 
intracellular calcium was increased in hypothalamic GT1-7 cells exposed to 10 
µM Aβ40 in the course of minutes, as revealed by fluorescence intensity 
measurements using the calcium dye Fura2-AM (Kawahara et al., 2000). 
Furthermore, imaging of transmembrane calcium currents of Xenopus laevis 
oocytes with a different fluorescent calcium indicator, Fluo4, and total internal 
reflection fluorescence (TIRF) microscopy revealed similar channel-like behavior 
to the described electrophysiological observations for Aβ42, with multiple 
permeability levels, voltage dependence and variable open probabilities 
(Demuro, Smith and Parker, 2011). Finally, a recent study on excised patches 
from HEK 293 cells showed that only Aβ42 oligomers (and not Aβ40) could 




conductance levels between 300 - 1000 pS (Bode, Baker and Viles, 2017). The 
channels described in these experiments do not display cation selectivity. 
Interestingly, for the first time since pore formation was observed, the authors 
stated the success rate of Aβ42 pore formation, which they observed in only 
~35% of the cases, although Aβ had been applied at concentrations that would 
theoretically saturate the patch membrane.  
By means of its varied effectors, calcium is a potent second messenger that 
controls manifold cellular processes ranging from exocytosis to cell death 
(reviewed in Brini et al., 2014). Among other mechanisms, disruption of the 
plasma membrane as an ionic barrier and dysfunction of endoplasmic reticulum 
calcium receptors (Ferreiro, Oliveira and Pereira, 2004) induced by Aβ can lead 
to calcium dyshomeostasis with deleterious consequences to neuronal function, 
such as calpain and calcineurin activation leading to enhanced long-term 
depression, impaired LTP and cytoskeleton alterations with spine retraction 
(reviewed in Bezprozvanny, 2009).  
1.3.4.5. Conclusions about Aβ toxicity mechanisms 
In conclusion, despite the large amount of work on the molecular toxicity 
mechanisms of Aβ, the described findings are not yet conclusive. The role of the 
putative Aβ downstream molecules and pathways has to be pondered over in the 
context of the human disease and ultimately be validated by clinical trials showing 
the prevention, detention, or reversion of cognitive decline by modulating the 
proposed targets.  
 Therapeutic strategies in AD 
A cure for AD has been intensively searched for in the last decades. With each 
hypothesis that aimed to explain AD physiopathology, corresponding drugs were 
developed to target and correct the putative toxic changes (see Table 3). Due to 
the hypothesis of cholinergic imbalance (Davies and Maloney, 1976), the first 
drugs approved by the United States Food and Drug Administration (US FDA) to 
treat AD were the acetylcholinesterase inhibitors. Within this group are tacrine, 
approved in 1993 but almost not used to date due to its hepatotoxicity; donepezil, 
approved in 1996 to treat all the clinical stages of AD; and rivastigmine - 
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galantamine, approved in 2000 and 2001 respectively to treat mild to moderate 
AD (reviewed in Aisen, Cummings and Schneider, 2012). Although they have 




different modes of action for cholinesterase inhibition, all acetylcholinesterase 
inhibitors are equally effective for the treatment of mild to moderate AD and have 
a good safety profile, with gastrointestinal side effects being the most commonly 
found (Birks, 2006). Memantine, an uncompetitive NMDA channel blocker, is the 
remaining drug approved by the US FDA to treat AD (Chen and Lipton, 2006). It 
can prevent Aβ-associated toxicity in animal models and has been proven 
effective and well-tolerated in patients at moderate to severe stages of the 
disease, alone or in combination with donepezil (Martinez-Coria et al., 2010; 
McShane et al., 2019).  
Since 1992, when the amyloid cascade hypothesis was posited, Aβ secretion, 
aggregation, deposition and clearance have been targeted for drug development. 
The main approaches used to date have been active and passive immunization 
to enhance Aβ clearance and impair aggregation, and the use of β- and γ- 
secretase inhibitors to reduce its production (Schenk, Basi and Pangalos, 2012; 
Panza, Lozupone, Logroscino, et al., 2019). Active immunization is the exposure 
to an Aβ-antigen that can trigger an immune response in the host. Pre-
aggregated Aβ42 was applied together with an adjuvant in a vaccine named AN-
1792. Immunization with this preparation reduced greatly the amyloid deposits in 
AD patients (Holmes et al., 2008). However, it did not improve the cognitive 
decline and 6% of the treated patients suffered from meningoencephalitis 
(Gilman et al., 2005; Holmes et al., 2008). Currently, only one vaccine is in a 
phase III trial, CAD106, whose antigen is composed by multiple copies of Aβ 1-6 
plus a carrier adjuvant. A study in mice and a phase I trial indicated that this 
vaccine displays a good safety profile (Wiessner et al., 2011; Winblad et al., 
2012). CAD106 is being evaluated in the Generation S1 study, which targets 
cognitively healthy homozygous APOE*ε4 carriers (US National Library of 
Medicine. ClinicalTrials.gov, 2019e). Passive immunization with monoclonal or 
polyclonal humanized or recombinant human antibodies against Aβ species has 
been widely studied in the past decade. Unfortunately, most of the clinical trials 
on mild to moderate AD patients have shown passive immunization to be 
ineffective (reviewed in Panza, Lozupone, Logroscino, et al., 2019). The ongoing 
phase II and phase III trials have sought to target patients with evidence of brain 
Aβ deposition in early stages of the AD spectrum such as mild AD patients, aged 
individuals at risk for memory loss or individuals at risk for early onset AD. The 
list of the currently actively tested antibodies include: 1) solanezumab, given to 
30 
 
aged individuals in the A4 study (sponsored by US National Library of Medicine. 
ClinicalTrials.gov, 2019k) and early-onset AD patients in the DIAN-TU 
(Dominantly Inherited Alzheimer Network Trial Unit) together with gantenerumab 
(US National Library of Medicine. ClinicalTrials.gov, 2019l); 2) crenezumab, 
which is being evaluated in presymptomatic carriers of the PSEN1 E280A 
mutation (US National Library of Medicine. ClinicalTrials.gov, 2019g); and 3) the 
protofibril-specific BAN2401 antibody, currently studied in a phase III trial in early 
AD patients (US National Library of Medicine. ClinicalTrials.gov, 2019i). 
Gantenerumab is also being tested in early AD in the GRADUATE 1 and 
GRADUATE 2 trials (US National Library of Medicine. ClinicalTrials.gov, 2019m, 
2019r). Aducanumab, a promising human recombinant IgG1 antibody that 
exhibits 10,000 higher affinity for fibrils in comparison to monomers, successfully 
reduced Aβ deposits accompanied by an improvement in cognitive status in a 
phase Ib trial (Sevigny et al., 2016). Recently, despite the early encouraging 
results, the company Biogen halted the ENGAGE and EMERGE trials due the 
lack of improvement in the primary outcome measure of efficacy (US National 
Library of Medicine. ClinicalTrials.gov, 2019p, 2019o). 
In late-onset AD, impaired clearance of plaques has been proposed as a 
mechanism of Aβ accumulation (Mawuenyega et al., 2010). In order to reach a 
production-elimination equilibrium and mitigate Aβ deposition, inhibition of the 
secretases has been attempted. The γ-secretase inhibitors (GSI) are classified 
by their mechanism of action into non-specific, which block the active site and 
therefore every kind of proteolytic activity, cleavage-site modulators, and the 
APP-selective/Notch-sparing inhibitors (Schenk, Basi and Pangalos, 2012). 
Semagacestat was the most studied non-selective GSI, but unfortunately failed 
in phase III trials in patients with probable AD, where it was found to worsen 
cognition and increase the incidence of skin cancer and infections (Doody et al., 
2013). Among the modulators of the cleavage site, which belong to the family of 
non-steroidal anti-inflammatory drugs (NSAIDs), are R-flurburprofen and 
tarenflurbil. They display a good safety profile but failed in altering the plasma 
levels of Aβ42 and did not produce any cognitive improvement in mild AD patients 
(Galasko et al., 2007; Green et al., 2009). Finally, a representative member of 
the group of APP-selective/Notch-sparing inhibitors is avagacestat, which is 193-
fold more selective for APP versus notch cleavage (Gillman et al., 2010). Despite 




events and increased incidence of skin cancer were reported in a trial for 
prodromal AD with avagacestat, in addition to a higher number of individuals who 
progressed to dementia and/or suffered from brain atrophy (Coric et al., 2015). 
There are no ongoing clinical trials with GSI to date.  
Inhibitors of the β-secretase have also been utilized to target the early steps of 
the amyloid cascade, since they act upstream of Aβ production and could prevent 
its toxic consequences. Although BACE1 KO mice showed no gross phenotype, 
when translated to humans, pharmacological BACE1 inhibition was not exempt 
from adverse effects and studies on drugs from this group have been 
discontinued due to a lack of improvement, or even worsening in cognition 
accompanied by whole brain and hippocampal volume reduction as well as 
elevation of liver enzymes (Luo et al., 2001; reviewed in Panza, Lozupone, 
Logroscino, et al., 2019). Currently elenbecestat and CNP520 are the only BACE 
inhibitors in phase II and/or III clinical trials in patients at risk or with early AD (US 
National Library of Medicine. ClinicalTrials.gov, 2019e, 2019f, 2019b, 2019c).  
Given that many anti-Aβ therapies have failed in protecting from cognitive 
decline, great interest has arisen in tau, a putative Aβ downstream effector, as a 
therapeutic target in AD. A high number of strategies are currently under study 
that cover almost every step of tau physiopathology (reviewed in Congdon and 
Sigurdsson, 2018). Since tau KO mice do not display gross abnormalities, 
inhibiting tau production by antisense oligonucleotides has been considered as 
an attractive therapeutic measure (Ke et al., 2012). Successful results have been 
reported with this strategy in a mouse model of tauopathy and a phase I trial has 
been initiated to treat patients with mild AD (DeVos et al., 2017; US National 
Library of Medicine. ClinicalTrials.gov, 2019q). At the core of tau toxicity lay its 
posttranslational modifications, which impair tau binding to microtubules and 
facilitate aggregation. Phosphorylation and acetylation are targeted respectively 
by sodium selenate, which activates the phosphatase PP2A, and salsalate, an 
NSAID dimer of salicylic acid that inhibits the p300 acetyltransferase (Corcoran 
et al., 2010; Min et al., 2015). Both compounds are currently being tested as 
therapy for mild to moderate AD (Australian New Zealand Clinical Trials Registry, 
2019; US National Library of Medicine. ClinicalTrials.gov, 2019s). Tideglusib, 
another modifier of tau phosphorylation by inhibition of glycogen synthase kinase 
3 β, has already been tested in mild to moderate AD showing good tolerance, but 
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unfortunately it did not produce any clinical improvement (Lovestone et al., 2015). 
The phenothiazine methylene blue strain/compound binds tau monomers and 
exerts its therapeutic effects by preventing their aggregation (Wischik et al., 
1996). This compound was tested in mild to moderate AD patients with no signs 
of beneficial effects (Gauthier et al., 2016). However, it is currently in a phase III 
trial that includes patients with early AD (US National Library of Medicine. 
ClinicalTrials.gov, 2019s). Stabilizers of microtubules are also being utilized to 
restore the cytoskeletal abnormalities caused by altered tau function. Currently, 
the drug TPI287 is in a phase I clinical trial as treatment for AD (US National 
Library of Medicine. ClinicalTrials.gov, 2019d). Finally, immunization against tau 
is also being intensively studied. Concerns have been expressed as to what tau 
region or conformational isomer to target, and whether antibodies will reach tau 
intracellularly (reviewed in Congdon and Sigurdsson, 2018). Active immunization 
in the P301L tau mouse model has already shown to successfully remove tau 
deposits and improve behavioral abnormalities without inducing autoimmunity 
(Asuni et al., 2007). There are currently two vaccines against tau, ADDvac-1 and 
ACI-35, in phase II and phase I trials respectively (International Clincal Trials 
Registry Platform., 2019; US National Library of Medicine. ClinicalTrials.gov, 
2019a). Regarding passive immunization, there are a considerable number of 
antibodies targeting different regions of tau in phase II trials directed to patients 
with early AD, such as BMS986168, C2N-8E12,  and L43303560, among others 
(US National Library of Medicine. ClinicalTrials.gov, 2019h, 2019j, 2019n). 
The negative results yielded by the trials with aducanumab, summed to the large 
body of failures with anti-amyloid strategies reinforced the criticisms to the 
amyloid cascade hypothesis (Herrup, 2015; Karran and De Strooper, 2016; 
Panza, Lozupone, Dibello, et al., 2019; Panza, Lozupone, Logroscino, et al., 
2019). However, the body of evidence supporting this hypothesis, with the current 
focus shifted to Aβ oligomers as toxic species, is also large and the failed studies 
might have included patients far too advanced in the natural history of the 
disease. Therefore, an invaluable insight to test the validity of the amyloid 
hypothesis will come from the results of the current clinical trials targeting patients 
in earlier phases of the AD spectrum (Selkoe, 2019). Targeting tau has opened 
new avenues in the therapeutic for AD, sparing toxicity (reviewed in Panza et al., 
2016; and Congdon and Sigurdsson, 2018). With the completion of the ongoing 




learn how to treat AD but also gain insight about its underlying physiopathological 
mechanisms. Likewise, as our understanding on how neurodegeneration occurs 
in AD deepens and expands, novel therapies can and will emerge. 
 Novel diphenylpyrazole derivatives in AD and other neurodegenerative 
diseases 
Misfolding and aggregation seem to be common features of multiple 
neurodegenerative disorders, with soluble intermediate oligomeric species 
putatively mediating the toxic effects, as explained in section 1.3.1 (Soto, 2003; 
Soto and Pritzkow, 2018). In the context of the development of therapeutic 
strategies this would imply that inhibiting or modulating aggregation could be 
beneficial to halt the physiopathological cascade triggered by toxic oligomers. In 
2013, Wagner et al. carried out a high throughput screening of 20,000 small 
molecules by testing their ability to inhibit PrP aggregation both in vitro and in 
vivo (Wagner et al., 2013). As a result, they discovered the novel leading 
compound diphenylpyrazole as an inhibitor of PrP aggregation. Further screening 
experiments indicated that the derivative with the highest protective effects in 
prion and Parkinson’s disease (PD) models was anle138b. This small molecule 
prolonged the survival of prion-infected mice to an extent that no other compound 
had achieved before, was as effective as hemivagotomy in preventing motor 
symptoms in the oral rotenone model of PD and extended significantly the 
disease-free survival of A30P mice, a transgenic mouse model of PD (Wagner et 
al., 2013). Interestingly, the authors also showed in sucrose gradients of whole-
brain homogenates from the A30P mice a reduction of oligomeric forms at 
expense of an increase in monomers, with no changes in the overall 
concentration of synuclein. This suggests that anle138b exerts its protective 
effects by modulating protein aggregation. Furthermore, the compound has an 
excellent oral bioavailability and blood-brain barrier penetration, which enable 
oral administration (Wagner et al., 2013). Recently, in a novel mouse model of 
PD that expresses a truncated form of α-synuclein, MI2 mice, anle138b restored 
striatal release of dopamine, reduced neuronal loss in the substantia nigra pars 
compacta and improved the gait pattern, even when the treatment had started at 
9 months of age after the onset of synuclein pathology (Wegrzynowicz et al., 
2019). In addition, direct stochastic optical reconstruction microscopy confirmed 
that anle138b treatment reduced the number of large α-synuclein aggregates 
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while increasing non-clustered α-synuclein (Wegrzynowicz et al., 2019). Further 
experiments performed in murine models of tauopathy and multiple system 
atrophy rendered similar results, with anle138b administration ameliorating the 
symptoms, reversing histopathological changes and reducing the accumulation 
of large amyloid deposits (Wagner et al., 2015; Heras-Garvin et al., 2018).  
AD pathology has also been targeted with anle138b. A comprehensive study was 
published in 2018 in which electrophysiological and behavioral tools 
accompanied by transcriptome analysis were applied to characterize the 
changes in APPSwe/PS1ΔE9 mice upon anle138b administration (Martinez 
Hernandez et al., 2018). The authors showed that anle138b restored 
hippocampal synaptic transmission as evidenced by an improvement in CA1-LTP 
measurements in acute slices in pre-plaque mice with treatment initiated at 2 
months of age as well as in post-plaque animals with treatment initiated at 6 
months of age. The electrophysiological effects were accompanied by an 
enhanced performance in both groups in the Morris water maze test when 
compared to untreated transgenic animals, although the post-plaque group could 
not reach the WT levels in the probe trial (Martinez Hernandez et al., 2018). A 
hippocampal transcriptome analysis was performed to characterize the alteration 
and restoration of gene expression in both the pre-plaque and post-plaque mice, 
and also upon anle138b treatment. From a total of 202 dysregulated genes in the 
pre-plaque group, only 27 remained altered in the anle-treated group. 
Importantly, APP and PS1 expression was not altered by the treatment (Martinez 
Hernandez et al., 2018). In the post-plaque group, expression of 220 genes was 
altered and a pathway analysis associated these changes with 
neuroinflammation. Remarkably, anle138b treatment did not prevent the 
expression these genes, indicating that the beneficial effects on the post-plaque 
group are not mediated by a reduction of neuroinflammatory processes. 
Moreover, histological examination using thioflavin S revealed a decreased 
plaque deposition in the cortex and hippocampus of anle138b-treated mice. 
When analyzed in the context of the previous studies of anle treatment in murine 
models of neurodegenerative diseases, the experiments on the AD model 
suggest that anle138b exerted its protective effects by acting as an anti-amyloid 
aggregation molecule. Besides undergoing misfolding and aggregation, another 
common feature of amyloid proteins is their ability to interact with lipid bilayers 




addition to restoring functional and behavioral defects in the APPSwe/PS1ΔE9 mice, 
anle138b was found to restrict the formation of Aβ42 pores in artificial 
phospholipidic bilayers and to protect cultured hippocampal neurons from Aβ40-
induced perturbation of membrane integrity (Martinez Hernandez et al., 2018). 
Taken together, these data indicate that anle138b could protect hippocampal 
neurons from amyloid toxicity by a dual mechanism, preventing Aβ aggregation 
into toxic oligomers and also inhibiting the formation of amyloid pores.  
 Aims of the present study 
AD is the most prevalent neurodegenerative disease and the main cause of 
dementia worldwide. Several lines of evidence indicate that accumulation of 
soluble aggregates of the Aβ peptide play a causative role in AD, a concept 
summarized in the amyloid cascade hypothesis more than 25 years ago. To date 
a large body of studies have associated the accumulation of Aβ in AD mouse 
models to learning and memory deficits. Moreover, these behavioral changes are 
often accompanied by aberrant dendrite and spine number and morphology. In 
addition, altered synaptic transmission in the hippocampus has been studied, 
most frequently utilizing LTP and field recordings. However, little is known about 
Aβ synaptotoxicity at the single-cell and molecular levels, which might represent 
the earliest event in AD. Therefore, in this study I aim to gain insight into the 
effects of Aβ exposure on neurotransmission by means of establishing an in vitro 
model system of amyloid toxicity. In a first step, I will establish a reproducible 
method to prepare putative synaptotoxic Aβ aggregates, which will be 
characterized thoroughly with multiple techniques. Next, I plan to take advantage 
of electrophysiological recordings on autaptic neuron cultures, which have been 
widely used in my host laboratory in the study of the physiology of transmitter 
release, to describe the molecular mechanisms that fail at the glutamatergic 
synapse upon Aβ incubation. In addition, I will examine whether putative Aβ 
synaptotoxic effects correlate or depend on morphological alterations of the 
autaptic neurons. 
AD is currently an incurable disease and after manifold efforts in the past 
decades, the field has seen promising therapeutic strategies fail in phase III 
clinical trials. The novel small molecule anle138b has been shown to positively 
modify the natural history of multiple neurodegenerative diseases in animal 
36 
 
models, including AD mice. Moreover, its mechanism of action is unconventional, 
in that it does not modify physiological processes like other therapeutic agents. 
The available information on anle138b in AD has revealed that treated mice show 
a restoration in behavioral and electrophysiological parameters, decreased 
amount of amyloid plaques and less gene deregulation. Yet the exact cellular and 
molecular causes of this phenotype amelioration remain unclear. In addition, 
there is currently no information available about synaptic function and neuronal 
morphology in the presence of anle138b. Furthermore, the lack of a clear 
mechanism of action impedes the prediction and anticipation of unwanted side 
effects upon treatment with anle138b in AD patients. In this context, I aim to get 
a better understanding of the protective effects of the small molecule anle138b. 
For this purpose, Aβ-treated autaptic cultures used as a model of AD-related 
synaptotoxicity will be exposed to anle138b and its physiological properties will 
be characterized by performing electrophysiological recordings. 
In the last part of my work I will focus on the formation of amyloid pores as 
mechanism of Aβ toxicity, a highly debated hypothesis in the field of AD. Amyloid 
pores have been observed in artificial bilayers and patches from cells grown as 
immortalized lines or primary cultures. in vitro evidence indicate that anle138b 
could exert its protective effects blocking these pores. Still, how the in vitro 
findings relate to neurotoxicity at the cellular and synaptic levels remains an open 
question. Hence, I aim to elucidate whether Aβ pores could relate to and also 
underlie the synaptotoxicity observed in autaptic neuronal cultures. In a first effort 
to observe pores, I will perform electrophysiological recordings from artificial 
bilayers to later move to the study of pore formation and its consequences on 
autaptic hippocampal cultures. Finally, I will make use of the enantiomeric Aβ42 
and compare its toxicity on autaptic hippocampal cultures to the WT peptide, 
since it has been hypothesized that the formation of Aβ pores is independent of 
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Acetic acid, glacial  Merck 
Adenosine 5’-triphosphate (ATP) magnesium salt Sigma-Aldrich 
Agarose type IIa, medium Sigma-Aldrich 
Ammonia 32% Merck 
Amyloid-β peptide, 1-42 Bachem (Cat. N. 4014447) 
Amyloid-β peptide, 1-42 scrambled  Bachem (Cat. N. 4064853) 
Amyloid-β peptide, 42-1 (“reverse” Aβ42) Bachem (Cat. N. 4027991) 
Aprotinin Roth 
Aqua-Poly/Mount Polysciences, Inc. 
B27 serum - free supplement (50X) Gibco 
Bovine serum albumin Sigma-Aldrich 
Bradford reagent  Bio-Rad 
Bromophenol blue Pierce 
Calcium chloride (CaCl2) Sigma-Aldrich 
Chloroform Sigma-Aldrich 
Collagen 1, rat tail Becton Dickinson GmbH 
Creatine phosphokinase from rabbit muscle Sigma-Aldrich 
Deuterium hydroxide Deutero 
Dimethyl sulfoxide Sigma-Aldrich 
Diphytanoyl phosphatidylcholine (DiphyPC) Avanti Polar Lipids 
Disodium hydrogen phosphate (Na2HPO4.2H2O) Merck 
Dry milk (skimmed milk) Reforma 
Dulbecco's modified eagle medium  Gibco 
Enhanced chemiluminescence reagents (Solutions 
I and II) 
GE Healthcare 
Table 4. Reagents. 
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Ent - amyloid-β peptide (AllD Aβ42) Bachem (Cat. N. 4037836) 
Ethanol Sigma-Aldrich 
Ethylendiaminetetraacetic acid (EDTA) Sigma-Aldrich 
Ethylenglycoltetraacetic acid (EGTA) Sigma-Aldrich 
Fetal bovine serum  Gibco 
GlutaMAX Gibco 
Glutamic acid Sigma-Aldrich 
Glycerin Merck 
Glycerol Sigma-Aldrich 
Glycine  Sigma-Aldrich 
Goat serum Sigma-Aldrich 
Guanosine triphosphate (GTP) sodium salt Sigma-Aldrich 
Hank's balanced salt solution  Gibco 
Hoechst solution  Thermo Fisher 
Hydrochloric Acid 37%, fuming (HCl) Merck 
L-aspartic acid Sigma-Aldrich 
L-cysteine  Sigma-Aldrich 
Leupeptin Peptide Institute 
Magnesium chloride (MgCl2) Merck 
MemCode® Reversible Protein Stain Kit Thermo Fisher 
Methanol J.T.Baker 
MITO + serum extender Becton Dickinson GmbH 
n-decane Merck 
Neurobasal A Gibco 
Oxidized cholesterol Prof. Roland Benz 
Papain Worthington Biomedical Corp. 
Paraformaldehyde (PFA) Serva 
Penicillin / streptomycin Gibco 
Phenylmethylsulfonylfluoride Roche 
Phosphocreatine disodium salt hydrate Sigma-Aldrich 
Poly-D-lysine Sigma-Aldrich 
Poly-L-lysine (PLL) Sigma-Aldrich 
Potassium chloride (KCl) Merck 
Potassium D-gluconate Sigma-Aldrich 
Potassium dihydrogen phosphate (KH2PO4) Merck 
Protein molecular weight standards - PageRuler® Thermo-Fischer 
Protein molecular weight standards - SeeBlue 2® Invitrogen 
Silver nitrate (AgNO3) Merck 
Sodium azide (NaN3) Merck 
Sodium carbonate (Na2CO3) Merck 




Sodium dihydrogen phosphate (NaH2PO4.H2O) Merck 
Sodium dodecyl sulfate (SDS) GERBU GmBH 
Sodium hydroxide (NaOH) Merck 
Sodium pyruvate Sigma-Aldrich 
Sodium thiosulphate (Na2S2O3) Merck 
Sucrose Merck 
Tetrodotoxin (TTX) Tocris Bioscience 
Thioflavin T (ThT) Sigma-Aldrich 
Tris base Sigma-Aldrich 
Triton X-100 Roche 
Trypsin inhibitor Sigma-Aldrich 
Trypsin-EDTA (0.05% (wt/vol) Gibco 
Tween 20 Sigma-Aldrich 
Uranyl acetate SPI Supplies 
 Solutions 
- Phosphate buffered saline solution (PBS): 136 mM NaCl, 2.68 mM KCl, 6.4 
mM NaH2PO4, 1.76 mM KH2PO4, pH= 7.40. 
- Phosphate buffer: 23.1 mM Na2HPO4.2H2O, 16.9 mM NaH2PO4.H2O, pH= 
7.00. 
2.1.2.1. Solutions for electrophoretic separation of proteins and Western blot 
- Glycine buffer: 0.1 M glycine, 0.05% sodium azide, pH= 8. 
- Laemmli sample buffer: 10% glycerol, 50 mM Tris HCl, 2 mM EDTA, 2% SDS, 
0.05% bromophenol blue). 
- MES buffer: 50 mM MES, 50 mM Tris base, 1 mM EDTA, 0.1% SDS, pH= 
7.3. 
- MOPS buffer: 50 mM MOPS, 50 mM Tris base, 1 mM EDTA, 0.1% SDS pH= 
7.7. 
- Transfer buffer: 25 mM Tris base, 190 mM Glycine, 20% Methanol. 
- Tris-buffered saline (TBS): 50 mM Tris HCl (pH= 7.50), 150 mM NaCl. 
- TBS-T: 50 mM Tris HCl (pH= 7.40), 150 mM NaCl, 10% Tween 20. 
- PBS-T: PBS + 0.1% Tween 20.  
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- Buffer A: 20 mM Tris-HCl pH= 7.5, 150 mM NaCl, 1 mM EDTA-NaOH, 1 mM 
DTT, 0.2 mM phenylmethylsulfonylfluoride, 1 μg/mL aprotinin, 0.5 μg/mL 
leupeptin. 
- Buffer B: 20 mM Tris-Cl pH= 7.5, 150 mM NaCl, 0.2% (w/v) Triton X-100, 1 
mM EDTA-NaOH pH= 8, 1 mM DTT, 0.2 mM phenylmethylsulfonylfluoride, 1 
μg/mL aprotinin, 0.5 μg/mL leupeptin. 
2.1.2.2. Solutions for neuron culture 
- Papain stock solution: 0.2 mg/mL cysteine, 1 mM CaCl2, 0.5 mM EDTA in 
Dulbecco’s Modified Eagle’s Medium. 
- Papain working solution: 20 UI of papain dissolved in 1 mL papain stock 
solution. In order to solubilize the papain, the solution was saturated with 
carbogen (95% oxygen, 5% carbon dioxide) and sterilized by filtering (0.22 μm 
syringe filter). 
- Stop solution: 2.5 mg/mL bovine serum albumin (BSA), 2.5 mg/mL trypsin 
inhibitor and 10% fetal bovine serum in Dulbecco’s Modified Eagle’s Medium. 
- Neurobasal plus supplements: 500 mL Neurobasal A, 5 mL GlutaMAX, 10 mL 
B-27 supplement, 1 mL penicillin/streptomycin. 
2.1.2.3. Solutions for electrophysiology 
- External solution (“Base Plus”): 140 mM NaCl, 4 mM CaCl2, 4 mM KCl, 10 
mM HEPES, 24 mM MgCl2, 10 mM Glucose (pH=7.3, ~ 310 mOsm/L). 
- Intracellular solution (for voltage-clamp recordings): 136 mM KCl, 17.8 mM 
HEPES, 15 mM phospho creatine, 1 mM EGTA, 0.6 mM MgCl2, 0.3 mM Na-GTP, 
4 mM Mg-ATP, 5 U/mL creatine phosphokinase (pH= 7.4, ~320 mOsm/L). 
- Intracellular solution – Low chloride (for current-clamp recordings): 20 mM 
KCl, 10 mM HEPES, 0.1 mM EGTA, 0.3 mM Na-GTP, 4 mM Mg-ATP (pH= 7.4, 
~320 mOsm/L). 






  Methods 
 Aβ42 monomerization and in vitro aggregation 
2.2.1.1. Dissolution by 0.5% ammonium hydroxide 
The first Aβ dissolution method that I tested was a modified version of a published 
protocol (Ryan et al., 2013) provided by Prof. Dr. Tiago Outeiro (personal 
communication). First, 1 mg of Aβ42 peptide was suspended in 100 µL PBS. 
Antibody Host Dilution Provider Use 
Chicken – Alexa Fluor 633 Goat 1:2000 Thermo Fischer Immunocytochemistry 
Guinea pig - Alexa Fluor 
488 
Goat 1:2000 Mobitec Immunocytochemistry 
Mouse - horse radish 
peroxidase (HRP) - Affinity 
purified 
Goat 1:10,000 Dianova Western Blot - 
Enhanced 
chemiluminescence 
Mouse - IRDye 680 RD Goat 1:5000 LI-COR Western Blot - LI-COR 
Odyssey® 
Rabbit - Alexa Fluor 555 Goat 1:2000 Thermo Fischer Immunocytochemistry 
Rabbit - IRDye 800 CW Goat 1:5000 LI-COR Western Blot - LI-COR 
Odyssey® 
Table 5. Secondary antibodies. 
Table 6. Primary antibodies. 
Antibody Host Dilution Provider Use 
Actin Rabbit 1:250 Sigma Western Blot - LI-COR 
Odyssey® 
Aβ peptide 1-16 
(6E10)  
Mouse 1: 7500 Biolegend Western Blot - HRP 
CAPS1 Mouse 1:500 BD Biosciences Western Blot- LI-COR 
Odyssey® 
GAPDH Rabbit 1:1000 Abcam Western Blot- LI-COR 
Odyssey® 
GluA2 Rabbit 1:1000 Synaptic Systems Western Blot- LI-COR 
Odyssey® 
MAP2 Chicken 1:1000 Novus Biologicals Immunocytochemistry 
Munc13-1 Rabbit 1:1000 Synaptic Systems Western Blot- LI-COR 
Odyssey® 
PSD95 Mouse 1:50,000 Neuromab Western Blot- LI-COR 
Odyssey® 
Shank2 Guinea pig 1:500 Synaptic Systems Immunocytochemistry 
Synaptophysin-1 Mouse 1:10,000 Synaptic Systems Western Blot- LI-COR 
Odyssey® 
Synaptotagmin-1 Mouse 1:1000 Synaptic Systems Western Blot- LI-COR 
Odyssey® 
VGluT1 Rabbit 1:1000 Synaptic Systems Immunocytochemistry 
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Afterwards, ammonium hydroxide was added to a final concentration of 0.5%, 
which led to a clear solution indicating a successful peptide dissolution. Finally, 
PBS was added to 1 mL for a final peptide concentration of 1 mg/mL. All steps 
were performed at 4°C.  
2.2.1.2. HFIP / 100 mM NaOH two-step dissolution 
The second Aβ dissolution protocol used in this study combined the use of the 
polyfluorinated alcohol HFIP with alkaline solution in 100 mM NaOH. In a first 
step, Aβ42 was dissolved in HFIP at a concentration of 2 mg/mL. After at least 
60 minutes of incubation at room temperature, the solution was lyophilized for 2 
hours to evaporate and remove the HFIP. In the second step, 100 mM NaOH 
was added to the lyophilized powder to a concentration of 2 mg/mL. After 3 hours 
of incubation at room temperature, the solution was aliquoted and stored at -80°C 
until use.  
2.2.1.3. In vitro preparation of oligomeric enriched Aβ42 solutions 
In order to prepare aggregates for the study of Aβ toxicity, phosphate buffer was 
added to an aliquot of monomerized Aβ42 and the pH was corrected to 7.40 with 
0.5 or 0.1 M HCl. The initial pH was >11.00. After pH correction, Sartorius water 
was added to a final Aβ42 concentration of 0.5 mg/mL and 20 mM phosphate 
buffer. The sample was centrifuged for 10 minutes at 23,000x g and 4°C. 
Supernatant and pellet were separated and both dissolved to the same final 
volume. The supernatant was then incubated at 37°C and 800 revolutions per 
minute in a Thermomixer®. For oligomerization and use in toxicity experiments 
the supernatant was incubated for 40 minutes. For characterization of the 
aggregation kinetics, samples were taken at several time points during 72 hours 
incubation.  
 Characterization of Aβ42 preparation 
Aβ preparations were characterized taking samples at increasing incubation 
periods by means of ThT fluorescence measurements, negative staining for 




2.2.2.1. Measurement of protein concentration in the monomeric solution 
Protein concentration of the monomeric solution was calculated by measuring 
absorbance in a Nanophotometer (Implen) with 5 µL samples, using the equation 
for Beer’s law:  
A280= εIC 
where A280 is absorbance at 280 nm, ε is the Aβ42 molar extinction coefficient 
(1490 cm-1M-1), I is the path length (for the Nanophotometer using 10 mm lid, I = 
0.1 cm) and C is the concentration. This procedure is described in the protocol 
by Jan et al (Jan, Hartley and Lashuel, 2010). 
2.2.2.2. ThT fluorescence measurements 
Sample preparation and ThT fluorescence upon Aβ binding was measured as 
described previously by others (Jan, Hartley and Lashuel, 2010). In brief, a 100 
µM ThT stock solution was prepared, kept in the dark at 4°C and discarded after 
7 days. Prior to fluorescence measurement, the sample was prepared by 
dissolving ThT to 5 µM or 50 µm in glycine buffer and adding 10 µl of sample or 
blank solution. Samples were measured by duplicates in a Quanta Master 
fluorometer, with excitation at 450 nm and emission detected at 480 nm for 60 
seconds. 
2.2.2.3. NuPAGE® polyacrylamide gel electrophoresis 
Aβ samples containing ~4 µg of protein were dissolved in Laemmli sample buffer 
and stored at -80°C. For electrophoretic separation, samples were loaded without 
boiling on NuPAGE® 4-12% Bis-Tris gradient gels. Samples ran in parallel with 
the protein molecular weight standards SeeBlue2® at constant voltage (110 V) in 
MES running buffer for ~ 2 hours.  
2.2.2.4. Western blot 
After gel electrophoresis, proteins were transferred onto a nitrocellulose 
membrane in transfer buffer by constant current at 250 mA for 2 hours. 
Membranes were blocked with 5% skimmed milk and 5% goat serum in TBST for 
one hour. Next, the membrane was incubated for one hour with the 6E10 anti-A 
peptide at 1: 7,500 in blocking buffer. After three washes with blocking buffer, a 
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HRP-conjugated secondary antibody was added to 1:10,000 and incubated for 
one hour. After incubation with the secondary antibody, the membrane was 
washed four times in TBST-5% skimmed milk. Two last washing steps using 
TBST and TBS were performed before detecting the signal on the membrane 
with the enhanced chemiluminescence system. 
2.2.2.5. Silver staining 
Silver staining was performed according to a modified protocol by Dr. O. Jahn 
and D. Hesse from Blum, Beier and Gross (Blum, Beier and Gross, 1987). In 
brief, gels were fixed for 2 hours in 40% ethanol and 10% acetic acid, washed 
two times with 30% ethanol and once with Sartorius water for 20 minutes. 0.012% 
sodium thiosulfate was used to sensitize the gels for 1 minute, followed by three 
20-second washes in Sartorius water. Afterwards, the gel was impregnated in 
0.2% silver nitrate, 0.05% formaldehyde solution and washed again three times 
for 20 seconds with Sartorius water. Finally, the gel was developed in 3% sodium 
carbonate, 0.05% formaldehyde solution for 2-10 minutes. Once the staining 
reached the expected intensity, the developing reaction was stopped by placing 
the gel in 5% acetic acid for 10 minutes followed by three 10-minutes washes 
with Sartorius water. 
2.2.2.6. Transmission electron microscopy (TEM) 
In order to visualize the Aβ aggregates, 10 µL of peptide sample was incubated 
for 20 minutes on glow discharged, PLL pretreated, Formvar coated copper grids 
at room temperature. After three washes with Sartorius water, the grid was 
contrasted by a 60-second incubation with 1% uranyl acetate. The grid was dried 
using filter paper, left to air-dry and stored until visualization. Images were taken 
with a LEO 912AB Omega TEM (Zeiss) in collaboration with Dr. Benjamin Cooper 
and Lydia Maus. 
2.2.2.7. Mass spectrometry and NMR spectroscopy 
Mass spectrometry was performed on Aβ42 and AllD Aβ42 samples dissolved in 
HFIP at 1 mg/mL by Uwe Pleßmann and Prof. Henning Urlaub (Bioanalytical 
Mass Spectrometry Research Group, Max Planck Institute for Biophysical 
Chemistry). For NMR spectroscopy, Aβ42 and AllD Aβ42 were dissolved in HFIP, 




2.2.1.2). pH was adjusted to 7.20 and deuterium oxide was added to 10%. 
Afterwards, the sample was sonicated for 1 minute and incubated it in the cold 
room with gentle agitation for 30 minutes. NMR spectroscopic registers were 
performed by Kris Runge and Dr. Nasrollah Rezaei-Ghalleh (NMR Based 
Structural Biology Department, Max Planck Institute for Biophysical Chemistry). 
 Dissolution of anle138b for application to primary hippocampal neurons 
Anle138b is a lipophilic compound (see Figure 4). For dissolution in hippocampal 
neuronal medium, a 200 mM anle138b stock solution in DMSO was prepared in 
a first step. Next, anle138b in DMSO was dissolved in fetal bovine serum (FBS) 
to a theoretical concentration of 660 µM. The measured concentration of this 
anle138b in DMSO/FBS solution was 484 µM (Sergey Ryazanov, personal 
communication). Using this corrected value, anle138b was applied to neurobasal 
medium plus supplements at 7 or 10 µM to treat the primary hippocampal 
neurons for electrophysiological experiments. 
 Preparation of dissociated mass and autaptic cultures of murine 
hippocampal neurons 
Hippocampal neurons were prepared as described by Burgalossi et al. 
(Burgalossi et al., 2012). In brief, following postnatal day 0 mice decapitation, 
hippocampi were dissected in ice-cold Hank's balanced salt solution, followed by 
enzymatic digestion at 37°C for 60 minutes in papain working solution with mild 
agitation (450 revolutions per minute). After discarding the papain working 
solution, the hippocampi were incubated in stop solution for 15 minutes, followed 
by three washes with Neurobasal-A medium plus supplements. In order to 
dissociate the cells, the digested hippocampi were triturated by pipetting using a 
200 µL filter tip. Neurons were counted in a Neubauer chamber and plated at 
20,000 / cm2, grown as mass cultures on PLL coated glass coverslips for 
quantification of picnotic nuclei and synaptic proteins. For autaptic cultures, 
Figure 4. Anle138b chemical formula. 
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neurons were seeded at ~400 / cm2 on glass coverslips previously stamped with 
poly-D-lysine and collagen where astrocytes were grown forming microislands. 
In the context of this work and in agreement with the conventions in the field of 
Electrophysiology this culture system was considered as in vitro.  
 Quantification of picnotic nuclei upon Aβ treatment 
Picnotic nuclei were quantified by a modified protocol from Ripamonti et al. 
(Ripamonti et al., 2017). In order to analyze chromatin condensation, neuronal 
mass cultures grown on PLL-coated glass coverslips were treated with 10 µM 
Aβ42 or vehicle buffer on day in vitro (DIV) 8. After 72 hours of treatment, the 
neurons were incubated for 30 minutes with Hoechst 33342 at 2 µg/mL, mounted 
with Aqua-Poly/Mount without fixation and imaged 15 minutes afterwards on a 
Zeiss Apotome microscope. Since these cells were not fixed and the quality of 
the staining varied within each coverslip, the exposure time was optimized for 
each image. The total nuclei number was obtained by manual count. The number 
of picnotic nuclei, which displayed a better signal to noise ratio due to the 
chromatin condensation, was automatically quantified by manually setting a 
threshold for each image and applying a custom-made macro based on the FIJI 
“Analyze Particles” built-in function (Schindelin et al., 2012). The criteria for 
including the nuclei within the picnotic group were: size= 50-1000, circularity= 
0.50-1.00, with a pixel size of 258 nm. Imaging and nuclei quantification were 
performed blinded to treatment condition.  
 Quantification of synaptic proteins by Western blot- LI-COR Odyssey 
In order to measure putative differences in the concentration of synaptic proteins 
upon Aβ42 treatment, primary hippocampal neurons were grown on PLL-coated 
6-well plates. After 8 days in vitro, neurons were treated with 10 µM Aβ42 or the 
vehicle buffer as control. 72 hours later, on DIV 11, the neurons were washed 
two times with buffer A, briefly incubated with ~30 µL / well of buffer B, collected 
and stored at -80°C. Prior to electrophoretic separation, the Bradford protein 
assay was used to measure absorbance of the samples at 595 nm and the 
protein concentration was calculated by extrapolation from a standard curve 
generated by measurements of BSA samples at increasing concentrations. 
Samples were subsequently diluted in Laemmli buffer at 0.8 µg/µL. After 5 




12% gel, along with protein molecular weight standards (PageRuler), and let run 
in MOPS buffer for ~3 hours at constant voltage of 100 V. Once optimal 
separation was achieved, the proteins were transferred onto a nitrocellulose 
membrane for 16 hours at 4°C, at a constant current of 40 mA. Later the 
membrane was dyed with the MemCode Reversible Protein Stain and imaged for 
later normalization of the immunolabelled protein bands to the lane signal. After 
MemCode destaining, the membrane was blocked for 1 hour with LI-COR 
blocking buffer diluted 1:2 in PBS and incubated with the primary antibodies for 
16 hours at 4°C. The primary antibodies used correspond to multiple synaptic 
proteins enumerated in Table 6 (labeled as LI-COR Odyssey) and in LI-COR 
blocking buffer with PBS-T. Afterwards, three 5-minutes washes with PBS-T were 
performed and the membrane was incubated for 2 hours with the secondary 
antibodies mentioned in Table 5 in LI-COR:PBS-T buffer. After washing three 
more times with PBS-T, the membrane was imaged using the Odyssey Infrared 
Imaging System (LI-COR). Protein band quantification was achieved with Image-
Studio software (Odyssey System). MemCode signal quantification was 
performed with FIJI (Schindelin et al., 2012) and used to normalize the 
fluorescence band signal to the total amount of protein in the lane. 
 Immunocytochemistry for quantification of synaptic puncta and Sholl 
analysis 
Immunocytochemistry was performed following a protocol kindly provided by Dr. 
Ali Shaib (Neurobiology Department, Max Planck Institute for Experimental 
Medicine). To observe the morphological signs of toxicity induced by amyloid 
aggregates, primary autaptic hippocampal cultures were treated on DIV 8 with 
10 µM Aβ42 or the corresponding vehicle control. After 24 or 72 hours of 
treatment, the Neurobasal-A medium was removed and neurons were washed 
two times with PBS and fixed with 4% PFA in PBS at room temperature for 20 
minutes. PFA was discarded and the neurons were washed three times with PBS 
and kept at 4°C until immunostaining was performed.  
Before starting the immunolabelling, the PBS was removed and samples were 
quenched with 50 mM glycine in PBS for 10 minutes. Afterwards, cells were 
permeabilized with 0.1% Triton X-100/ 2.5% goat serum in PBS for 30 minutes. 
Neurons were subsequently washed two times with 2.5% goat serum in PBS for 
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5 minutes. The primary antibodies were diluted in 2.5% goat serum in PBS and 
are listed in Table 6. The autaptic cultured neurons were incubated on top of a 
~200 µL drop of the solution with the primary antibodies for 60 minutes at room 
temperature in a wet chamber. When the incubation was complete, the neurons 
were washed with 2.5% goat serum in PBS three times for 5 minutes. Next, the 
neuronal cultures were incubated for 45 minutes on a ~200 µL drop of solution 
containing the secondary antibodies and DAPI in a 1:2000 dilution in a wet dark 
chamber. Finally, neurons were washed five times with 1% Triton X-100/ 2.5% 
goat serum in PBS for 5 minutes, three times with PBS for 5 minutes and 
mounted using Aqua-Poly/Mount mounting medium. The fixed and 
immunolabelled neurons were stored at 4°C in a closed coverslip holder until 
imaging.  
 Fluorescence microscopy 
Images from autaptic hippocampal neurons were acquired using a Leica TCS 
SP2 or in collaboration with Dr. Ali Shaib on a Leica TCS SP5 confocal 
microscope, using the 40x oil-immersion objective, with image format= 1024 x 
1024, zoom=1.05, voxel size= 360.75 nm x 360.75 nm x 300 nm. Z-stacks of 
images from autaptic neurons were acquired with a step size of 280 – 300 nm 
(17-22 slices per neuron). Power, gain and offset of lasers were adjusted at the 
beginning of each session and kept constant across images for that session. 
Equal number of images were obtained during each session for all the conditions 
to be compared. Image acquisition was performed blinded to experimental 
condition. 
 Image analysis 
2.2.9.1. Sholl analysis 
In order to study dendritic branching, Sholl analysis was performed as described 
in previous publications (Ripamonti et al., 2017). In brief, a manual threshold was 
applied on the MAP2 signal to obtain a binary image. Any remaining isolated 
background signal was manually removed. A circle was drawn around the cell 
somata and its center was automatically detected by a custom-made function. 
The “Sholl analysis” plugin for FIJI was used for characterization of dendritic 




from the center of neuronal somata, ending radius = 250 µm away from the center 
of neuronal somata, radius step = 5 µm. The outcome values analyzed were: 
total number of intersections, enclosing radius and number of intersections at 
increasing distance from the cell center.  
2.2.9.2. Synapse count 
In order to investigate putative changes in synapse number, image analysis was 
performed by modifying a protocol published by Ripamonti et al. (Ripamonti et 
al., 2017). In a first step, background signal from astrocytes was deleted from the 
image stack by manually selecting the area containing the MAP2, VGluT1 and 
Shank2 signals and applying the “Clear Outside” FIJI built-in function. Then, 
background signal was subtracted using a custom-made macro provided by Dr. 
Ali Shaib and Prof. Ute Becherer. In order to restrict the area of analysis and to 
minimize the amount of noise detected, regions of interest (ROIs) containing 
synaptic signal were generated by the “WEKA Trainable Segmentation” plugin 
(Arganda-Carreras et al., 2017). To this aim, 10 random image stacks were 
selected from the data sets, and the slice with the largest area of signal from each 
stack was detected and duplicated by a custom-made function. The 10 images 
were used as data set for training the WEKA classifier using the following 
segmentation settings: Classifier = FastRandomForest, Training features = 
Gaussian blur, Hessians, Membrane projections, Laplacian, entropy, sobel filter, 
Difference of gaussians, structure and neighbors, Minimum thickness = 1, 
Membrane Patch size = 19, Minimum sigma = 1. The classifier was trained by 
manually selecting representative regions of the signal and the background on 
the training data set. Once optimal segmentation was accomplished, the 
classifier was saved and then applied to the image stack. A ROI containing the 
signal detected by the classifier was generated and juxtaposed to the 
preprocessed stack (raw stack after astrocyte signal deletion and background 
subtraction). The “Clear Outside” function was applied to remove the signal not 
detected by the classifier. A manual threshold was then applied to the stack and 
number of puncta were detected by using the “3D Object Count” plugin (Bolte 
and Cordelieres, 2006). Particles were then reclassified and those larger than 80 
voxels were counted as two synaptic puncta. This process was executed 
independently for the VGluT1 and the Shank2 channels. To obtain the number of 
puncta positive for both VGluT1 and Shank2, which were considered as a proxy 
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for synapse number, the Shank2 signal was converted into a ROI and enlarged 
by 1 pixel. This ROI was applied to the VGluT1 channel and the VGluT1 signal 
outside the ROI was deleted. The manual threshold was applied again to the 
Shank-corrected VGluT1 channel and the number of objects per stack was 
obtained with the 3D Object Count plugin, as described before.  
The representative images in the Results section are maximum intensity 
projections of a stack for a representative neuron for each condition. The 
brightness and contrast settings optimized for visualization used are identical for 
the compared conditions. 
 Electrophysiology 
2.2.10.1. Whole-cell recordings of autaptic hippocampal neurons 
In order to study effects of Aβ42 and anle138b on synaptic transmission, autaptic 
hippocampal neurons were treated after at least 7 days in vitro and recorded 
between DIV11 and DIV13. Electrophysiological recordings were performed as 
described previously (Burgalossi et al., 2012; Ripamonti et al., 2017). Neurons 
were transferred from the culture medium into a recording chamber containing 
Base Plus at room temperature. A glass pipette with tip resistance between 2 and 
3.5 MΩ was back-filled with intracellular solution and, after gigaseal formation, 
the membrane patch was ruptured to perform whole-cell recordings. The 
membrane potential was voltage-clamped at -70 mV using an EPC9 (HEKA) 
amplifier. Recordings were performed only if the series resistance was below 12 
MΩ during the experiment. In order to record evoked EPSCs, neurons were 
depolarized by a 2-millisecond (ms) square pulse to 0 mV at 0.2 Hz. To study 
short-term plasticity, neurons were stimulated with the same square pulse but at 
a frequency of 10 Hz for 5 seconds. External solutions were gravity-based applied 
for chemical or pharmacological stimulation as puffs onto the autaptic neuron in 
a precisely regulated manner by a Trigger Interface TIB 14S (HEKA), which 
controlled the opening and closing of valves and also the position of perfusion 
micro-pipes. A 6-second application of 0.5 M sucrose in Base Plus was utilized 
to record the size of the RRP. Spontaneous release as mEPSCs were recorded 
in the presence of 300 nM TTX diluted in Base Plus. Finally, a 5-second pulse of 




of AMPA receptors, since NMDA currents are blocked by the presence of high 
magnesium concentration in the Base Plus solution.  
For current clamp experiments, the glass pipettes were backfilled with 
intracellular solution containing low chloride. After gigaseal formation and 
membrane rupture, the neuron was voltage-clamped at -70 mV and a single 
EPSC was recorded. The recording mode was immediately switched to current 
clamp. Subsequently, five hyperpolarizing square pulses from -100 pA to 0 pA 
were applied in 20 pA increments, followed by depolarizing pulses from 0 pA and 
10 pA increments. The depolarizing pulses were applied until the current pulse 
was three times the value of the rheobase.  
The obtained data were imported into Igor Pro (Wavemetrics). Igor waves were 
converted using the ABF Utilities Software into Axograph-readable files. Data 
analysis was performed in Axograph (AxoGraph Scientific). For the current clamp 
results, the junction potential was calculated using an extension contained in the 
Patcher’s Power Tools package for Igor Pro, and corrected offline. 
The following parameters were obtained from the recordings: 
Voltage-clamp mode: 
- EPSC amplitude: minimum value in the EPSC after baseline correction.  
- RRP size: integral of the response to sucrose application, when baseline was 
corrected to the last part of the sucrose response. 
- Pvr: ratio of EPSC integral over the RRP, expressed as percentage.  
- Paired-pulse ratio: ratio of the amplitude of the second over the amplitude of the 
first event in a high frequency train of stimuli. 
- Depression ratio: ratio of the average amplitude of the last ten EPSCs over the 
amplitude of the first in a high frequency train of stimuli. 
- mEPSC frequency: number of mEPSCs per second. For mEPSC detection, a 
template-matching method was applied using the following parameters: 
amplitude= -20 pA, rise time = 0.5 ms, decay time = 3 ms.  
- mEPSC amplitude: the minimum current value of a model mEPSC obtained by 
averaging all the events detected in 100 seconds.  
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- Response to exogenous glutamate: minimum current value within the initial 
phase of the response to glutamate application.  
Current-clamp mode: 
- Membrane resting potential (Vm): voltage value with no current injected, 
immediately after switching to current clamp mode. 
- Input resistance (Rin): slope of the linear fit when plotting voltage vs current 
from the negative current injections.  
- Rheobase: the amount of current injected to elicit the first AP. 
- Number of action potentials per second: the number of AP elicited by the first 
stimulus after the rheobase. 
- Action potential threshold (as calculated with the method of third derivative): 
membrane potential value in the original trace at the time of the first peak of the 
third derivative. 
- Action potential overshoot: maximum value of the AP.  
- Action potential amplitude: maximum value of the AP when threshold was 
subtracted. 
- Action potential width: time between two cursors at AP threshold. 
- Action potential half width: time between two cursors at half amplitude. 
- Afterhyperpolarization amplitude: minimum value of the AP when value after HP 
was subtracted. 
- Afterhyperpolarization half-decay time: period between time of minimum peak 
to its half. 
2.2.10.2. Preparation and recordings from artificial bilayers 
Recordings from artificial bilayers exposed to Aβ42 isomers were performed in 
collaboration with Prof. Roland Benz (Jacobs University), following published 
protocols (Benz et al., 1978; Martinez Hernandez et al., 2018). In brief, 0.3 mm2 
planar bilayers were formed by spreading a solution of 1% oxidized cholesterol 
or 1% diphyPC in n-decane using a Teflon loop over a hole in a wall that divided 




clamped by a pair of Ag/AgCl electrodes using a Multiclamp 700 (Axon 
Instruments). After a 5-minutes baseline, Aβ42 or its isomers were added into 
one side of the chamber at 10 µM. Recordings were performed at varying holding 
potentials for at least 20 minutes. The recorded data were analyzed using 
Axograph (AxoGraph Scientific).  
 Statistics and graphic design software 
Data were collected, organized and stored in Microsoft Excel sheets. Statistical 
analysis was performed using Prism 6 (GraphPad). In a first step, descriptive 
statistics for each data set were obtained in order determine the distribution of 
the data. Normally distributed data were analyzed using parametric statistical 
tests (t-test, one-way ANOVA), whereas not normally distributed data or small 
data sets were analyzed using non-parametric (Mann-Whitney test, Kruskall-
Wallis test) tests depending on the number of groups and variables to compare. 
For all tests the critical significance level α was 0.05. All data are represented as 
mean ± standard error of the mean (SEM). The distribution of the data points is 
depicted by the scatter plots.  




 Aβ42 species preparation and characterization 
Unlike non-amyloid proteins, the effects of in vitro preparations of amyloids 
depend not only on the concentration but also on their aggregation state 
(Dahlgren et al., 2002; Deshpande, 2006). In aqueous solutions that mimic 
physiological conditions of temperature and pH, Aβ is prone to fold into hairpin-
like structures and its low-entropy C-terminus, to adopt a β conformation (Yan 
and Wang, 2006; Lim et al., 2007). These two structural features favor 
intermolecular aggregation into increasingly larger oligomeric species up to 
insoluble, thermodynamically-stable amyloid fibrils (Lim et al., 2007; Rezaei‐
Ghaleh et al., 2011). The kinetics of the aggregation process depend on the 
temperature, agitation, peptide concentration, and presence of aggregate seeds 
in the starting material, among other factors (reviewed in Thal et al. 2015 and 
Tycko 2015). The dissolution of commercially available protein powder into an 
aqueous solution of monomers used in aggregation experiments is of critical 
importance to ensure reproducibility in the effects of the resulting Aβ species 
solution (Teplow, 2006). In the present study, I initially compared two dissolution 
methods to disrupt and minimize the presence of large insoluble aggregates that 
could act as seeding material and bring the Aβ peptide to its monomeric 
conformation. The solution obtained using a two-step dissolution protocol was 
further incubated to generate aggregates that were biochemically and 
morphologically characterized and utilized for investigation of Aβ toxic effects on 
hippocampal neurons. All experiments were performed with Aβ42, hereafter Aβ. 
 Characterization of Aβ species yielded by dissolution in HFIP / NaOH 
followed by in vitro aggregation 
In an initial approach, I used an alkaline treatment in which the Aβ peptide was 
first dissolved in sterile PBS and subsequently ammonia was added to 0.5%. 
Despite the high pH of the initial solution (>10.5), this method did not remove the 
large aggregates as evidenced by the presence of smear in the Western blot 




not modify the relative concentration of aggregates. Moreover, using ThT 
fluorescence measurements I observed that the emission of the Aβ solution upon 
dissolution was eight times higher than the blank, indicating the presence of large 
aggregates (Figure 5B). 
On the next attempt to monomerize the peptide, I used a two-step method 
involving the organic solvent HFIP and the alkaline solution 100 mM NaOH. Upon 
dissolution (“0 h”), the ThT emission values were 1-2 times the blank, and these 
values increased ~10 times after 24 hours (Figure 5B, Figure 6A). The Western 
blot of the initial supernatant (“S0”) showed that 50% of the peptide formed 
species smaller than 28 kDa (monomers to pentamers) and less than 20% was 
larger than 98 kDa (Figure 6B). The initial pellet (“P0”) showed 50% less signal 
than the S0, indicating a low concentration of insoluble species (Figure 6B ii). In 
addition, in the pellet the proportion of species larger than 98 kDa was higher 
than in the supernatant (Figure 6B ii). These data demonstrated that the two-step 
method successfully reduced the presence of large aggregates upon dissolution.  
In order to describe the aggregation kinetics, samples were taken at increasing 
incubation periods and analyzed using ThT, Western blot, and TEM. Already at 
the first time point evaluated after dissolution (“0.6 h”), protofibrillar structures 
were present evidenced by a 10-fold increase in the ThT emission values, a 
reduction of the <28-kDa fraction to 20% and an increase in the concentration of 
Figure 5. Dissolution with 0.5% ammonia could not reduce the concentration of seeding 
material.  (A) Samples of Aβ taken at increasing time points after dissolution with 0.5% ammonia. 
(B) Normalized ThT fluorescence emission of the 0.5% ammonia dissolved sample and the 
sample dissolved with the two-step method, immediately after dissolution (“0 h”) and after 24 
hours of incubation (“24h”). 
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Figure 6. Characterization of Aβ aggregation upon dissolution with HFIP/ NaOH. (A) ThT 
fluorescence intensity measured at increasing intervals after dissolution, at three different 
concentrations of Aβ. The values were normalized to the blank for each time point. Note that 
initially the fluorescence was minimal and increased after 40 minutes of incubation. A plateau 
was reached after 6 hours of incubation. No lag phase was present. (B) Representative Western 
blot of Aβ samples at increasing incubation intervals at 0.5 mg/ml. The aggregation state of the 
samples used in the electrophysiological and morphological experiments is indicated by the red 
arrow. (i) Profile of gray intensities versus molecular weight in kDa. Each lane represents a time 
point after dissolution. Solid and dashed lines represent the 0 and 255 values respectively. (ii) 
Analysis of the normalized signal density per lane. Each narrow bar represents a fraction of the 
lane corresponding to a range of molecular weights in kDa. The initial supernatant (S0) was 
composed mostly of Aβ monomers (~0.5 < 28 kDa) although some aggregates between 29 and 
62 kDa could be found (~0.3). The proportion of larger aggregates increased with incubation and 
after 72 hours most of the sample was in protofibrillar/ fibrillar state (0.40 > 62 kDa and 0.42 > 98 
kDa). The monomeric fraction was also reduced and was minimal after 72 hours (0.21 < 28 kDa). 
Thick bars represent the total density per lane in absolute values (n= 3 Aβ preparations). Error 
bars represent the SEM. (C) TEM images of negatively stained samples at increasing times of 
incubation (20,000x). The red arrows indicate protofibrillar / fibrillar aggregates. Brightness and 





species larger than 63 kDa to up to ~50% in the Western blot (Figure 6A, B). 
Analysis of the successive samples showed that monomers were consumed and 
in turn the proportion of large aggregates increased (Figure 6B). No lag phase 
was found in the ThT emission measurements (Figure 6A), indicating that despite 
the efforts to eliminate the seeding material, some fibrils remained thus 
accelerating the aggregation process.  
The respective TEM grids were smothered with protofibrils of 200-nm length and 
10-nm width (Figure 6C) already at 0.6 hours. At the last time point evaluated 
(“72 h”), a large part of the TEM grid was empty, only covered by contrasting 
material and isolated accumulation of protofibrils or mature fibrils were 
occasionally found. Despite the reproducibility in the aggregation patterns 
evidenced by ThT measurements and Western blot, the morphology of the 
aggregates by TEM displayed some variation between preparations (Figure 7). 
At 0 hours in two of the grids no aggregates could be visualized, whereas in 
Figure 7. TEM reveals conformational variability among aggregates with identical Western 
blot patterns. TEM images at 20,000X of aggregates at selected incubation time points to 
compare the morphology of three sets of samples (left) and the corresponding Western blots 
(right). Although the blots showed similar patterns of aggregation the relative amount of 
protofibrils and fibrils seemed to vary. The red arrows indicate protofibrillar / fibrillar aggregates. 
Brightness and contrast have been adjusted in the EM images to improve visualization. Scale 




sample #1 there were globular or short protofibrillar structures (red arrows). 
Although all samples showed protofibrillar aggregates at 0.6 hours, their density 
on the grid varied. Similarly, at 72 hours isolated clusters of protofibrils or fibrils 
were observed, with variation in the density across samples.  
Taken together, these data showed that the two-step dissolution method 
successfully minimized the presence of fibrils in the initial solution of monomers 
which aggregated in a reproducible manner, despite some variation in the 
conformational state of the aggregates in the EM images.  
 Effects of Aβ treatment on survival, synaptic function and morphology of 
hippocampal neurons 
Once its reproducibility was established, I used the product of the protofibrillar Aβ 
preparations at different concentrations and treatment durations to study toxic 
effects on primary hippocampal neurons. The aggregation process was stopped 
after 0.6 hours of incubation, the time point at which the solution contained ~50% 
of high molecular weight oligomeric aggregates (protofibrils according to the EM 
data) and ~20% monomeric Aβ. The concentrations mentioned in the following 
experiments correspond to monomeric equivalents since protein concentration 
could only be measured before starting the in vitro aggregation.  
 Effects of 10 µM Aβ treatment for 72 hours 
3.2.1.1. Analysis of cell death upon 72-hour Aβ treatment 
On DIV 8, 10 µM Aβ (“Aβ”) or equal volume of phosphate buffer (“Vehicle”) was 
added to primary hippocampal neurons cultured at a high density. After 72 hours 
of treatment, the coverslips were stained with Hoechst dye and approximately 20 
images of neuronal nuclei per coverslip were immediately acquired without 
fixation (Figure 8A). Although the total nuclei per image were nearly identical in 
both groups (Figure 8B i), I found an increase in the fraction of picnotic nuclei 
from 27.5% in the vehicle to 35.6% in the Aβ-treated neurons (Figure 8B ii) 
reflecting a mild increase in cell death, in accordance to data published by others 
(Jan et al., 2008). It has been shown that synaptic dysfunction precedes neuronal 
death and that loss of synapses is the best correlate with cognitive decline (see 




reduction in neuronal survival did not prevent or interfere with the study of 
synaptic function in the remaining neurons.  
3.2.1.2. Effects of 72-hour Aβ exposure on synaptic transmission 
AD has been described as a “synaptic failure” already decades ago (Selkoe, 
2002). However, the exact nature of synaptic dysfunction is still not completely 
understood. In the next set of experiments, I aimed to describe the effects of Aβ 
exposure on glutamatergic synaptic transmission, which might underlie the 
symptoms of early-stage dementia before gross alterations occur. Hippocampal 
autaptic neurons were grown at low density on astrocytic feeder islands and 
treated with 10 µM Aβ or vehicle on DIV 8. After 72 hours Aβ-treated neurons 
showed a 60% reduction in EPSC amplitude compared to vehicle-treated 
neurons (Figure 9A). The RRP size of Aβ-treated neurons was also decreased 
to 48% compared to vehicle-treated neurons (Figure 9B). No change in Pvr was 
observed (Figure 9C). Previously it had been reported that Aβ could induce 
synapse loss, which could explain the reduced evoked response (reviewed in 
Spires-Jones and Hyman 2014). However, in these experiments the response to 
exogenous glutamate application of the Aβ-treated neurons was moderately 
reduced to 80% the value of the vehicle-treated neurons (Figure 9D). Since 95% 
Figure 8. Mild increase in picnotic nuclei count upon Aβ treatment. (A) Representative 
images of Hoechst-stained neuronal nuclei from vehicle- or Aβ-treated cultures and the respective 
masks of picnotic nuclei. Scale bar= 50 µm. (B) Quantification of (i) total nuclei per image and (ii) 
percentage of picnotic nuclei with respect to the total (n= 9 coverslips, from N= 3 cultures and Aβ 
preparations; unpaired t-test, **p= 0.002). Bars represent the mean and error bars, the SEM. 
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of the AMPA receptors are localized at postsynaptic sites, these data indicate 
that the release defect was most likely due to an alteration in presynaptic function, 
unless AMPA receptors had been relocated to extrasynaptic sites (Lee et al., 
2017). In accordance with this, a reduction in mEPSC frequency with no change 
in the amplitude in the Aβ-treated neurons compared to the vehicle-treated 
neurons was observed (Figure 9E). Short-term plasticity was not affected as 
shown by unchanged paired-pulse ratio and depression ratio (Figure 9F). 
3.2.1.3. Quantification of synapse number and dendritic branching in 72-hour Aβ-
treated neurons 
To further investigate the cause of the presynaptic defects in Aβ-treated neurons, 
I performed a morphological analysis on autaptic neurons treated identically to 
those used for electrophysiological experiments. After 72 hours of treatment, the 
neurons were fixed and later immunolabelled against MAP2, VGluT1, and 
Shank2.  
Sholl analysis of binarized MAP2 signal was used to quantify and analyze the 
distribution of dendrites in vehicle- or Aβ-treated neurons (Figure 10A). A plot of 
the average number of intersections versus the distance from the center of the 
cell soma showed that the spatial distribution of dendrites was similar in both 
groups, but suggested that the Aβ-treated neurons had a reduced number of 
branches (Figure 10B). To quantify these putative effects, I first compared the 
radius of the largest circle that could contain the complete dendritic tree 
(“enclosing radius”), an indicator of the cell size, which was not modified by Aβ 
exposure (Figure 10C i). Subsequently, I analyzed the sum of all intersections 
from a neuron, a proxy measurement for dendritic branching, which showed a 
20% reduction in the Aβ-treated neurons (Figure 10C ii). These changes in the 
number of dendrites could explain the reduction in the response to exogenous 
glutamate application seen in electrophysiological experiments. Finally, the 
intersections were grouped in bins to analyze the effects in branching at 
increasing distances from the cell soma (Figure 10C iii). Although not statistically 
significant, the Aβ-treated neurons showed a tendency towards a reduction in the 
number of intersections at distances between 40-80 µm (Mann-Whitney test, p= 
0.0603) and 85-250 µm (Mann-Whitney test, p= 0.0673) from the center of the 





Figure 9. 72-hour Aβ treatment reduces evoked and spontaneous glutamate release.  (A) 
(i) Representative traces and (ii) quantification of EPSCs evoked by a 2-ms depolarizing pulse 
(n= 52-60 neurons, from at least N= 3 cultures and Aβ preparations; Mann-Whitney test, ***p< 
0.001). (B) (i) Representative traces and (ii) quantification of RRP evoked by application of 0.5 
M sucrose (n= 31-52, N= 3; Mann-Whitney test, ***p< 0.001). (C) Quantification of Pvr. (D) (i) 
Representative traces and (ii) quantification of postsynaptic response to the application of 100 
µM glutamate (n= 24-42, N= 3; Mann-Whitney test, *p= 0.038). (E) (i) Representative traces and 
(ii) quantification of mEPSCs amplitude and (iii) frequency of events recorded in the presence of 
300 nM TTX (n= 25, N= 3; Mann-Whitney test, *p= 0.009). (F) (i) Normalized amplitudes of the 
first 50 EPSCs in a train of stimuli at 10 Hz. (ii) Ratio between the 2nd to the 1st EPSCs in the train 
(“Paired-pulse ratio”) and (iii) the 41th- 50th to the 1st EPSCs (“Depression ratio”). Bars represent 




I also compared VGluT1 and Shank2 puncta as well as puncta with juxtaposed 
VGluT1 and Shank2 signal (“VG+/Sh2+”) between the Aβ- and vehicle-treated 
neurons (Figure 10A). The quantitative analysis of these markers showed no 
differences between the groups (Figure 10B i-iii). These results indicated a 
conserved number of pre- and postsynaptic structures as well as entire synapses 
upon Aβ exposure. In addition, the mean intensity of VGluT1 puncta did not differ 
between the Aβ- and vehicle-treated neurons, suggesting that the number of 
vesicles in the presynaptic terminals was not modified by the presence of Aβ 
(Figure 10B iv).  
A summary of the results of 10 µM Aβ treatment for 72 hours on cell death, 
synaptic transmission and neuronal morphology can be found in Table 7. 
3.2.1.4. Effects of 72-hour exposure to Aβ on synaptic protein composition 
Given that Aβ markedly impaired glutamate release in hippocampal neurons with 
no gross alterations in their morphology, I hypothesized that a change in the 
protein composition at synapses could underlie these effects. Autaptic cultures 
Figure 10. Aβ treatment reduces dendritic branching. (A) Representative images of 
skeletonized MAP2 signal for Sholl analysis from vehicle- or Aβ-treated neurons. Scale bar= 50 
µm. (B) Distribution of intersections with respect to the distance from the cell soma. A similar 
profile of dendrite distribution was found in both groups. (C) (i) Enclosing radius. (ii) Total 
intersections per neuron (n= 46-49 neurons from N= 6 cultures and Aβ preparations; unpaired t-
test, *p= 0.033). (iii) Total intersections grouped in bins by distance from the center of cell soma. 





could not be used to test this hypothesis because of their low density and 
consequently low yield of protein sample; and also due to the presence of 
supporting glial cells, which would contaminate the neuronal lysate. I therefore 
cultured hippocampal neurons at high density and treated them in the same way 
as the cultures for electrophysiological and morphological experiments. On DIV  
Figure 11. Conserved morphology and number of synapses in 72-hour Aβ-treated 
neurons. (A) Representative images of neurons fluorescently labelled with antibodies against 
MAP2, VGluT1 and Shank2. Scale bar= 50 µm. (B) Quantification of puncta per image of (i) 
VGluT1, (ii) Shank2 and (iii) puncta positive for both VGluT1 and Shank2. (iv) The mean gray 
intensity for VGluT1-positive puncta was also quantified and compared. Bars represent the mean. 




11, after 72 hours of treatment with either Aβ or the equivalent vehicle volume, 
the cells were lysed and samples were collected. Later, the lysates were 
processed using SDS-PAGE and Western blot to mark a battery of synaptic 
proteins. Overall, no biologically relevant changes between the conditions were 
found and only a 20% reduction in the presynaptic protein synaptotagmin-1 was 
statistically significant (Figure 12, values summarized in Table 8). 
 
Table 7. Summary of effects of 72-hour treatment with 10 µM Aβ on hippocampal neurons. 
Fig. Parameter Vehicle Aβ p 
value 
Summary Test 
Mean SEM n Mean SEM n 
 
Cell death  
(mass cultures) 
         
8B i Total nuclei 77.610 3.955 9 77.460 7.104 9 0.986 n.s. t test 




         








9C Pvr (%) 7.902 0.472 52 7.523 0.616 31 0.626 n.s. Mann-
Whitney 
9D ii Glutamate-induced 
current (nA) 
-3.067 0.307 42 -2.475 0.436 24 0.038 * Mann-
Whitney 
9E ii mEPSC frequency 
(Hz) 
7.446 0.812 41 4.918 0.920 25 0.009 ** Mann-
Whitney 
9E iii mEPSC amplitude 
(pA) 
-24.7 1.571 41 -21.24 1.456 25 0.071 n.s. Mann-
Whitney 
9F ii Paired-pulse ratio 0.8682 0.016 54 0.893 0.042 37 0.538 n.s. t test 
9F iii Depression ratio 0.5455 0.025 54 0.470 0.027 37 0.057 n.s. Mann-
Whitney 
 
Sholl - syn. puncta 
(autaptic cultures)  
         
10C i Enclosing radius 
(µm) 
141.0 6.327 49 125.7 6.426 46 0.091 n.s. t test 
10C ii Total intersections 197.0 10.48 49 166.3 9.559 46 0.033 * t test 
11B i VGluT1 puncta 377.5 36.78 50 360.50 31.97 45 0.924 n.s. Mann-
Whitney 
11B ii Shank2 puncta 450.2 47.04 50 414.90 40.05 45 0.802 n.s. Mann-
Whitney 
11B iii VG+/Sh2+ puncta 227 27.11 50 177.00 16.70 45 0.313 n.s. Mann-
Whitney 
11B iv VGluT1 intensity 
(16-bit) 





 Effects of 10 µM Aβ treatment for 24 hours 
After having established a model for chronic toxicity with the 72-hour treatment, 
I explored the effects of a shorter exposure to Aβ, aiming to find earlier alterations 
which could be potentially reverted. In this set of experiments, autaptic 
hippocampal neurons were treated on DIV 10 with 10 µM Aβ for 24 hours. With 
this shorter exposure I expected to find a milder but still similar phenotype to the 
72-hour treatment. Surprisingly, the 24-hour Aβ-treated neurons displayed a 59% 
increase in EPSC amplitudes (Figure 13A), and a trend towards larger RRPs 
(Figure 13B), although the latter were not statistically significant. Additionally, the 
Pvr increased from an average of 8.1% in the control neurons to 11.26% upon 
Aβ treatment (Figure 13C). Neither the response to exogenous glutamate 
application (Figure 13D) nor the amplitude of mEPSCs (Figure 13E ii) were  
Fig. Protein Mean SEM n p value Summary Test 
12 VGluT1 1.054 0.092 3 0.590 n.s. t test 
12 Syphy1 1.043 0.051 4 0.433 n.s. t test 
12 PSD95 1.036 0.166 4 0.835 n.s. t test 
12 Munc13 1.036 0.120 4 0.772 n.s. t test 
12 Actin 0.972 0.026 4 0.353 n.s. t test 
12 GluA2 0.948 0.139 4 0.722 n.s. t test 
12 GAPDH 0.931 0.134 4 0.629 n.s. t test 
12 NMDAR-1 0.899 0.243 3 0.702 n.s. t test 
12 CAPS1 0.782 0.202 4 0.325 n.s. t test 
12 Synaptotagmin-
1 
0.794 0.078 4 0.039 * t test 
12 Shank2 0.677 0.156 3 0.108 n.s. t test 
Table 8. Summary of the Western blot results of synaptic proteins from neurons treated with 10 
µM Aβ for 72 hours. 
Figure 12. Protein composition of Aβ-treated synapses is unchanged upon 72-hour 
treatment.  Representative Western blot bands for the corresponding synaptic proteins and band 
signal normalized to the values of samples from vehicle-treated neurons (n= 3-4 cultures, N= 1-
2 Aβ preparations; Kolmogorov-Smirnov test, *pSynaptotagmin-1= 0.028). 
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modified, indicating a functionally conserved postsynaptic site as well as 
unchanged quantal size. Despite the increase in Pvr, there was no change in 
mEPSC frequency (Figure 13E iii) or in short term plasticity as reflected by 
unaltered paired-pulse ratio and depression ratio (Figure 13F). The results from 
this section are summarized in Table 9. 
 Comparison of the joint effects of development and Aβ exposure on 
neuronal morphology 
The duration of the exposure to Aβ was found to be a factor that not only defined 
the magnitude of the effects but also the type of the electrophysiological changes 
in the treated neurons. EPSC amplitudes were reduced in the 72-hour treatment, 
whereas both EPSC amplitude and Pvr increased upon exposure for 24 hours. 
Since opposing effects were found in synaptic transmission depending on the 
time of Aβ exposure, I compared the morphological effects of the chronic, 72-
hour Aβ exposure to the shorter, 24-hour treatment. While electrophysiological 
recordings were performed on neurons of the same age (DIV 11), this 
morphological analysis was performed on cells at different developmental stages. 
Specifically, autaptic neurons were treated on DIV 8 with 10 µM Aβ or equivalent 
volume of the vehicle and later, on DIV 9 a group of coverslips was fixed to 
investigate effects at 24 hours and another, on DIV 11 after 72 hours of exposure. 
Immunolabelling of the autaptic neurons, quantification of synaptic puncta, and 
Sholl analysis were performed as described previously for the 72-hour treatment 
(see section 3.2.1.3). In this experiment, two-way ANOVA was used for statistical 
analysis of the influence of “duration of exposure” and “treatment” as categorical 
independent variables on the tested morphological parameters. Additionally, the 
interaction between these variables was analyzed. As previously described, the 
complexity of the dendritic tree was investigated in all the groups using Sholl 
analysis of the binarized MAP2 signal (Figure 14A). The profile of the dendrite 
distribution (Figure 14B) showed that the vehicle treated neurons at 72 hours of 
exposure (DIV 11) presented a higher number of branches at longer distances 
from the center of the cell soma than the neurons of the same condition at 24 
hours (DIV 8), describing normal dendritic development of autaptic neurons in 
vitro. This process seemed to be impaired in the 72-hour Aβ-treated neurons. 
Neither the duration of exposure to Aβ nor the treatment as independent factors 





Figure 13. 24-hour Aβ treatment enhances evoked glutamate release with no change in 
postsynaptic response or short-term plasticity. (A) (i) Representative traces and (ii) 
quantification of EPSC amplitude (n= 35-36, N=3 cultures and Aβ preparations; Mann-Whitney 
test, *p= 0.015). (B) (i) Representative traces of the response evoked by 0.5 M sucrose 
application. (ii) Quantification of RRP size. (C) Quantification of Pvr. (n= 34, N= 3; Mann-Whitney 
test, **p= 0.007). (D) (i) Representative traces and (ii) quantification of postsynaptic response to 
exogenous glutamate application. (E) (i) Representative traces and quantification of (ii) amplitude 
and (iii) frequency of mEPSCs recorded in the presence of TTX. (F) (i) Normalized amplitudes of 
the first 50 EPSCs in a train of stimuli at 10 Hz. Quantification of (ii) paired-pulse ratio and (iii) 





intersections (Figure 13C ii). However, a statistically significant reduction in the 
interaction p-value for both the enclosing radius and total intersections confirmed 
the observation from the Sholl profile that branching increases over the course of 
the experiment in the control group, while this process is impaired in neurons 
exposed to Aβ, and even dendritic loss may occur.  
VGluT1 and Shank2 immunoreactive puncta, as well as co-labeled puncta were 
quantified and compared in Aβ and vehicle-treated groups at DIV 9 and DIV 11 
(Figure 14A). No changes were found between the tested groups (Figure 14B i-
iii). Since the 24-hour treated neurons showed larger EPSCs, I decided to 
evaluate the fluorescence intensity of the VGluT1 puncta as an indicator of the 
quantity of vesicles in the synapses (Figure 14B iv). Similarly, this parameter 
showed no differences among the experimental groups.  
When analyzed together, these morphological data described no major changes 
in autaptic neurons upon the 24-hour Aβ treatment, even though the 
electrophysiological measurements showed an altered glutamate release. In 
addition, these experiments confirmed the findings of section 3.2.1.3 of a 
moderate deleterious Aβ effect in dendrite development, which becomes more 
evident when analyzed over time.  
Fig. Parameter 
Vehicle Aβ p 
value 
Summary Test 
Mean SEM n Mean SEM n 
13A ii EPSC (nA) -5.323 0.670 36 -8.492 0.969 35 0.015 * 
Mann-
Whitney  
13B ii RRP (nC) -0.497 0.006 34 -0.844 0.012 34 0.146 n.s. 
Mann-
Whitney  


















7.483 1.245 26 6.752 1.110 24 0.925 n.s. t-test 
13F ii Paired-pulse ratio 0.867 0.032 34 0.895 0.024 33 0.144 n.s. 
Mann-
Whitney  
13F iii Depression ratio 0.371 0.023 34 0.418 0.033 33 0.258 n.s. t-test 
 Table 9. Summary of the electrophysiological effects of 24-hour treatment with 10 µM Aβ on 




The descriptive statistics for the data set corresponding to each condition are 
summarized in Table 10. The results of the two-way ANOVA analysis can be 
found in Table 11. 
 Analysis of 72-hour Aβ treatment concentration dependence 
In the previous experiments I observed that the duration of the exposure to the 
Aβ peptide was a factor that determined the magnitude of the impairment of 
synaptic transmission in the autaptic neurons, as indicated by reduced EPSC 
amplitudes, among other effects. Next, I wanted to investigate whether a 
correlation existed between the concentration of Aβ in the culture medium and 
putative neurotoxicity. To this aim, I cultured and treated autaptic hippocampal 
neurons as described before, but in these experiments utilizing 200 nM and 1 µM 
(in monomeric equivalent concentrations) in addition to the vehicle and 10 µM 
Aβ, which were used as negative and positive controls for toxicity respectively. 
After 72 hours of treatment, the neurons were used for patch-clamp recording of 
their synaptic activity. EPSCs were evoked as before by a 2-ms depolarizing 
pulse (Figure 15A i) and the amplitudes were compared between groups (Figure 
Figure 14. Aβ detrimental effects on dendritic development.  (A) Representative images of 
skeletonized MAP2 signal for Sholl analysis from vehicle- or Aβ-treated neurons after 24 or 72 
hours of exposure. Scale bar= 50 µm. (B) Distribution of intersections with respect to the distance 
from the center of the cell soma. (C) (i) Enclosing radius (n= 26-28, N= 3; two-way ANOVA; 
interaction “duration of exposure” x “treatment”: F(1,106)= 5.956, *p= 0.001). (ii) Total intersections 
per neuron (n= 26-28, N= 3; two-way ANOVA; interaction “duration of exposure” x “treatment”: 
F(1,106)= 4.631, *p= 0.0337). (iii) Total intersections grouped in bins by distance from the cell soma. 
Bars represent the mean. Error bars represent SEM. 24 h - Vehicle, gray bars; 24 h - Aβ, green 
bars, 72 h - Vehicle, black bars; 72 h - Aβ, pink bars. 
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15A ii). No statistically significant differences were found, but still the tendency 
remained for the 10 µM Aβ-treated neurons to have smaller amplitudes compared 
to the vehicle-treated neurons, and a trend was observed of larger EPSCs with 
increasing Aβ concentrations below 10 µM. To investigate the size of the RRP, 
0.5 M sucrose was applied (Figure 15B i), with no changes observed between  
Figure 15. Conserved number of synapses in 24-hour and 72-hour Aβ-treated neurons. (A) 
Representative images of vehicle or Aβ-treated neurons after 24 or 72 hours of exposure, 
fluorescently labelled with antibodies against MAP2, VGluT1 and Shank2. Scale bar= 50 µm. (B) 
Quantification of puncta per image of (i) VGluT1, (ii) Shank2 and (iii) puncta positive for both 
VGluT1 and Shank2. (iv) The mean gray intensity for VGluT1-positive puncta was also quantified 
and compared between the groups. Bars represent the mean. Error bars represent SEM. 24 h - 




the groups (Figure 15B ii). The calculated Pvr (Figure 15C) was not changed in 
the 10 µM Aβ-treated neurons as seen in the previous experiments. The neurons 
exposed to Aβ concentrations lower than 10 µM showed a trend of a directly 
proportional increase in Pvr with respect to the Aβ concentration. Glutamate was 
applied exogenously and the postsynaptic response was similar in all groups 
(Figure 15D). Spontaneous release in the presence of TTX was additionally 
recorded (Figure 15E i). No alterations were observed in the mEPSC frequency 
(Figure 15E ii) or in the amplitude (Figure 15E iii) in any of the groups exposed to 
Aβ. Finally, short-term plasticity was evaluated by high-frequency stimulation at 
10 Hz (Figure 15F i). Despite the changes observed in Pvr, the paired pulse ratio 
Table 10. Summary of morphological changes induced by Aβ on dendrite development 
Fig. Parameter 
24 h - Vehicle 24 h - Aβ 72 h - Vehicle 72 h - Aβ 




111.8 7.223 28 124.6 6.588 28 135.4 8.599 28 112.9 6.128 26 
14C ii Total intersections 165.4 15.42 28 181.9 12.03 28 194.8 18.46 28 149.3 9.311 26 
15B i VGluT1 puncta 322.2 39.66 27 306 40.97 28 299.4 34.05 28 294 43.4 26 
15B ii Shank2 puncta 323.1 37.64 27 311.5 33.43 28 327.6 31.52 28 345.5 41.23 26 




485.6 19.29 27 456.6 14.83 28 467.5 16.27 28 465.7 19.71 26 




TwA - main effect  
Duration of exposure 
TwA - main effect 
Treatment 
TwA - Interaction MCT 






F (1, 106) = 
0.665 
0.416 F (1, 106) = 
0.441 
0.508 F (1, 106) = 
5.956 





F (1, 106) = 
0.012 
0.912 F (1, 106) = 
1.016 
0.315 F (1, 106) = 
4.631 
 0.033(*) n.s. 
15B i 
VGluT1 F (1, 105) = 
0.193 
0.661 F (1, 105) = 
0.074 




Shank2 F (1, 105) = 
0.286 
0.593 F (1, 105) = 
0.007 




VG+/Sh2 F (1, 105) = 
0.047 
0.827 F (1, 105) = 
0.035 






F (1, 105) = 
0.063 
0.800 F (1, 105) = 
0.764 




TwA: two-way ANOVA 




Figure 16. Analysis of concentration dependence of the 72-hour Aβ treatment.  (A) (i) 
Representative traces and (ii) quantification of EPSCs amplitude. (B) (i) Representative traces 
and (ii) quantification of RRP size evoked by application of 0.5 M sucrose. (C) Quantification of 
Pvr (n= 16-35 neurons, from at least N= 3 cultures; Kruskal-Wallis test, *p < 0.032, post-hoc 
Dunn’s multiple comparisons test: n.s.). (D) (i) Representative traces and (ii) quantification of 
postsynaptic response to the application of 100 µM glutamate. (E) (i) Representative traces and 
(ii) quantification of frequency and (iii) amplitude of mEPSCs recorded in the presence of TTX. 
(F) (i) Normalized amplitudes of the first 50 EPSCs in a train of stimuli at 10 Hz. Quantification of 
(ii) paired-pulse ratio and (iii) depression ratio. Bars represent the mean. Error bars represent 





(Figure 15F ii) and depression ratio (Figure 15F iii) were conserved between the 
groups. These results are summarized in Table 12. 
  Effects of anle138b on morphology and synaptic physiology of hippocampal 
autaptic neurons 
Great efforts have been made in the last decades to find an effective treatment 
for AD and its devastating consequences (Guerrero-Muñoz, Castillo-Carranza 
and Kayed, 2014). In this context, the diphenylpyrazole compound and its 
derivatives were discovered as modulators of aggregation that inhibit oligomer 
formation and have been proven effective in ameliorating the symptoms in mouse 
models of a variety of neurodegenerative disorders such as prion disease, 
Parkinson’s Disease and tauopathies, among others (Wagner et al., 2013, 2015). 
Within this group of compounds, anle138b was the most effective in preventing 
oligomer formation (Wagner et al., 2013) and, importantly, neuroprotective 
effects were found in transgenic mouse models of AD (Martinez Hernandez et 
al., 2018). I therefore aimed to investigate whether this compound might also 
ameliorate the synaptic defects triggered by Aβ in hippocampal autaptic neurons. 
Fig. Parameter Vehicle 200 nM Aβ 1 µM Aβ 10 µM Aβ p 
value 
Sum. Test MCT 
Mean SEM n Mean SEM n Mean SEM n Mean SEM n Dunn’s 
15A 
ii 



























































Sum.; summary; MCT:  multiple comparisons test.  
 Table 12. Summary of Aβ concentration dependent electrophysiological effects at 72 hours. 
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However, before performing the combined treatment with anle138b and Aβ, I 
characterized the effects of anle138b per se on the physiology and morphology 
of autaptic neurons. 
 Effects of 96-hour exposure to 10 µM anle138b 
In a first set of experiments, I treated hippocampal autaptic neurons on DIV 7 with 
10 µM anle138b, which was the highest concentration that could be dissolved in 
the neuronal culture medium, or equivalent volume of the vehicle. After 96 hours 
of treatment whole-cell patch-clamp experiments were performed as described 
in the previous sections. Unexpectedly, the neurons exposed to anle138b 
showed a 40% reduction in their EPSC amplitudes (Figure 17A) as well as a 35% 
reduction in the RRP size (Figure 17B). The Pvr was not changed (Figure 17C) 
and the application of exogenous glutamate induced similar postsynaptic 
currents in both groups (Figure 17D). I also recorded spontaneous glutamate 
release in the presence of TTX (Figure 17E). The frequency of mEPSCs was 
reduced by 30% after 96 hours of exposure to anle138b, which correlated to the 
reduction in the RRP size (Figure 17E ii). In addition, mEPSC amplitudes were 
5% smaller in the anle138b-treated group with respect to the control (Fig. 13E 
iii). The analysis of short-term plasticity (Figure 17F) did not evidence any 
changes between groups, neither in the paired-pulse ratio (Figure 17F ii) nor in 
the depression ratio (Figure 17F iii). These data indicated that 96-hour treatment 
with 10 µM anle138b had negative effects per se on synaptic transmission in the 
autaptic hippocampal neurons and therefore this concentration was not used in 
further experiments.  
 Effects of 96-hour exposure to 7 µM anle138b 
Since the goal of the use of anle138b was to prevent the synaptotoxicity of Aβ 
oligomers, the direct effects of anle138b on synaptic transmission per se 
represented a confounding factor. Therefore, I decided to further seek for a 
maximal concentration of anle138 that would not exert negative effects on 
synaptic properties. To this aim, autaptic neurons were treated with 7 µM 
anle138b or equivalent vehicle volume on DIV 7 and used for recordings on DIV 
11, as described in the previous sections. The synaptic responses were found to 
be similar in both groups (Figure 18A). The RRP size evoked by application of 




unchanged. In addition, the exposure to 7 µM anle138b did not affect the 
postsynaptic response to exogenous glutamate application (Figure 18D) nor the 
Figure 17. 10 µM anle138b treatment alters synaptic physiology on hippocampal autaptic 
neurons. (A) (i) Representative traces and (ii) quantification of EPSC amplitude (n= 48-53 
neurons, from at least N= 3 cultures; Mann-Whitney test, ***p< 0.001). (B) (i) Representative 
traces of the response evoked by 0.5 M sucrose application. (ii) Quantification of RRP size (n= 
37-39, N= 3; Mann-Whitney test, *p= 0.024). (C) Quantification of the calculated Pvr. (D) (i) 
Representative traces and (ii) quantification of postsynaptic response to exogenous glutamate 
application. (E) (i) Representative traces of mEPSCs recorded in the presence of TTX. (ii)  
Quantification of mEPSC frequency (n= 24-26, N= 3; Mann-Whitney test, *p= 0.016). (iii) 
Quantification of mEPSC amplitudes (n= 24-26, N= 3; Mann-Whitney test, **p= 0.006). (F) (i) 
Normalized amplitudes of the first 50 EPSCs in a train of stimuli at 10 Hz. Quantification of (ii) 
paired-pulse ratio and (iii) depression ratio. Bars represent the mean. Error bars represent SEM. 
Vehicle, black bars; Anle138b, purple bars. 
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spontaneous activity recorded in the presence of TTX (Figure 18E), as indicated 
by a conserved mEPSC frequency (Figure 18E ii) and amplitude (Figure 18E iii). 
Finally, the response to high-frequency stimulation at 10 Hz (Figure 18F) was not 
modified by the anle138b treatment, with similar values of paired-pulse ratio 
(Figure 18F ii) and depression ratio (Figure 18F iii). In conclusion, all 
electrophysiological parameters tested remained unmodified by the 96-hour 
exposure to 7 µM anle138b, thus indicating the absence of detectable deleterious 
effects at this concentration.  
The results of 96-hour exposure to 7 µM and 10 µM anle138b are summarized in 
Table 13. 
 Effects of anle138b as protective pretreatment against Aβ toxicity 
To investigate the putative neuroprotective effects of anle138b, I performed a 
combined treatment together with Aβ using the protocols described in the 
previous sections. 7µM anle138b or equal volume of the vehicle was added to 
the culture medium of hippocampal autaptic neurons on DIV 7. After 24 hours, 
on DIV 8, the neurons were treated with 10 µM Aβ (or equivalent volume of the 
vehicle). Later, on DIV 11, electrophysiological recordings were performed. The 
results for the tested parameters were analyzed using two-way ANOVA to 
evaluate the effects of anle138b and Aβ independently, as well as the result of 
their interaction. This last parameter was used to test whether the pretreatment 
with anle138b could modify the changes induced by Aβ. The exposure to 
anle138b, when considered as a main variable, showed no effects on the EPSCs 
(Figure 19A). Aβ exposure induced a statistically significant reduction in the 
amplitude of EPSCs, akin to the effects described in section 3.2.1. Since 
anle138b had been shown to rescue memory deficits in a mouse model of AD 
and restored the changes in LTP induced by Aβ accumulation (Martinez 
Hernandez et al., 2018), I expected a statistically significant interaction between 
the treatments on EPSC amplitude, provided that the pretreatment with anle138b 
could protect from Aβ-induced toxicity and normalize the evoked release. This 
hypothesis was not verified, since the EPSCs of neurons pretreated with 
anle138b and later exposed to Aβ were as reduced in amplitude as the vehicle 
pretreated ones. Similarly, the RRP size was reduced in all the groups of Aβ- 




anle138b effects were also found to be statistically significant in the analysis of 
the RRP size, suggesting a mild toxicity of the anle compound which had not 
been detected in the previous experiments of section 3.3.2. The interaction 
Figure 18. Exposure to 7 µM anle138b has no effects on synaptic transmission in 
hippocampal autaptic neurons. (A) (i) Representative traces and (ii) quantification of EPSC 
amplitude. (B) (i) Representative traces of the response evoked by 0.5 M sucrose application and 
(ii) quantification of RRP size. (C) Quantification of Pvr. (D) (i) Representative traces and (ii) 
quantification of postsynaptic response to exogenous glutamate application. (E) (i) 
Representative traces and quantification of (ii) amplitude and (iii) frequency of mEPSCs recorded 
in the presence of TTX. (F) (i) Normalized amplitudes of the first 50 EPSCs in a train of stimuli at 
10 Hz. Quantification of (ii) paired-pulse ratio and (iii) depression ratio. Bars represent the mean. 
Error bars represent SEM. Vehicle, black bars; Anle138b, blue bars. 
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between anle138b and Aβ treatments was also analyzed for the RRP size. The 
absence of statistical significance indicated that 7 µM anle138b could not rescue 
the Aβ-induced reduction of the RRP. No changes in Pvr were found with either 
of the treatments or with their combination. The Aβ effects on the exogenous 
glutamate-evoked response could not be rescued by anle138b. Spontaneous 
glutamate release was recorded during the application of TTX (Figure 19E). 
Neither the frequency (Figure 19E ii) nor the amplitude (Figure 19E iii) of 
mEPSCs were modified in any of the treated groups. No interaction between the 
treatments was found on these parameters. Regarding short-term plasticity, no 
differences were observed between the experimental groups or their interaction 
(Figure 19F ii). However, the ratio between the responses at the end of the train 
(41th-50th) and the 1st EPSC was found to be reduced as an Aβ-dependent 
effect (Figure 19F iii). Interestingly, the Tukey’s post-hoc test indicated that the 
neurons pretreated with anle138b and subsequently with Aβ exhibited larger 
Table 13. Summary of the electrophysiological effects of 96-hour treatment with 10 µM and 7 µM 
anle138b. 
Fig. Parameter Vehicle Anle138b p value Summary Test 




         
16A ii EPSC (nA) -10.38 0.737 48 -6.429 0.641 53 < 0.001 *** Mann-
Whitney 
16B ii RRP (nC) -0.960 0.012 39 -0.626 0.088 37 0.024 * Mann-
Whitney 





-3.801 0.461 40 -3.552 0.302 42 0.600 n.s. Mann-
Whitney 
16E ii mEPSC 
frequency (Hz) 
5.937 0.624 36 3.967 0.554 42 0.016 * Mann-
Whitney 
16E iii mEPSC 
amplitude (pA) 
-27.57 1.24 39 -22.17 1.314 42 0.006 ** t test 
16F ii Paired-pulse 
ratio 
0.863 0.016 36 0.925 0.026 36 0.050 n.s. t test 
16F iii Depression 
ratio 
0.420 0.025 36 0.404 0.027 36 0.524 n.s. Mann-
Whitney  
7 µM anle138b 
         
17A ii EPSC (nA) -5.005 0.635 50 -4.497 0.505 55 0.888 n.s. Mann-
Whitney 
17B ii RRP (nC) -0.506 0.008 48 -0.333 0.004 53 0.160 n.s. Mann-
Whitney 





-3.226 0.299 41 -3.276 0.387 41 0.590 n.s. Mann-
Whitney 
17E ii mEPSC 
frequency (Hz) 
4.53 0.504 42 3.526 0.362 38 0.394 n.s. Mann-
Whitney 
17E iii mEPSC 
amplitude (pA) 
-18.12 0.645 42 -17.35 0.757 38 0.200 n.s. Mann-
Whitney 
17F ii Paired-pulse 
ratio 
0.943 0.025 46 1.030 0.041 29 0.177 n.s. Mann-
Whitney 
17F iii Depression 
ratio 






Figure 19. Pretreatment with 7 µM anle138b does not modify Aβ toxic effects on synaptic 
transmission in autaptic hippocampal neurons. (A) (i) Representative traces and (ii) 
quantification of EPSC amplitude (n= 12-24 neurons from at least N= 3 cultures and Aβ 
preparations; two-way ANOVA; main effect Aβ: F(1, 72)= 11.09, **p= 0.001; Tukey’s post-hoc test, 
Vehicle vs Vehicle+Aβ: *p= 0.012, Vehicle vs Anle+Vehicle: **p= 0.003).  (B) (i) Representative 
traces of the response evoked by 0.5 M sucrose application and (ii) quantification of RRP size 
(n= 7-19, N= 3; two-way ANOVA; main effect Aβ: F(1, 53)= 4.652, *p= 0.035; main effect anle138b: 
F(1, 53)= 5.948, *p= 0.018; Tukey’s post-hoc test, Vehicle vs Anle+Vehicle: *p= 0.023, Vehicle vs 
Anle+Aβ: *p= 0.021). (C) Quantification of Pvr. (D) (i) Representative traces and (ii) quantification 
of postsynaptic response to exogenous glutamate application (n= 8-19, N= 3; two-way ANOVA; 
main effect Aβ: F(1, 51)= 6.812, *p= 0.011; Tukey’s post-hoc test: n.s.). (E) (i) Representative traces 
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depression in the EPSC amplitudes at the end of the train when compared with 
the neurons not exposed to anle138b. This suggested that the combination of 
anle138b pretreatment together with exposure to Aβ could alter ability of the 
autaptic neurons to sustain an efficient release over the course of milliseconds-
seconds rather than affecting the rapid initial plasticity. 
When analyzed altogether, these results showed that the anle138b pretreatment 
failed in protecting against Aβ-induced synaptic toxicity, mostly indicated by an 
absence of significant interaction between the treatments. The descriptive 
statistics for the compared data sets are summarized in Table 15. The two-way 
ANOVA values are presented in Table 14.  
 Pore formation as toxicity mechanism of Aβ 
In the previous sections I described changes in neuronal function and 
morphology induced by exposure to the Aβ peptide. In the final part of my work, 
I aimed to explain the cellular and molecular causes for the toxic effects of Aβ, 
focusing on the hypothesis of amyloid pore formation. 
 Effects of Aβ treatment on artificial bilayers 
The phenomenon of pore formation by amyloid proteins was described initially by 
means of recordings of the occurrence of currents steps on artificial bilayers 
(Arispe, Rojas and Pollard, 1993). In an effort to replicate those findings and to 
further characterize the effects of the protofibrillar aggregates described in 
section 3.1., I performed electrophysiological recordings from lipid bilayers 
exposed to Aβ. Two different Aβ isomers were used as negative controls for these 
experiments: the reverse Aβ peptide (“Aβ 42-1”) and the scrambled Aβ42 (“scr 
Aβ”), which has an identical amino acid composition to Aβ42 but a randomized 
primary structure (De Felice et al., 2009; Gilson et al., 2015). Voltage-clamp 
recordings were performed on membranes formed using two kinds of lipids: 1% 
(w/v) oxidized cholesterol in n-decane and 2% (w/v) diphyPC in n-decane. In the  
and quantification of (i) amplitude and (ii) frequency of mEPSCs recorded in the presence of TTX. 
(F) (i) Normalized amplitudes of the first 50 EPSCs in a train of stimuli at 10 Hz. Quantification of 
(ii) paired-pulse ratio and (iii) depression ratio (n= 8-22, N= 3; two-way ANOVA; main effect Aβ: 
F(1, 56)= 8.488, **p= 0.005; Tukey’s post-hoc test, Vehicle vs Vehicle+Aβ: *p= 0.014, Vehicle vs 
Anle+Vehicle: **p= 0.010. Bars represent the mean. Error bars represent SEM. Vehicle, black 
bars; Vehicle +Aβ, pink bars; Anle138b+Vehicle, blue bars; Anle138b+Aβ, purple bars. Black 
lines represent the two-way ANOVA results. Stars represent the main Aβ effect. Hash marks 







Table 14. Two-way ANOVA comparison of the effects of anle138b and Aβ combined treatment. 
Fig. Parameter Vehicle Vehicle+Aβ Anle+Vehicle Anle+Aβ 
Mean SEM n Mean SEM n Mean SEM n Mean SEM n 
19A EPSC (nA) -7.694 1.049 24 -3.729 0.863 16 -5.021 0.664 24 -2.752 0.735 12 
19B RRP (nC) -0.564 0.097 19 -0.290 0.081 12 -0.264 0.053 19 -0.150 0.053 7 




-3.955 0.608 17 -2.165 0.592 13 -3.592 0.758 19 -1.537 0.499 8 
19E ii mEPSC 
amplitude (pA) 
-26.230 2.019 13 -24.470 2.820 7 -25.420 2.810 12 -20.230 4.217 5 
19E iii mEPSC 
frequency (Hz) 
6.825 1.744 13 8.391 1.873 7 6.146 1.861 10 4.806 2.036 5 
19F ii Paired-pulse 
ratio 
0.869 0.028 22 0.864 0.106 13 0.962 0.067 17 0.684 0.090 8 
19Fiii Depression 
ratio 
0.371 0.019 22 0.332 0.050 13 0.371 0.038 17 0.179 0.058 8 
Table 15. Summary of the effects of anle138b and Aβ combined treatment. 
Figure Parameter  TwA - main effect 
anle138b 
TwA - main effect 
Aβ 
TwA - Interaction MCT 
F value p 
value 
F value p 
value 
F value p 
value 
Tukey's   
19A EPSC (nA) F (1, 72) = 
3.802 




F (1, 72) = 
0.820 













F (1, 53) = 
0.800 
0.375 Vehicle vs 
Anle+Vehicle *p=0.023 
Vehicle vs Anle+Aβ   
*p=0.021 
19C Pvr (%) F (1, 53) = 
2.274 
0.138 F (1, 53) = 
2.025 







F (1, 51) = 
0.351 




F (1, 51) = 
0.057 
0.811 n.s. 
19E ii mEPSC 
amplitude 
(pA) 
F (1, 33) = 
0.705 
0.407 F (1, 33) = 
1.342 
0.255 F (1, 33) = 
0.325 
0.572 n.s. 
19E iii mEPSC 
frequency 
(Hz) 
F (1, 31) = 
1.067 
0.310 F (1, 31) = 
0.003 





F (1, 6) = 
0.370 
0.545 F (1, 56) = 
3.883 





F (1, 56) = 
3.728 




F (1, 56) = 
3.681 
0.060 Anle+Vehicle vs 
Anle+Aβ *p=0.014 
Vehicle vs Anle+Aβ 
*p=0.010 
Vehicle: Neurons treated with vehicle for anle138b on DIV7 and vehicle for Aβ on DIV 8. 
Vehicle+Aβ: Neurons treated with vehicle for anle138b on DIV7 and 10 µM Aβ on DIV 8. 
Anle+Vehicle: Neurons treated with 7 µM anle138b on DIV7 and vehicle for Aβ on DIV 8. 
Anle+Aβ:  Neurons treated with 7 µM anle138b on DIV7 and vehicle for Aβ on DIV 8. 
TwA: two-way ANOVA 
MCT:  multiple comparisons test. 
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first set of experiments, oxidized cholesterol membranes were formed and after 
5 minutes of recording a stable baseline at 20 mV, Aβ or Aβ 42-1 were added to 
one of the chambers at a concentration of 10 µM (Figure 20A i). Both isomers 
induced current steps after a latency period, which were accompanied by an 
increased standard deviation of the baseline current. However, the latency period 
for the activity induced by Aβ was shorter, and in two out of three recordings the 
total charge transferred was two to four times the Aβ 42-1 induced charge (Figure 
20A ii). Similar experiments were conducted on diphyPC membranes but using 
higher holding potentials of 50 mV and 100 mV (Figure 20B i-ii). In the case of 
these phospholipidic membranes, no current steps were found at either of the 
holding potentials, and the transferred charge was equally low upon exposure to 
both peptides when compared to the effects in oxidized cholesterol membranes 
(Figure 20B iii).  
Figure 20. Aβ treatment disrupts the integrity of oxidized cholesterol membranes but has 
no effects on diphyPC membranes.(A) (i) Representative recordings from oxidized cholesterol 
membranes treated with Aβ42 or Aβ 42-1 at 20 mV and (ii) quantification of the charge transferred 
in 20 minutes. (B) Representative recordings from diphyPC membranes treated with Aβ42 or Aβ 
42-1 (i) at 50 mV and (ii) 100 mV. (iii)  Quantification of transferred charge in 20 minutes at 50 
mV and 5 minutes at 100 mV. (C) (i) Representative recordings from oxidized cholesterol 
membranes treated with Aβ42 or scr Aβ at 20 mV and (ii) quantification of the charge transferred 
in 20 minutes. (D) (i) Representative recordings from diphyPC membranes treated with Aβ42 or 
scr Aβ (i) at 50 mV and (ii) 70 mV. (iii)  Quantification of transferred charge in 20 minutes at 50 
mV and 70 mV. Thick lines represent the mean. Error bars represent SEM. Aβ42, pink lines; Aβ 




The scr Aβ was used as negative control for the next set of experiments on 
oxidized cholesterol at 20 mV (Fig. 16C i). Both Aβ and scr Aβ at 10 µM induced 
current steps with similar latency periods, but the scr Aβ was active in two out of 
three recordings showing large charges, while Aβ showed activity only in one 
case (Figure 20C ii). Next, diphyPC membranes were used for recordings at 50 
mV and 70 mV (Figure 20D i-ii). Almost no activity was found with either of the 
peptides as evidenced by no changes in the charge transferred, except for one 
recording in which a single and stable step in the baseline was found (Figure 20D 
iii). 
These data highlight the importance of the lipidic composition of the membrane 
in the formation of Aβ pores, since the oxidized cholesterol membranes were 
more easily perforated than the diphyDPC ones, which resemble cell membranes 
biologically relevant in the context of this study. Surprisingly, both peptides used 
as negative controls could induce current steps indicating that either they can 
form active, pore-forming oligomeric species or that the Aβ-membrane interaction 
and pore formation does not depend on the aggregation state.  
 Effects of Aβ treatment on the plasma membrane of hippocampal autaptic 
neurons 
Since membrane composition was found to be an important factor determining 
the formation of amyloid pores in the experiments of the previous section, I 
performed the subsequent measurements on the plasma membrane of autaptic 
hippocampal neurons, a biologically more relevant membrane model for a human 
disease like AD.  
3.5.2.1. Use of GABA-induced currents recorded in cell-attached configuration to 
investigate perforated patch-like effects of 10 µM intrapipette Aβ 
One of the major technical challenges of the study of amyloid pore formation was 
to set an experimental design that would allow me to distinguish the signal 
derived from the insertion of actual discrete pores from noise generated by the 
spontaneous, partial rupture of the neuronal membrane during the recording. 
Unlike classical pores constituting defined subunits in channels or receptors, 
amyloid pores had been reported to be only transiently located in the membrane 
and to have multiple conductance levels. For this reason, their electrical signal 
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would be very similar to recording artifacts found if the tightness of the membrane 
seal were lost during the experiment (Arispe, Pollard and Rojas, 1993). In this 
context, I performed cell-attached recordings of autaptic hippocampal neurons 
combined with measurements of the rundown of GABA-induced currents over 
time when an ATP-free intracellular solution was utilized. 
Figure 21. Measurements of GABA currents and perforated patch-like configuration using 
10 µM intrapipette Aβ.  (A) Whole-cell recordings of GABA-induced currents over time using 
hippocampal intracellular solution with or without ATP. Low access resistance (series resistance 
<15 MΩ) was maintained over the course of the experiments. (i) Representative traces of GABA-
induced currents. A faster rundown was found in the neurons dialyzed with intracellular solutions 
without ATP. (ii) Quantification of GABA amplitudes over time. (n= 6-7, from at least N=3 different 
cultures and Aβ preparations; two-way ANOVA, main effect “intracellular solution”: F(1,60)= 71.87, 
***p< 0.001; interaction: F(6,60)= 2.861, *p= 0.0162; Sidak’s multiple comparisons test: see table  
10). Black stars represent the effect of intracellular solution as main effect using two-way ANOVA. 
The gray stars represent the results of Sidak’s multiple comparisons test. (B) (i) Schematic of the 
experimental design for the cell-attached/perforated patch experiments. Recordings were 
performed on cell-attached configuration using intracellular solution without ATP, with 10 µM 
oligomeric Aβ or equivalent volume of the vehicle in the patch pipette. Pulses of 3 µM GABA were 
applied every 10 minutes. (ii) Quantification of GABA-induced currents over time in cell attached 
configuration with 10 µM Aβ or vehicle within the patch pipette. Inset: representative traces of 






Initially, I performed whole-cell recordings on hippocampal autaptic neurons and 
applied pulses of 3 µM GABA every 3-4 minutes. Regular intracellular solution or 
a modified ATP-free intracellular solution were used to dialyze the neuronal 
cytoplasm, provided that the access resistance was low for the duration of the 
entire experiment (<15 MΩ). When compared over time, the amplitudes of GABA-
induced currents measured in the absence of ATP showed a marked rundown 
that was not observed in the control condition (Figure 21A i-ii, Table 16).  
Afterwards, I used the GABA rundown effect as an indicator of dialysis of the 
cytoplasm in the study of Aβ pore formation. I hypothesized that Aβ might form 
pores that would provide electrical access to the neuron without physically 
permitting the dialysis, thus allowing the recording of increasingly larger GABA- 
induced currents as more pores were added to the membrane, with no rundown, 
in a perforated patch-like configuration (Figure 21B i). Aβ oligomers were freshly 
prepared before the recordings and dissolved in the ATP-free intracellular 
solution at 10 µM. Unlike the protocols for the Aβ treatments described so far, 
Aβ was applied for a shorter period (40-70 minutes) only onto a small patch of 
the neuronal plasma membrane at the tip of the pipette, in cell-attached 
configuration. No GABA-induced currents were found in either of the 
experimental groups in the first 20 minutes of recordings indicating a tight 
membrane seal and the absence of pores (Figure 21B ii). After 20 minutes, the 
GABA-induced current amplitudes increased in both groups, but more markedly 
in the Aβ-exposed patches. However, after reaching a peak at 40 minutes, the 
GABA-induced currents showed a decreasing pattern similar to the rundown 
found when the tight seal was purposely broken to gain access to the whole cell. 
These results suggested that a partial rupture of the membrane patch could be 
responsible of the gain of electrical access to the cell rather than the formation of 
discrete pores.  






Presence of ATP 
Interaction Sidak’s MCT 
Time p value Summary 




F (6,60) = 
1.912 
0.093 








5 0.060 n.s. 
8 0.020 * 
11 0.006 ** 
14 0.002 ** 
TwA: two-way ANOVA, MCT: multiple comparisons test. 17 >0.001 *** 
20 >0.001 *** 
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3.5.2.2. Analysis of membrane properties of hippocampal autaptic neurons upon 
Aβ treatment 
Next, I tested the effects of Aβ exposure for 72 hours on the passive and active 
membrane properties of hippocampal autaptic neurons. The electrical membrane 
properties depend largely on its population of ionic channels. I therefore 
hypothesized that membrane properties would be altered if amyloid pores were 
present, since they would allow aberrant movements of ions. In these 
experiments, the cultured neurons were treated on DIV 8-9 and recordings were 
performed on DIV 11-12 in current-clamp mode. The first parameter tested was 
the resting membrane potential (Figure 22A), which indicated that membranes 
from Aβ-treated cells were slightly hyperpolarized when compared to the 
controls, although this difference was not statistically significant. Afterwards I 
stimulated the neurons by injecting a series of 1-second hyperpolarizing pulses 
of current from -100 pA to -20 pA (Figure 22B i). The voltage responses to these 
steps were used to calculate the membrane input resistance, which was similar 
in both Aβ-treated and control neurons (Figure 22B ii). I also utilized a series of 
1-second depolarizing pulses of current to trigger action potentials, in order to 
observe their properties upon Aβ treatment. Square pulses of 10 pA were used 
and the number of steps applied were either three times the rheobase or up to a 
maximum of 400 pA (Figure 22C). The rheobase, defined as the minimum 
amplitude of a current pulse that could elicit an action potential, was not changed 
in Aβ-treated neurons (Figure 22D). The frequency of action potential firing 
measured as the number of action potentials triggered by a voltage step 10 pA 
larger than the rheobase, was conserved upon exposure to Aβ (Figure 22E). The 
first action potential triggered by a current pulse was used to analyze the kinetics 
of the depolarization and hyperpolarization (Figure 22F). The action potential 
threshold was calculated as the voltage in the raw trace that coincided with the 
peak of the third derivative of the raw trace (Figure 22G). No changes were 
observed in the action potential threshold in neurons exposed to Aβ. To 
characterize the depolarizing phase, the action potential overshoot was 
measured as the voltage amplitude from 0 mV to the maximum voltage reached 
(Figure 22H i) and the amplitude, as the value of the maximum voltage reached 
when the baseline was adjusted to the action potential threshold (Figure 22H ii). 





Figure 22. Changes in membrane properties and action potential shape in Aβ-treated 
neurons.  (A) Resting membrane potential. (B) (i) Representative traces of voltage responses to 
1-second steps of hyperpolarizing currents. (ii)  Input resistance calculated from the traces in (i). 
(C) Representative traces of voltage responses to the injection of depolarizing currents. (D) 
Rheobase. (E) Frequency of action potential firing at a current step 10 pA larger than the rheobase 
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overshoot and a 10% reduction in the amplitude. The action potential half-width 
was measured as the duration of the peak when the voltage was half the value 
of the amplitude. A 15% increase in half-width duration was observed when 
neurons were exposed to 10 µM Aβ for 72 hours (Figure 22 H iii). The properties 
of the afterhyperpolarization (AHP) phase were also characterized. The AHP 
amplitude was measured as the voltage between the threshold and the minimum 
value of the action potential after the depolarization peak (Figure 22I i) and the 
AHP half-decay time as the duration of the action potential at a voltage half the 
AHP amplitude (Figure 22I ii). No changes were observed in the AHP phase upon 
Aβ treatment. Finally, recordings of EPSCs in voltage-clamp were obtained from 
each cell as a control for Aβ toxicity on synaptic transmission (Figure 22J). As 
observed in previous sections, the Aβ treatment induced a 50% reduction in the 
EPSC amplitude. Taken together, these results suggest that the conductance to 
potassium might be increased in the Aβ-treated neurons, which could explain a 
mild hyperpolarization and the reduction in the action potential amplitude.  
A summary of the results from this section is presented in Table 17. 
 Comparison of toxicity of Aβ and its stereoisomer AllD 
In this final set of experiments, I compared the deleterious effects on hippocampal 
autaptic neurons of the “wild type” L-Aβ42 peptide versus the artificial 
stereoisomer AllD Aβ42, which is composed of D- amino acids. These 
experimental settings allowed me to define whether stereospecific Aβ- 
membrane interactions were involved in the occurrence of the previously 
observed toxic effects. 
3.5.3.1. AllD Aβ showed identical structural properties and aggregated with 
similar kinetics to Aβ, with different stereospecificity 
A set of experiments were performed to compare the structural properties of AllD 
Aβ and Aβ monomers. In collaboration with Uwe Pleßmann and Prof. Henning 
Urlaub (Bioanalytical Mass Spectrometry Research Group, Max Planck Institute 
(F) Representative traces of isolated action potentials. (G) Action potential threshold. (H) Action 
potential depolarizing phase. (i) Action potential overshoot. (n= 18-21 neurons from N=2 cultures; 
Mann-Whitney test, **p= 0.004). (ii) Action potential amplitude (n= 18-21, N=2 cultures; Mann-
Whitney test, **p= 0.008). (iii) Action potential half-width (n= 18-21, N=2 cultures; Mann-Whitney 
test, *p= 0.015). (I) Action potential afterhyperpolarization. (i) Amplitude. (ii) Half decay time. (J) 
EPSC amplitude. (n= 21-23, N=2; Mann-Whitney test, **p= 0.008). Bars represent the mean. 





for Biophysical Chemistry), a mass spectrometric analysis (Figure 23A i-ii) 
showed that the monomerized Aβ and AllD Aβ had the same molecular weight. 
Together with Kris Runge and Dr. Nasrollah Rezaei-Ghalleh (NMR Based 
Structural Biology Department, Max Planck Institute for Biophysical Chemistry), 
two-dimensional homonuclear NMR experiments were performed and 1H-
TOCSY spectra were obtained from Aβ and AllD Aβ (Figure 23B). The spectra 
from both stereoisomers highly overlapped, indicating that the primary structures 
of both peptides were identical.  
In order to compare the aggregation kinetics between the Aβ and AllD Aβ, the 
peptides were monomerized and incubated at 37°C with external agitation at 800 
rpm, as described in section 3.1. In addition to the AllD Aβ and Aβ, the 
aggregation of scr Aβ was also characterized in this experiment. Samples were 
taken at increasing incubation time points, then separated using SDS-PAGE and 
labelled with silver staining (Figure 23C). The gel images showed that Aβ and 
AllD Aβ were dissolved and aggregated in a similar fashion, but with differences 
in the relative concentration of species at each given time point. At S0, the Aβ 
solution was mostly composed by species smaller than 17 kDa, whereas a smear 
Fig. 
Parameter 
Vehicle Aβ p 
value 
Summary Test 
Mean SEM n Mean SEM n 




35.88 4.016 23 39.73 3.896 18 0.366 n.s. 
Mann-
Whitney 
21D Rheobase (pA) 69.52 20.17 21 73.89 16.37 18 0.56 n.s. 
Mann-
Whitney 
21E AP frequency (Hz) 5.571 0.826 21 3.944 0.822 18 0.089 n.s. 
Mann-
Whitney 
21G AP threshold (mV) -34.27 0.981 21 -33.22 1.171 18 0.497 n.s. t-test 
21H i AP overshoot (mV) 46.88 1.436 21 40.22 2.267 18 0.004 ** 
Mann-
Whitney 
21H ii AP amplitude (mV) 81.14 1.889 21 73.45 2.91 18 0.008 ** 
Mann-
Whitney 






-16.45 0.992 16 -14.32 1.075 15 0.154 n.s. t-test 
21I ii 
AHP half decay 
time (ms) 




-7.205 1.063 23 -3.691 0.775 21 0.008 ** 
Mann-
Whitney 
Table 17. Summary of membrane properties and action potential shape changes in hippocampal 
autaptic neurons treated with 10 µM Aβ for 72 hours. 
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could be found between 49 and 62 kDa in the AllD Aβ sample. At later time points, 
however, Aβ formed high molecular aggregates larger than 98 kDa, while species 
between 62 and 98 kDa could be found until the end of the experiment in the 
case of the AllD Aβ solution. The scr Aβ remained mostly in monomeric state 
Figure 23. AllD Aβ has identical structural properties and aggregates with similar kinetics 
to Aβ, but with different stereospecificity. (A) Deconvoluted mass spectrum of (i) Aβ and (ii) 
AllD Aβ. (B) Juxtaposed 1H-TOCSY spectra of Aβ and AllD Aβ. (C) Silver staining of Aβ, AllD Aβ 
and scr Aβ samples taken at increasing incubation times. (D) TEM images of AllD Aβ. Scale bars 
at 5,000x = 500 nm; at 20,000x = 250 nm. (E) Samples from hippocampal autaptic neuronal 
culture medium treated with Aβ, AllD Aβ or vehicle were loaded by duplicates and separated using 
SDS-PAGE. (i) Silver staining of one half of the gel. The bands correspond to serum proteins 






until the end of the experiment, but surprisingly, some species larger than 98 kDa 
could be found after 72 hours of incubation. In addition to silver staining, TEM 
grids were prepared and imaged, showing that upon dissolution some fibrillar 
aggregates could be found in the AllD Aβ solution. After 24 hours of incubation 
the most abundant species were protofibrillar aggregates (Figure 23D). Finally, 
the culture medium of hippocampal neurons was collected after 72 hours of 
treatment with 10 µM Aβ, 10 µM AllD Aβ or the vehicle. Duplicate samples were 
loaded on a SDS-PAGE gel. After separation, the gel was cut in half to be 
processed by silver staining and Western blot. Multiple bands were found in the 
silver staining which corresponded to serum proteins from the neuronal culture 
medium (Figure 23E i). The signal corresponding to the Aβ peptides could not be 
distinguished from the serum protein bands and it was also possible that the 
concentration was too low to be detected by silver staining. The remaining half of 
the gel was processed for Western blotting using the sequence specific anti-Aβ 
antibody 6E10 (Figure 23E ii). As expected, bands were found only in the lane 
loaded with Aβ, with no signal in the AllD Aβ or the vehicle lanes.  
These results confirmed that Aβ and AllD Aβ are structurally identical and they 
aggregated with similar kinetics, but had opposite stereospecificity.  
3.5.3.2. AllD Aβ did not share the toxic properties of Aβ on synaptic transmission 
and morphology of hippocampal autaptic neurons  
In this last set of experiments, I compared the effects of the stereoisomers Aβ 
and AllD Aβ on neuronal morphology and synaptic transmission. Autaptic 
hippocampal neurons were treated on DIV 8 with 10 µM oligomerized Aβ, 10 µM 
oligomerized AllD Aβ or equivalent volume of the vehicle. After 72 hours of 
exposure to the peptides, the cultures were fixed to study neuronal morphology 
or used to obtain electrophysiological recordings. 
After fixation on DIV 11, the cultures were immunolabelled with antibodies 
against MAP2, VGluT1, and Shank2 to quantify dendritic branching and the 
number of synaptic puncta. Sholl analysis was performed on binarized images 
from the MAP2 signal as before (Figure 24A). The plot of the number of 
intersections versus the distance from the cell soma showed a similar distribution 
of dendritic branches for all the experimental groups (Figure 24B). The enclosing 
radius (Figure 24C i) and total number of intersections (Figure 24C ii) were also 
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compared, with no statistically significant differences found between the 
treatments. However, there was a trend in both Aβ-treated groups towards a 
smaller enclosing radius (n= 36-38 neurons from at least N=3 cultures and Aβ 
preparations; one-way ANOVA, p= 0.071). 
VGluT1 and Shank2 signals were used to label and quantify synaptic structures 
(Figure 25A). When compared, neither the number of VGluT1-positive 
presynaptic puncta (Figure 25B i), the postsynaptic Shank2-positive puncta 
(Figure 25B ii), or the number of puncta positive for both markers used as a proxy 
for synapse number (Figure 25B iii) were modified by exposure to either of the 
Aβ peptides. The fluorescence intensity of the VGluT1 signal was used as a 
measurement of the number of synaptic vesicles per presynaptic terminal (Figure 
25B iv). No changes were found in this parameter between the compared groups. 
After establishing that the exposure to AllD Aβ did not induce any obvious 
changes in neuronal morphology, electrophysiological recordings were 
performed to investigate putative synaptic functional defects induced by AllD Aβ. 
On DIV 11, after 72 hours of exposure to 10 µM Aβ, 10 µM AllD Aβ, or the vehicle, 
synaptic transmission was studied using whole-cell recordings. As found in other 
sections of this study, the exposure to Aβ induced a 58% reduction in the EPSC 
amplitude (Figure 26A i-ii). In contrast, no changes were found in AllD Aβ-treated 
neurons. 
Figure 24. AllD Aβ treatment did not alter dendritic branching.  (A) Representative images of 
the skeletonized MAP2 signal used for Sholl analysis to describe dendritic branching. (B) 
Distribution of dendrite number versus distance from the center of the cell somata. (C) 
Comparison of (i) the enclosing radius and (ii) the total number of intersections per neuron 
measured from vehicle, AllD Aβ- or Aβ-treated neurons. Bars represent the mean. Error bars 




Similarly, the RRP size evoked by application of 0.5 M sucrose showed a 46% 
reduction in the Aβ-treated neurons whereas a conserved RRP was observed in 
the AllD Aβ exposed group (Figure 26B i-ii). No changes were observed in the 
Pvr (Figure 26C). A pulse of 100 µM glutamate was applied to study the 
postsynaptic response, which was similar in all experimental groups (Figure 26D 
i-ii). Recordings of mEPSCs in the presence of TTX were obtained (Figure 26E 
i). Both the frequency (Figure 26E ii) and the amplitude (Figure 26E iii) of the 
Figure 25. AllD Aβ treatment did not modify the number of synaptic puncta. (A) 
Representative images of autaptic hippocampal neurons fluorescently labelled against MAP2, 
VGluT1 and Shank2. (B) Quantification of (i) VGluT1 puncta, (ii) Shank2 puncta and (iii) puncta 
with juxtaposed VGluT1 and Shank2 signal. (iv) Comparison of the VGluT1 intensity between 
groups. Bars represent the mean. Error bars represent SEM. Vehicle, black bars; AllD Aβ, orange 
bars. Aβ, pink bars. 
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mEPSCs were conserved between the groups, with a trend towards a reduced 
frequency in the Aβ-treated group. Finally, a train of depolarizing stimuli at 10 Hz 
was applied (Figure 26F). Neither the calculated paired-pulse ratio nor the 
depression ratio were changed upon treatment with the Aβ peptides.  
In summary, the lack of morphological or functional effects of the AllD Aβ peptide 
suggested that the Aβ toxicity depended on molecular interactions that were 
stereospecific, such as the ligand-receptor binding.  





Figure 26. AllD Aβ treatment induced no toxic effects on synaptic transmission. (A) (i) 
Representative traces of EPSCs upon stimulation with a 2-ms depolarizing pulse. (ii) 
Comparison of EPSC amplitudes (n= 26-39 neurons from at least N=3 cultures and Aβ 
preparations; Kruskal-Wallis test, ***p<0.001; post-hoc Dunn’s multiple comparisons test: 
Vehicle vs Aβ: ***p<0.001, AllD Aβ vs Aβ: **p= 0.002 ) (B) (i) Representative traces of the RRP 
evoked by application of 0.5 M sucrose (ii) Quantification of RRP size (n= 17-36,N=3; Kruskal-
Wallis test, *p=0.024; post-hoc Dunn’s multiple comparisons test: Vehicle vs Aβ: *p=0.020). (C) 
Comparison of the calculated Pvr. (D) (i) Representative traces and (ii) quantification of 
glutamate-induced currents. (E) (i) Representative recordings of spontaneous activity measured 
in the presence of TTX. (ii) Quantification of mEPSC frequency and (iii) amplitude. (F) (i) Short 





Table 18. Statistical analysis of AllD Aβ versus Aβ effects on hippocampal neurons.  
Fig. Parameter Vehicle AllD Aβ Aβ p 
value 
Summary Test 
Mean SEM n Mean SEM n Mean SEM n 
Sholl - synaptic puncta (autaptic cultures)  
23C i Enclosing 
radius (µm) 
138.9 6.616 36 122.9 5.937 36 120.1 5.872 38 2.702 n.s.  one-way 
ANOVA 
23C ii Total 
intersections 
197.8 11.6 36 168.3 9.82 36 180.1 11.68 38 0.176 n.s.  one-way 
ANOVA 
24B i VGluT1 
puncta 
404.8 43.69 36 321.4 33.59 38 348.9 34.84 36 0.330 n.s.  Kruskall-
Wallis  
24B ii Shank2 
puncta 
510.3 60.96 36 445.8 56.41 38 446.3 46.12 36 0.531 n.s.  Kruskall-
Wallis 
24B iii VG+/Sh2+ 
puncta 
250.6 34.77 36 180.2 23.54 38 185.9 19.53 36 0.148 n.s.  Kruskall-
Wallis 
24B iv VGluT1 
intensity (16-
bit) 
109.2 6.395 36 112.6 6.756 38 112.8 6.625 35 0.925 n.2. Kruskall-
Wallis 
Electrophysiology (autaptic cultures) 




25B ii RRP (nC) -0.719 0.108 28 -0.588 0.088 36 -0.394 0.100 17 0.024 * Kruskall-
Wallis  





-2.963 0.349 28 -3.314 0.371 27 -2.763 0.556 18 0.252 n.s. Kruskall-
Wallis 
25E ii mEPSC 
frequency 
(Hz) 
7.793 1.117 26 7.303 0.868 28 5.374 1.128 18 0.159 n.s. Kruskall-
Wallis 
25E iii mEPSC 
amplitude 
(pA) 
-26.54 2.33 26 -24.46 1.16 28 -21.45 1.487 18 0.125 n.s. Kruskall-
Wallis 
25F ii Paired-pulse 
ratio 
0.876 0.021 31 0.871 0.028 35 0.930 0.051 23 0.432 n.s. one-way 
ANOVA 
25F iii Depression 
ratio 
0.482 0.029 31 0.453 0.029 35 0.438 0.037 23 0.481 n.s. Kruskall-
Wallis 
EPSC amplitude: Dunn's multiple comparisons test; Vehicle vs. Aβ: ***p< 0.001; AllD Aβ vs. Aβ: **p=0.002. 
RRP size: Dunn's multiple comparisons test; Vehicle vs. Aβ: *p= 0.020  
(iii) depression ratio. Bars represent the mean. Error bars represent SEM. Vehicle, black bars; 







After more than 25 years since the amyloid cascade hypothesis was formulated 
to explain the role of Aβ in AD, many questions have been answered but central 
ones remain open (Selkoe and Hardy, 2016). The original hypothesis has been 
reformulated, shifting the focus from plaque deposition to the accumulation of 
soluble oligomeric aggregates. In addition, the use of standardized biomarkers 
and the widespread use of passive immunization in phase II/III clinical trials will 
hopefully generate in the near future new evidence that will help to finally explain 
the molecular nature of Aβ toxicity. 
A still open question that I aimed to answer in the present study is how an excess 
of Aβ peptide in the surroundings of neurons can induce deleterious effects in 
synaptic function, focusing on the amyloid pore hypothesis and intending to set 
the stage for testing putative protective effects of the novel small molecule 
anle138b.  
In the first part of my work I focused on establishing a reproducible method for 
obtaining synthetic Aβ oligomers that could be applied to diverse model systems. 
To this end, I utilized a two-step method for Aβ dissolution which yielded 
oligomer-enriched solutions, extensively characterized here using biochemical 
and imaging methods.  
Later, I observed that the treatment of autaptic hippocampal cultures with Aβ 
oligomers impaired synaptic transmission, which was mostly caused by 
presynaptic dysfunction and devoid of gross accompanying morphological 
alterations, besides a small but statistically significant reduction in branching. 
This observation is in agreement with previous work by others and points to the 
presynaptic terminal as a target of Aβ toxicity. Further analysis of neurons 
exposed to Aβ oligomers for shorter periods pointed towards an enhancement in 
synaptic transmission, indicating that the quality of Aβ effects depend on the 
duration of treatment. In addition, I analyzed the efficacy of the small molecule 
anle138b, which could not prevent Aβ synaptotoxicity when applied as amyloid 
pore blocker. However, further experiments testing its properties as inhibitor of 
the amyloid aggregation might render different results.  
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Finally, I took advantage of several model bilayers to investigate the putative 
formation of pores by Aβ oligomers. Here I demonstrated that the same oligomer 
preparation that impaired presynaptic release failed in altering membrane 
properties in most of the models used or induced pore formation in a very low 
frequency (see Supplementary Material). Moreover, I could show that AllD Aβ, 
the enantiomer of the naturally occurring Aβ42, despite a similar aggregation 
propensity, lacks the toxicity of the L-counterpart. I therefore propose that the Aβ 
toxic effects on synaptic transmission that I observed in the in vitro model depend 
on a stereospecific molecular interaction yet to be elucidated, rather than on the 
formation of membrane perforations.  
 In vitro oligomeric preparations are a versatile tool to study Aβ toxicity 
Recapitulating Aβ toxicity using in vitro generated oligomers offers several 
advantages. For example, a single isoform of synthetic or recombinant Aβ can 
be analyzed at a time and the aggregation conditions can be adjusted to obtain 
mixtures of well-characterized species, which minimizes the variability of the 
results. A key step in the preparation of toxic aggregates is the dissolution method 
(Teplow, 2006). In this study I tested two different methods for Aβ42 
solubilization: an alkali-based using double-distilled water and 0.5% ammonia, 
and a two-step dissolution protocol comprising the initial application of 100% 
HFIP, a lyophilizing step and a final dissolution in 100 mM NaOH. Although the 
ammonia dissolution method has been validated by others, in the experiments 
reported here it failed to dissolve large Aβ aggregates and was therefore not 
further utilized (Ryan et al., 2013). Conversely, HFIP could successfully dissolve 
the peptide in the first step. The use of HFIP to erase the peptide “structural 
history” was validated 15 years ago (Stine et al., 2003). However, a recent study 
suggested that HFIP and film formation during lyophilization could induce the 
aggregation of Aβ into low-molecular weight oligomers, which were not 
detectable by TEM but were observed by dynamic light scattering in the literature 
reports. These low-molecular weight oligomers were linked to a faster rate of fibril 
formation evidenced by ThT fluorescence measurements and reduced toxicity 
when applied to PC12 cells (Ryan et al., 2013). In the present study, HFIP was 
always followed by solubilization in 100 mM NaOH. It is therefore not possible to 




The two-step dissolution protocol yielded an Aβ solution that contained ~ 50% 
monomers to hexamers. This is in agreement with previous reports that Aβ 
monomers, even when purified by SEC, are readily in equilibrium with 
pentamers-hexamers (Bitan et al., 2003). In addition, the monomer-enriched 
solution contained a percentage of aggregates larger than 63 kDa (~17%) which 
would theoretically correspond to 12-mers. This initial aggregation is almost 
unavoidable without using SEC at the Aβ concentrations used in these 
experiments. The presence of these aggregates that could act as seeds, 
correlate with the lack of a lag phase in the ThT fluorescence measurements and 
the presence of some isolated fibrillar aggregates observed in TEM.  
By means of incubating the monomeric solution for 40 minutes at 37°C with 
external agitation, the content of oligomers larger than 12-mers was increased, 
and this corresponded with the emergence of protofibrillar structures evidenced 
by TEM. Unexpectedly, after 3 days of incubation no typical single, isolated 
mature fibrils were found. In turn, I observed an entangled accumulation of fibrillar 
aggregates, highly contrasted, from which single structures were not possible to 
be resolved (Figure 27, left). In addition, TEM also revealed lateral interaction of 
the fibrils (Figure 27, center) as reported by Tycko and collaborators for Aβ40 
fibrils grown in agitation (Figure 27 right, from Petkova et al., 2005. Reprinted 
with permission from AAAS. Licence number: 4622571423534). Given the 
unconventional morphology of these fibrillar species, it is possible that the 
oligomers described before represent “off-pathway” aggregates, i.e., that they 
escape the amyloidogenic path towards fibril formation and remain in solution as 
oligomers.  
In conclusion, I found here that the two-step protocol is more effective in 
disassembling preformed Aβ42 aggregates than a single solubilization step with 
Figure 27. Fibrillar species observed by TEM grown under agitation.  (Left) Accumulation of 
highly stained protofibrillar aggregates and (center) lateral interacting fibrils obtained using the 
Aβ42 preparation protocol described here. Aβ42 was incubated at 110.25 µM for 72 hours, with 
external agitation. (Right) Aβ40 fibrils with lateral interaction obtained by Tycko and collaborators 
by gentle circular agitation. Inset is 2x. 
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ammonia. Furthermore, the incubation conditions used here allowed for the rapid 
preparation of a protofibril-enriched solution that can be diluted in culture medium 
for the investigation of Aβ synaptotoxic properties. 
 Aβ effects on neuronal survival, physiology, morphology and development 
 72-hour Aβ treatment mildly reduce neuronal viability without limiting the 
use of the surviving neurons for morphological and functional studies 
Here I aimed to gain insight into Aβ-induced changes in synaptic transmission, 
which have been shown to occur before frank neuronal loss. Therefore, in a first 
set of experiments I sought to determine putative deleterious Aβ effects on 
neuronal survival, since a significant increase in neuronal death would not be 
compatible with functional and morphological studies. Hippocampal neurons 
grown in mass cultures at high density were exposed to 10 µM oligomeric Aβ 
aggregates for 72 hours. I observed a ~30% increase in cell death upon Aβ 
exposure with respect to the vehicle-treated condition, expressed as a higher 
count of picnotic nuclei. A limitation of this experiment was the use of the DNA-
binding dye Hoechst to obtain the total number of nuclei per coverslip. It is 
possible that some of the counted nuclei corresponded to astrocytes, which 
occasionally are able to survive despite the growing conditions being optimized 
for nerve cells. It was not possible to immunolabel nuclei with a neuronal marker 
because the experiments were performed without permeabilization or fixation.  
Whereas here I measured the excess of pyknotic nuclei as a proxy for cell death, 
Jan et al. used the count of NeuN-immunolabelled neuronal nuclei to determine 
the survival of rat hippocampal neurons in the presence of mixtures of synthetic 
Aβ species (Jan et al., 2008). Interestingly, the authors could show that the 
preparation containing 10 µM protofibrillar Aβ42 induced a ~35% reduction of 
neuronal nuclei, whereas the mixture of 5 µM protofibrillar and 5 µM monomeric 
Aβ42 produced a ~50% reduction in the nuclei count. The Aβ species preparation 
that I established here yields a mixture of oligomeric and monomeric species of 
Aβ. Whereas here I observed a ~30% increase in picnotic nuclei, Jan et al. 
reported more than 50% of neuronal loss. I hypothesize that the main cause of 
this discrepancy is the exposure time to Aβ. Whereas I exposed the neurons to 




These results show that 72 hours are a convenient duration of treatment to study 
effects of Aβ on synaptic transmission, before the cultures have suffered an 
increase in neuronal death. In addition, considering its limitations, these results 
are in agreement with the findings in human AD patients, in which the 
accumulation of Aβ does not correlate with gross neuronal loss (Gómez-Isla et 
al., 1997).   
 Aβ induced a prominent impairment of presynaptic function in autaptic 
cultures when applied for 72 hours, most likely mediated by interaction with 
proteins of the synaptic vesicle release machinery 
The main open question I aimed to answer here was that of the nature of Aβ 
synaptic toxicity. In this context, I aimed to determine whether treatment of 
autaptic glutamatergic hippocampal neurons with 10 µM oligomeric Aβ for 72 
hours could replicate in vitro the synaptotoxic effects reported in other AD 
models. My main finding was a drastic reduction in basal synaptic transmission. 
EPSC amplitude and RRP size showed a 60% and 48% decrease, respectively. 
There was a moderate but significant change in the response to exogenous 
glutamate application, which was reduced ~20% with respect to the vehicle-
treated neurons, and mEPSC frequency showed a 35% reduction. In addition, I 
observed no changes in the Pvr. Importantly, the release of glutamate in an 
effective and temporally precise manner plays a central role in brain function as 
a whole, but is especially relevant in memory- and learning-related synaptic 
plasticity in the hippocampus (Basu and Siegelbaum, 2015). Therefore, the deficit 
in neurotransmitter release observed here would have devastating 
consequences in hippocampal function, if such Aβ-exposed neurons were 
integrated in its circuits. Several mechanisms could potentially explain the above 
described phenotype:  
 Synapse/ spine loss. Synapse and spine loss are hallmarks of AD 
neuropathology. Hence, they have been widely studied in relation to 
Aβ deposition (see section 1.3.3; Ripoli et al., 2013). I consequently hypothesized 
that synapse loss could underlie the findings presented above, namely a 
reduction in evoked release and RRP. However, to cause the 60% EPSC 
amplitude reduction observed in Aβ-treated neurons, loss of synapses or 
dendritic spines should have resulted in reduced AMPA currents induced by 
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exogenous glutamate application to a much greater extent. Alternatively, it is also 
possible that synapses and spines were indeed reduced in number but with no 
change in surface extrasynaptic AMPA expression, which would explain the 
observed impairment of basal synaptic transmission accompanied by an almost 
normal glutamate-induced current. In order to determine whether the dendritic 
tree was altered and to investigate synaptic number, I performed 
immunostainings on Aβ-treated autaptic hippocampal neurons. In contrast with 
the findings by Ripoli et al., immunocytochemistry of the treated neurons revealed 
an unchanged number of pre- and postsynaptic puncta by VGluT1 and Shank2 
staining, as well as VGluT1/ Shank2 co-labelled puncta, with a mild reduction 
(~15 %) in dendritic branching. Altogether, the results I presented indicate that 
Aβ-treated neurons displayed a normal morphology, with no synapse loss, and 
consequently the electrophysiological results must be explained by ultrastructural 
or molecular Aβ-induced changes. Since the electrophysiological and imaging 
experiments were performed using different sets of cultures and Aβ preparations, 
further experiments could be done to directly correlate electrophysiology with 
fluorescence microscopy by biocytin-filling for fluorescent labelling of the autaptic 
neurons that have been used for recordings.  
 Alterations in the synaptic proteome. The loss of presynaptic proteins has 
been reported previously by others in Aβ-treated neurons (Parodi et al., 2010; 
Ripoli et al., 2013). Here protein quantification could not be performed using 
samples from autaptic cultures due to two factors: first, autaptic cultures are 
grown at low neuronal density (~400 / cm2) and second, feeder astrocytes are 
used to support neuronal development. As a result, the protein yield would have 
been too low for Western blotting and also the sample would have been 
contaminated with proteins from the supporting glial cells. Therefore, in order to 
investigate whether Aβ incubation could change the protein composition of 
synapses, I used mass cultures for these experiments. In discrepancy with 
previous findings by others, using Western blot analysis I found no changes in 
the pre- or postsynaptic proteins tested with exception of Synaptotagmin-1, which 
was reduced by 20%. Previous studies with the Synaptotagmin-1 KO mouse line 
revealed that only homozygous KO animals displayed a lethal phenotype at birth, 
and cultured homozygous neurons showed a drastic reduction in synchronous 
release (Geppert et al., 1994). These alterations were absent in heterozygous 




decrease in in Synaptotagmin-1 protein expression is necessary to induce a 
funtional presynaptic defect. These results, if extrapolated to the experiments 
described here, indicate that it is highly unlikely that the observed 
Synaptotagmin-1 reduction induced by exposure of dissociated neurons to Aβ 
explains the electrophysiological alterations caused by the Aβ incubation in 
autaptic neurons.  
 Alterations of synaptic vesicle pools. Several studies that have addressed 
presynaptic alterations in Aβ-exposed neurons focused on the depletion of the 
total pool of synaptic vesicles as a putative mechanism of synaptic dysfunction. 
Parodi et al. observed that dissociated mass hippocampal neuronal cultures 
exposed to 500 nM Aβ40 for 24 hours showed more than a 50% reduction in the 
number of vesicles per area of the terminal using EM, which was accompanied 
by a reduction in AMPA mEPSCs (Parodi et al., 2010). In order to study the size 
of the RRP, the authors applied a pulse of hypertonic sucrose solution and 
measured the miniature-current frequency, which was reduced in Aβ40-treated 
neurons. In addition, direct application of AMPA induced similar currents in both 
control and Aβ40-treated group, indicating an unchanged expression of surface 
AMPA receptors. Interestingly, the authors showed that acute application of 500 
nM to 5 µM Aβ to the culture induced a transient increase in Ca2+ measured in 
selected regions of the cell somata, mediated by putative amyloid pores. Blockers 
of these pores such as the NA7 peptide could not only inhibit the Ca2+ influx but 
also prevented the decrease in mEPSC frequency observed after 24 hours of 
treatment. In another approach, Kelly et al. showed in neuronal cultures exposed 
to 2 µM Aβ for 24 hours that an NMDA-mediated enhancement of intracellular 
Ca2+ caused the activation of calpain, which in turn led to loss of dynamin-1 and 
impaired vesicle recycling (Kelly, Vassar and Ferreira, 2005; Kelly and Ferreira, 
2006, 2007). More recently, Zhou et al. proposed that pathogenic tau can bind 
and cross-link synaptic vesicles and F-actin, reducing vesicular mobility and 
impairing vesicle release (Zhou et al., 2017). In principle, a depletion of the total 
synaptic vesicle pool could explain the decrease in the size of EPSCs and RRPs 
as well as the reduced mini frequency that I observed in this study. However, I 
did not observe alterations in the intensity of VGluT1 puncta, suggesting that the 
number of vesicles per terminal was intact. Nevertheless, it is possible that using 
a higher resolution method, such as EM, changes in the vesicle distribution within 
Aβ-treated terminals could be revealed. With respect to the Aβ-mediated 
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impairment of vesicle recycling and mobility, such alterations would induce a 
larger depression of EPSC amplitudes in the final phase of high-frequency trains, 
as seen in dynamin-1 KO neurons, and also found as a consequence of tau 
accumulation in the work by Zhou et al. (Ferguson et al., 2007; Zhou et al., 2017). 
Conversely, I did not find any alteration in the refilling of the synaptic vesicle pool 
as indicated by an unchanged depression ratio in Aβ-treated neurons. Therefore 
neither a reduction in the total vesicle pool nor a refilling defect are likely to 
underlie the results presented here.  
In addition, Park et al. showed that exposure of dissociated rat hippocampal 
neurons to soluble Aβ42 at 200 nM for 2 hours increased intracellular Ca2+ and 
impaired its clearance. Accumulation of Ca2+ led to activation of the 
Ca2+/calmodulin-dependent protein kinase IV, which in turn phosphorylated 
synapsin, inhibiting intersynaptic and axonal vesicle trafficking, impairing 
forskolin-induced LTP (Park et al., 2017). In agreement with this, the authors 
showed that Aβ increased the resting vesicle pool, with no changes in the 
recycling pool. This same group had previously reported, using a similar 
approach, an increase in the RRP with a delayed recovery after high frequency 
stimulation (Park, Jang and Chang, 2013). The effects seen by Park et al. partly 
contradict the studies by Parodi et al. indicating that Aβ exposure depleted the 
total pool of vesicles. However, it is possible that acute exposure to soluble Aβ 
accompanied by a Ca2+ increase induces a temporary enlargement of the total 
pool of vesicles as seen in the work by Park et al., whereas chronic exposure 
(longer than 24 hours), could deplete the pool as reported by Parodi et al. 
Regarding the data that I presented here, I observed a clear reduction in the RRP 
size when autaptic hippocampal neurons were exposed to 10 µM Aβ for 72 hours, 
which is in disagreement with the results by Park et al. 
 Altered Pvr. Recent work by He et al. pointed to a different mechanism of 
toxicity for soluble Aβ oligomers (He et al., 2019). Using a short incubation of 20 
minutes with 400 nM Aβ42 on dissociated hippocampal neurons, the authors 
found a reduction in mEPSC frequency accompanied by a depletion of PIP2 that 
depended on phospholipase C activation, in an mGluR5-PrP dependent 
mechanism. The presynaptic changes observed in this study are mainly related 
to a reduction in Pvr linked to the loss of PIP2 in contrast to the results presented 




 Interaction of Aβ with proteins of the vesicle release machinery. Finally, 
another presynaptic mechanism of Aβ toxicity that has been proposed is the 
direct interaction between soluble oligomers and the H3 domain of syntaxin-1a, 
one of the SNARE proteins at the plasma membrane. This aberrant binding would 
cause the inhibition of vesicle membrane fusion without affecting docking, as 
shown mainly using in vitro membrane fusion assays (Yang et al., 2015). 
Furthermore, it was recently demonstrated that expressing a syntaxin1-a point 
mutant of the H3 domain (syntaxin-1aA240V) in the syntaxin-1a/b double KO 
background showed a similar phenotype to the generated by the syntaxin1a-
Aβ binding, in which vesicle docking but not fusion can be rescued by the mutants 
(Vardar et al., 2016). The mutant-infected neurons which expressed exclusively 
syntaxin-1aA240V showed an almost complete arrest of evoked and spontaneous 
vesicle release. However, in the Aβ-syntaxin interaction scenario only a fraction 
of syntaxin molecules should have to be affected to explain a residual vesicle 
release as seen in the present study. In this context, to confirm the involvement 
of the Aβ-syntaxin interaction, it would be interesting to observe whether an 
overexpression of syntaxin-1a could protect autaptic neurons from Aβ-induced 
toxicity. This mechanism or a similar interaction of an oligomeric form of Aβ with 
a protein of the fusion machinery provides the most plausible explanation for the 
results that I presented in this study.  
 Shorter treatment with Aβ enhanced synaptic transmission in autaptic 
cultures 
Since 72-hour treatment of neurons with 10 µM Aβ greatly reduced synaptic 
transmission, I aimed to induce milder effects that could represent an earlier and 
possibly reversible stage of Aβ-related toxicity. Consequently, I exposed autaptic 
hippocampal neurons to 10 µM Aβ, the concentration used previously, but for a 
shorter period of 24 hours. Surprisingly, instead of observing the expected milder 
version of the 72-hour treatment, I found the opposite effects. EPSCs were ~50% 
larger with a Pvr increased ~40%. No changes in paired-pulse ratio were 
observed, despite the increase in Pvr.  
I posit two hypotheses to explain these results. First, I speculate that the 
enhancement in synaptic transmission and Pvr could be an effect of the 
remaining monomers present in the oligomer solution, which account for ~20% 
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of the Aβ species. As described by others, low Aβ concentrations in the picomolar 
range can enhance synaptic transmission. Abramov et al. showed more than a 
decade ago that Aβ exposure induces an increase in the Pvr (Abramov et al., 
2009). A later study by the same group explained that APP homodimerization 
and Ca2+ influx mediated this effect (Fogel et al., 2014). Alternatively, Lazarevic 
et al. indicated that Aβ can bind α7-nAchR and increase the recycling of the 
synaptic vesicle pool in a CN-CDK5 dependent manner (Lazarevic et al., 2017). 
A second possible explanation is that increased Pvr is part of the initial phase in 
the spectrum of Aβ toxic effects. Park et al. reported that exposure to 200 nM 
Aβ for 2 hours can enhance the Pvr, accompanied by an enlargement of the 
resting pool and a reduction of the recycling pool. However, this group also 
indicated that neurons that had been treated with Aβ for 72 hours showed also 
an increased Pvr. As discussed in the previous section, the results presented 
here suggest that oligomeric Aβ probably exert its toxic effects by binding to 
proteins of the fusion machinery and blocking membrane fusion, which would 
then result in the opposite to an increased Pvr.  
More experiments are necessary to decipher the meaning of these puzzling 
findings. Pharmacological inhibition of the proposed pathways (α7-nAchR, CN-
CDK5, p38MAPK) could be useful to discard or confirm a putative physiological 
enhancement of Pvr mediated by Aβ monomers or oligomers. In addition, 
addressing separately the effects of monomers and oligomers would clarify what 
species is responsible for the changes in Pvr. Finally, immunocytochemistry 
could reveal whether the electrophysiological effects are accompanied by 
morphological changes after 24 hours. On the whole, the question remains open 
as to whether the variation between the effects observed after 24 and 72 hours 
of treatment is a manifestation of the different biological activities of the Aβ 
species contained in the sample or it represent the evolution in stages of the 
same pathophysiological continuum. 
 Dendritic development is moderately altered by the exposure to oligomeric 
Aβ  
As described in the previous sections, treatment with 10 µM Aβ for 72 
hours impaired synaptic transmission on hippocampal autaptic neurons, whereas 




similar time-dependent effects could be induced upon oligomeric Aβ treatment 
on neuronal morphology. In consequence, I exposed autaptic neurons to 10 µM 
Aβ on DIV 8 and fixed them after 24 and 72 hours of treatment. Using the two-
way ANOVA test, I analyzed several morphological parameters considering 
duration and type of treatment as variables. Although the individual variables 
showed no significant changes in either of the analyzed parameters, the 
interaction between type and duration of treatment was statistically significant for 
enclosing radius and total number of intersections, which I interpreted as the Aβ 
treatment having effects in opposite directions over time. This observation is in 
agreement with the data obtained from the electrophysiology, and support the 
notion that two (or more) species of amyloid aggregates, which would exert 
opposing effects, are present at increasing time points upon treatment. It is 
possible that a longer duration of treatment might be required for the effects of 
Aβ in branching to become evident. In this context, performing a similar 
experiment extending the treatment duration and increasing the number of 
studied time points would provide a more accurate description of Aβ effects on 
the dendritic tree.  
Although in this study I focused mostly on the presynaptic effects of exposure to 
Aβ, the morphological changes described in this section state that there is a 
postsynaptic component of amyloid toxicity which, according to the results 
presented here, occur at a later stage of treatment. It has been proposed that 
loss of presynaptic afferents in AD could result in simplification of the dendritic 
tree of the postsynaptic neuron (Anderton et al., 1998; reviewed in Cochran, Hall 
and Roberson, 2014). However, recent evidence suggests that postsynaptic 
structures in most hippocampal synapses follow an autonomous path of 
development which is independent from neurotransmitter release, therefore 
indicating that possibly loss of presynaptic input does not induce the postsynaptic 
abnormalities observed here (Sando et al., 2017; Sigler et al., 2017).  
Regardless of the initiating injury, the accumulation of tau in the neuronal 
somatodendritic compartment, a phenomenon briefly described above (see 
Section 1.3.4.3), has been directly related to neuritic dystrophy (reviewed in 
Cochran, Hall and Roberson, 2014; reviewed in Herms and Dorostkar, 2016). 
Tau mislocalization can be induced by phosphorylation in the microtubule-binding 
as well as in its proline-rich domain, among other mechanisms (Zempel et al., 
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2010; Jin et al., 2011; X. Li et al., 2011; Mairet-Coello et al., 2013). As a 
consequence, there is an increase in Fyn concentration at the synapse 
associated with NMDA-receptor mediated excitotoxicity, a cleavage of 
polyglutamylated microtubules and disruption of dendritic organization mediated 
by aberrant binding of tau to PSD-95 (Ittner et al., 2010; Larson et al., 2012; 
Zempel et al., 2013). The mislocalization of tau as well as the activation of Fyn 
are attractive candidate mechanisms to explain the postsynaptic abnormalities 
depicted here and could be further studied in the autaptic cultures by means of 
immunostainings as well as Western blot (Li and Götz, 2017). 
 Aβ concentrations below 10 µM do not induce deleterious changes in 
synaptic function 
Concentration has been reported as an important factor in defining Aβ 
physiological, trophic versus pathological, toxic effects on synaptic function 
(Puzzo et al., 2008; Mucke and Selkoe, 2012). In order to study the concentration 
dependence of Aβ effects I treated autaptic hippocampal neurons with 200 nM 
and 1 µM Aβ for 72 hours. In addition, 10 µM Aβ and vehicle solution were used 
as positive and negative controls respectively. As reported here previously, the 
neurons exposed to 10 µM Aβ tended to display an impaired basal synaptic 
transmission, although statistical significance was not reached. Interestingly, 
neurons treated with lower Aβ concentrations of 200 nM and 1 µM showed a 
tendency towards larger EPSCs with respect to the untreated neurons and 
displayed a statistically significant increase in Pvr. Similar findings of an 
increased synaptic transmission upon exposure to low Aβ concentrations were 
reported by Puzzo and colleagues, who observed an enhancement of postetanic 
potentiation, hypothetically associated to α7-AchR activation and increased 
calcium entry during an action potential (Puzzo et al., 2008). However, in the 
latter study, the lowest concentration used was in the picomolar range, which is 
thousand times smaller than the minimum Aβ concentrations applied here. As 
mentioned before, and also discussed by Puzzo et al., it is likely that the actual 
concentration of the active species is lower than the measured monomeric 
concentration, because a mixture of aggregates coexists in solution (Puzzo et al., 
2008). This could partially explain the discrepancy between the results presented 




 Anle138b does not rescue the functional defects induced by Aβ treatment in 
the autaptic cultures 
Anle138b is a novel small molecule that was shown to prevent AD related 
neuropathological and behavioral changes in murine models (Wagner et al., 
2013; Martinez Hernandez et al., 2018). Despite the vast number of reports of 
anle138b protective effects in animal models of neurodegenerative diseases, the 
cellular and molecular effects underlying its benefits remain still unclear (Wagner 
et al., 2013, 2015; Fellner et al., 2016; Heras-Garvin et al., 2018; Qin et al., 2019; 
Wegrzynowicz et al., 2019). Two main mechanisms of action have been 
proposed for anle138b, namely the inhibition of aggregation of Aβ and other 
amyloid proteins, and the blocking of amyloid pores. The latter mechanism has 
been mainly studied using artificial lipid bilayers reconstituted in the presence of 
anle138b and later exposed to Aβ applied to the recording chamber to induce 
pore formation. To compare these findings in bilayers with putative similar effects 
on autaptic cultures, I incubated the hippocampal neurons with anle138b for 24 
hours before applying Aβ to the bath. Given anle138b liposolubility, I assumed 
that the compound would accumulate at the neuronal plasma membranes, where 
it could block the perforation by amyloid pores. Autaptic hippocampal neurons 
were initially treated with 10 µM anle138b, the maximum soluble concentration 
of the compound in our culture medium when dissolved in DMSO and FBS 
(Sergey Ryazanov, personal communication). After 96 hours of anle138b 
exposure, the autaptic neurons showed reduced EPSC amplitudes and RRP 
sizes, as well as a smaller mEPSCs amplitude and lower frequency. Conversely, 
no toxic effects have been reported in mice thus far. It is therefore possible that 
these synaptic effects constitute an artifact of the treatment in the in vitro model 
system. On the one hand, the concentration ranges used in the present work 
have been extrapolated from the anle138b concentrations measured in murine 
brain homogenates. This method for estimation of drug concentration in a certain 
tissue does not take into account the variation in lipid concentration in the 
different brain regions (Zhang et al., 1996). Since anle138b is a highly lipophilic 
compound, it is possible that it gets “trapped” in the white matter and therefore 
the concentrations measured in the homogenates do not reflect the actual 
amount of drug present in the gray matter, and could overestimate it (Wagner et 
al., 2013). On the other hand, in the model system that I used, namely autaptic 
neuronal cultures, the lipid fraction represented by the plasma membrane of 
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neurons and astrocytes constitutes only a minimum part of the total volume. In 
this case, if anle138b accumulates in the lipidic fraction it is possible that the 
actual concentration in the neuronal membrane is higher than the nominal 
concentration. Regarding the mechanisms of anle138b effects on autaptic 
cultures, it is possible that its accumulation in the neuronal membranes could 
modify the membrane’s lipidic composition, which is tightly regulated at the 
presynaptic site, as well as the physical properties of the membrane altering the 
energy barrier for vesicle fusion.  
Since it was not possible to measure the concentration of anle138b in the cellular 
fraction of the cultures because amounts of tissue in the range of grams would 
have been needed, I empirically searched for a concentration devoid of negative 
effects on the autaptic cultures. I thus tested whether 7 µM of the compound were 
still able to induce synaptic alterations. No statistically significant changes were 
observed after 96 hours of application and therefore this dose was used as 
putative protective treatment.  
For the study of protective effects on synaptic function, anle138b was added to 
the culture medium of autaptic neurons on DIV 7, and 10 µM Aβ were added as 
co-treatment 24 hours later, on DIV 8. Electrophysiological recordings were 
performed after 72 hours of Aβ incubation, on DIV11. As reported previously, Aβ-
treated neurons showed smaller EPSC amplitudes and RRP sizes. Surprisingly, 
anle138b-Aβ co-treated neurons displayed similarly reduced responses to the 
vehicle-Aβ treated. In addition, anle138b-Aβ co-treated neurons showed a 
decreased depression ratio accompanied by an increase, although not 
statistically significant, of Pvr.  
There is a clear discrepancy between the lack of protective effects of anle138b 
when applied with Aβ to autaptic hippocampal cultures and the in vivo reported 
benefits of the compound. A limitation of the anle138b data set presented here is 
the low number of recordings in comparison to the rest of the data sets presented 
in other sections of this study. Further experiments must be performed to confirm 
these data, but the trend is very clear towards a lack of efficacy of anle138b in 
protecting from Aβ synaptotoxicity in this experimental setting. A potential 
explanation could be that anle138b would exert its protective effects on autaptic 
cultures by acting as an inhibitor of amyloid aggregation. If this were the case, 




order for the compound to neutralize oligomerization. Another interpretation of 
these data could be that anle138b performs its protective effects on a cell type 
that is not present in autaptic cultures, like GABAergic neurons or microglia. 
Regarding microglial cells, there is a growing interest in the field about its role in 
neurodegeneration and AD (Sarlus and Heneka, 2017; Deczkowska et al., 2018). 
However, Martinez Hernandez et al. reported that although anle138b was 
effective in protecting post-plaque AD mice from Aβ induced electrophysiological 
and behavioral changes, the transcriptome analysis revealed that most of the 
deregulated genes in this group were related to neuroinflammation and could not 
be modified by anle138b treatment (Martinez Hernandez et al., 2018). It is 
therefore unlikely that anle138b protective effects are dependent on microglia or 
inflammation-related mechanisms. 
Taken together, these data point to several directions to explore and experiments 
to perform, such as the study of GABAergic neurons or the application of 
anle138b together with Aβ in the medium, in order to better understand the 
mechanisms of the protective effects of this compound.  
 Pore formation does not explain the synaptic defects induced by exposure to 
Aβ 
Pore formation is a potential mechanism of toxicity of Aβ that would mainly cause 
its downstream effects via deregulation of calcium homeostasis (Arispe, Rojas 
and Pollard, 1993; Arispe, Pollard and Rojas, 1996; Kawahara et al., 1997; 
Demuro, Smith and Parker, 2011). The formation of amyloid pores could 
theoretically at least partially explain the electrophysiological alterations of 
autaptic cultures exposed to 10 µM Aβ for 72 hours. Therefore, I sought to 
investigate whether the oligomeric preparation that I used on hippocampal 
cultures could also induce pore formation. To this aim, I initially performed 
experiments on artificial bilayers exposed to Aβ or a control peptide for 20 
minutes. The advantage of these model membranes to study pore formation is 
the absence of proteins or receptors, which can act as confounding factors in 
living cells, and the possibility of controlling the lipidic composition of the 
membrane. I initially utilized oxidized cholesterol membranes and exposed them 
to 10 µM of Aβ42 or two control peptides, the reverse Aβ 42-1 and the scrambled 
peptide, scr Aβ. In all the conditions tested, a stepwise current increase was 
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observed upon treatment, pointing to the assembly of conducting structures in 
the bilayer that could correspond to Aβ pores. However, when experiments were 
performed in phospholipid membranes (dyphyPC), a bilayer that resembles the 
neuronal plasma membrane in its lipidic composition, no induction of currents 
was observed. A limitation of these experiments is the use of the reverse and 
scrambled Aβ as negative controls. Recently, the group of Serpell and 
collaborators showed that both control peptides have a tendency to aggregate 
similar to the wild type Aβ42 peptide, although with less neurotoxic effects 
(Vadukul et al., 2017). Therefore, if pore formation is a phenomenon that depends 
on aggregation and conformation, the Aβ 42-1 or scr Aβ are not valid as negative 
controls and have to be considered as potential amyloidogenic proteins. Another 
conclusion that can be drawn from these experiments is that Aβ aggregates show 
a great avidity to interact with cholesterol-enriched membranes, as has been 
reported before by Arispe and Doh (Arispe and Doh, 2002). Regarding the 
experiments with phospholipidic membranes, most of the experiments reported 
in the literature have included negatively charged phospholipids such as 
phosphatidylserine in their lipid mixture. In addition, some of the studies have 
even reconstituted the membranes after dissolving Aβ in the lipid mixture, thus 
skipping the insertion step (Arispe, Rojas and Pollard, 1993; Arispe, Pollard and 
Rojas, 1996; Rhee, Quist and Lal, 1998; Simakova and Arispe, 2007; Diaz et al., 
2009). These differences in membrane composition and preparation could 
explain the discrepancies between the absence of pore formation in the 
dyphyDPC membranes used here and the findings reported by others. 
Next, I performed cell-attached recordings upon repetitive application of 3 µM 
GABA puffs and using an internal solution devoid of ATP. I had previously 
established that GABA currents would suffer a rundown if the cytoplasm was 
dialyzed and somatic ATP was removed. I hypothesized that observing a 
progressive increase of GABA currents when still in cell attached mode would be 
indicative of electrical access to the cell. Additionally, measurement of large 
GABA currents with absence of rundown would point to a perforated patch-like 
state, whereas GABA current rundown would be the outcome of patch rupture. 
During the first 20 minutes of these experiments, the GABA current increased 
only mildly in both control and Aβ-intrapipette exposed patches. This is already 
in contrast with previous reports by others in which pore formation occurred within 




studies have reported that at least 40 minutes are necessary to reach a 
perforated patch-like state (Sepúlveda et al., 2010). Nevertheless, in later time 
points, after ~30 minutes of recording, both control and Aβ-treated patches 
showed increased GABA currents, with no rundown observed in the control 
patch. Since the control patch contained only the intracellular solution and 
phosphate buffer used as vehicle, it is highly unlikely that a perforated patch state 
had formed. This indicated that most likely a partial rupture of the patch with 
relatively high series resistance could simulate a perforated patch configuration. 
In the Aβ-intrapipette exposed patch, a GABA rundown current was observed 
after 50 minutes of recording, which could be explained by a total rupture of the 
patch regardless of pore formation, or due to an inadequate response of the 
neuron which had been in the recording chamber more than 40 minutes. The 
main conclusions that I drew from these experiments are that Aβ did not induce 
a perforated patch-like configuration during the first 20 minutes, and that cell 
attached recordings longer than 20 minutes have to be analyzed carefully, using 
proper negative controls.  
Since I had observed that 10 µM Aβ altered synaptic transmission when applied 
for 72 hours to autaptic neurons, I next investigated whether these effects could 
relate to changes in membrane properties. I hypothesized that membrane 
alterations had to be present if aberrant pores would perforate the cell surface to 
an extent that triggered synaptic dysfunction. As in previous experiments, I 
exposed autaptic hippocampal neurons for 72 hours to 10 µM Aβ and performed 
electrophysiological recordings but in current clamp mode. To have a positive 
control for Aβ toxicity, I started the experiments by evoking an EPSC, which 
showed a reduced amplitude in Aβ-treated neurons, as reported before in this 
study. Importantly, the resting membrane potential and input resistance were not 
changed in Aβ-treated neurons, indicating that at rest the population of open 
channels was similar in both groups, and against the possibility that open amyloid 
pores are present and would induce toxicity. However, the Aβ-treated neurons 
displayed mild but statistically significant alterations in the shape of the action 
potential including a reduction in the amplitude and overshoot, and an increase 
in the half-width. These changes could be explained by an increase in the 
conductance to potassium. However, it is unlikely that altered conductance to 
potassium would not alter the resting membrane potential. In addition, this kind 
of ion specificity has not been observed in amyloid pores, which on the contrary 
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would be either cation selective or non-selective, and their effects on the plasma 
membrane would tend to be depolarizing. (Kawahara et al., 1997; Bode, Baker 
and Viles, 2017). Alternatively, APP has been shown to modulate a potassium / 
chloride cotransporter in GABAergic neurons (Chen et al., 2017). A potential 
explanation of the data presented here could be that Aβ retains the ability of APP 
of limiting potassium channel phosphorylation, thus increasing its membrane 
abundance. However, with no alteration in the resting membrane potential, these 
data have to be interpreted carefully.  
Pore formation is believed to depend on the secondary structure of the amyloid 
aggregates, and it has been reported that many peptides with different primary 
structure can induce a similar pore-like behavior when applied to artificial bilayers 
(Quist et al., 2005). In addition, the work by Cribbs et al. showed that the AllD 
stereoisomer of Aβ, which retained its aggregation properties, could also induce 
pore formation and cause neurotoxicity (Cribbs et al., 1997). Moreover, Lal and 
collaborators used the AllD Aβ enantiomer to distinguish between a mechanism 
of toxicity dependent on intermolecular interactions, which would be 
stereospecific, and a conformation-dependent and unspecific mechanism, like 
membrane binding and amyloid pore formation (Capone et al., 2012; Connelly et 
al., 2012). In this context, in the last set of experiments I used the AllD Aβ 
enantiomer to investigate whether it retained the aggregation properties, and if 
its oligomers would induce similar electrophysiological deficits on autaptic 
neurons as its L- counterpart. In collaboration with colleagues from the Max 
Planck Institute for Biophysical Chemistry, we performed a mass spectrometric 
analysis and compared the NMR fingerprint regions of the TOCSY spectra of 
samples from both enantiomers. Both methods confirmed the identical primary 
structure of the enantiomers. Furthermore, I compared the aggregation kinetics 
of the peptides by analyzing samples taken at increasing incubation times using 
silver staining, which indicated a similar distribution of species for both 
stereoisomers. In addition, Western blot with the 6E10 antibody, which is specific 
for the L-Aβ showed no signal in the lane containing AllD Aβ. Finally, I exposed 
autaptic hippocampal neurons for 72 hours to Aβ or AllD Aβ and compared their 
morphology and electrophysiological properties. In agreement with the data 
presented in other sections, the morphology of the autaptic neurons was not 
changed. Surprisingly, although the L- isomer showed a marked reduction in 




in AllD-treated neurons, which displayed responses similar to the controls, 
indicating a requirement for stereospecific interactions in Aβ toxicity.  
In sum, although pore formation could be reproduced in cholesterol bilayers and 
other membrane models at low frequency (see Supplementary Material, Figure 
30 and Figure 31), I could not find evidence to support the hypothesis of amyloid 





AD is the most prevalent neurodegenerative disorder, characterized clinically by 
cognitive decline with amnestic presentation, and histopathologically by 
deposition of Aβ and hyperphosphorylated tau. Although a great number of 
studies in postmortem human tissue and in murine models have been performed, 
the cellular and molecular events leading to cognitive decline remain obscure. 
Moreover, the disease has still no treatment that can modify its natural history.  
Here I aimed to study the mechanisms by which Aβ peptide induces deleterious 
effects on glutamatergic synapses. In a first part of my work, I successfully 
established a protocol to dissolve synthetic Aβ42 and to generate oligomer-
enriched solutions in a reproducible manner. Later, I made use of the autaptic 
culture system and showed that Aβ42 impairs basal synaptic transmission and 
depletes the RRP, exerting synaptotoxic effects mainly by altering presynaptic 
function. Additionally, I observed moderate morphological changes in Aβ-treated 
neurons. I also studied a shorter exposure to Aβ aggregates, which resulted in a 
paradoxical increase in synaptic transmission.  
In addition, Aβ-exposed neurons were used to explore putative protective effects 
of the small molecule anle138b, a novel therapeutic agent successfully utilized in 
multiple mouse models of neurodegenerative diseases. I unexpectedly found that 
anle138b can be toxic per se in a concentration dependent manner. Moreover, 
when applied in combination with Aβ, anle138b failed in protecting glutamatergic 
autaptic neurons from synaptotoxicity.  
Finally, I took advantage of the oligomeric Aβ preparation to study whether 
synaptotoxic aggregates could also assemble as amyloid pores. No evidence of 
pore formation was found neuronal membranes, among other membrane types. 
Furthermore, by means of using the AllD Aβ, the D-Aβ42 enantiomer, I could 








Figure 28. Graphical summary.   
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6. Supplementary Material 
The data included in the present section was obtained after the submission and 
defense of the present work. Since it might be helpful to clarify some of the points 
discussed in the main body of the thesis I decided to attach them as a 
supplement.  
 
Figure 29. Synapse density is not altered in 72-hour Aβ-treated neurons. (A) Distribution of 
puncta with juxtaposed VGluT1 and Shank2 signal with respect to the center of the cell soma. (B) 
Distribution of synapse density calculated as the quotient between the number of synapses in a 
Sholl segment and divided by the number of dendritic crossings for that segment. (C) Number of 
synapses calculated from the maximum intensity projection images used for the calculation of 
synapse density. These results are in agreement with the data shown in Figure 11, where puncta 
positive for both VGluT1 and Shank2 were quantified in a z-stack using a 3D-particle counter. (D) 
The number of synapses analyzed in discrete bins of distance from the center of the cell soma 
shows no difference between the vehicle- and the 72-hour Aβ-treated neurons. In A and B the 
lines connect the means for given points of distance from the center of the cell soma and the error 
bars represent the SEM. In C and D, bars represent the mean and error bars represent SEM. 





Figure 30. Pore formation could be observed in one out of 40 inside-out patches 
exposed to 5 µM Aβ. 80 inside-out patches were obtained from HEK cells in collaboration 
with Prof. JeongSeop Rhee and Prof. Luis Pardo under the same experimental conditions as 
in Bode, Baker and Viles 2017, with the exception of the use of a different method for the 
preparation of the oligomer-enriched Aβ solution. From these 80, 40 patches were exposed to 
5 µM Aβ from within the patch pipette (data not shown). The remaining 40 patches were 
exposed to the vehicle solution and used as control. In the group of Aβ-exposed patches, only 
one showed pore-like activity. (A) Representative traces of the patch which showed 
electrophysiological activity resembling single-channel currents. Note that the pore-like activity 
started after 25 minutes after patch excision. (B) Representative traces of the remaining 39 




Figure 31. The Aβ-treated patch with pore-like activity displayed two levels of 
membrane permeability. (A) Comparison of juxtaposed traces of the patch with pore-
like currents at 25 and 29 minutes after patch excision at -60 mV of holding potential. G1 
is the calculated permeability for the first current step upon putative pore formation. G2 is 
the calculated permeability for the second current step. It is possible that the insertion of 
a second pore occurs, or that new molecules of Aβ are added to the existing pore. (B) 
Current/Voltage (IV) curves from the patch with pore-like activity at 20 and 29 minutes 
(solid lines) and linear-fitted curves (dashed lines) to calculate the membrane 
permeability. Black lines: 20 minutes after patch excision; blue lines: 29 minutes after 
patch excision, first current step; red lines: 29 minutes after patch excision, second current 
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